Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0043005 neuron projection	IBA GO_REF:0000033	ACCEPT	Summary: IBA annotation based on phylogenetic analysis. Perlecan localizes at neuromuscular junctions where it anchors acetylcholinesterase and maintains synaptic stability. The deep research document confirms perlecan's role at neuromuscular junctions and in neural tissues including blood-brain barrier basement membranes. UniProt features list "Interaction with PRPH" (peripherin) suggesting neuron projection localization. Reason: Well-supported by both phylogenetic inference and experimental evidence. Perlecan is present at neuromuscular junctions (a specialized neuron projection) and in neural basement membranes. This represents a core function of perlecan in neural tissues. Supporting Evidence: PMID:14702351 The collagen-tailed form of acetylcholinesterase (A(12)-AChE) appears to be localized at the neuromuscular junction in association with the transmembrane dystroglycan complex through binding of its collagenic tail (ColQ) to the proteoglycan perlecan.
GO:0001525 angiogenesis	IEA GO_REF:0000043	ACCEPT	Summary: IEA annotation from UniProtKB keyword mapping. Perlecan has dual pro- and anti-angiogenic roles. Full-length perlecan promotes angiogenesis through its heparan sulfate chains that bind and present VEGF and FGF-2 to their receptors. Proteolytically cleaved endorepellin (domain V) exhibits potent anti-angiogenic activity through dual antagonism of VEGFR2 and α2β1 integrin. Deep research extensively documents both activities. Reason: Core function of perlecan. Despite the dual nature (both pro- and anti-angiogenic depending on proteolytic state), perlecan is fundamentally involved in angiogenesis regulation. The term captures the biological process without specifying direction, which is appropriate given perlecan's context-dependent activities. Supporting Evidence: PMID:21596751 Endorepellin, the C-terminal module of perlecan, negatively regulates angiogenesis counter to its proangiogenic parental molecule. file:human/HSPG2/HSPG2-deep-research-perplexity.md Perlecan exerts pro-angiogenic activity principally through modulation of the FGF-2 pathway via its heparan sulfate side chains, which present this ligand to its receptor and induce complex downstream signaling cascades promoting cell proliferation, motility, and adhesion. Additionally, perlecan positively affects angiogenesis through modulation of the VEGFR2-Neuropilin-1 signaling axis.
GO:0005509 calcium ion binding	IEA GO_REF:0000002	MARK AS OVER ANNOTATED	Summary: IEA annotation from InterPro domain IPR001881 (EGF-like calcium-binding domain). Perlecan domain V contains multiple EGF-like repeats that may have calcium-binding capacity. However, calcium binding is not a characterized or functionally important activity for perlecan. UniProt does not list calcium as a cofactor. Reason: While perlecan contains EGF-like domains that structurally may bind calcium, this is not a characterized molecular function of perlecan and does not contribute to its known biological activities. This represents computational over-annotation based on domain presence without functional validation.
GO:0005576 extracellular region	IEA GO_REF:0000044	ACCEPT	Summary: IEA annotation from UniProtKB subcellular location. Perlecan is secreted and localized to extracellular spaces including basement membranes, extracellular matrix, and extracellular space. This is universally accepted. Reason: Core localization. Perlecan is a secreted protein that functions entirely in the extracellular space. The term is appropriately general for this widely distributed ECM protein.
GO:0005604 basement membrane	IEA GO_REF:0000120	ACCEPT	Summary: IEA annotation combining ARBA and UniProtKB subcellular location. Perlecan is the major heparan sulfate proteoglycan of basement membranes throughout the body. This is perlecan's canonical and most important localization, critical for basement membrane structural integrity, growth factor sequestration, and barrier function. Reason: Core localization representing perlecan's primary and most important site of action. Basement membrane is where perlecan carries out its essential structural and signaling functions. Supporting Evidence: file:human/HSPG2/HSPG2-deep-research-perplexity.md Perlecan functions as a critical cross-linking component of basement membranes, interacting with and stabilizing the major basement membrane proteins including laminin, type IV collagen, and nidogens. Through its multiple binding partners, perlecan bridges and stabilizes the laminin network with the type IV collagen network within basement membranes.
GO:0005796 Golgi lumen	IEA GO_REF:0000117	KEEP AS NON CORE	Summary: IEA annotation from ARBA machine learning. Perlecan transits through the Golgi during biosynthesis where heparan sulfate chains are added and modified. This is a transient biosynthetic localization, not a functional site. Reason: Accurate but non-core annotation. All secreted proteoglycans transit through the Golgi for glycosylation. This does not represent a functional localization where perlecan carries out its biological activities, merely a biosynthetic transit point.
GO:0007420 brain development	IEA GO_REF:0000117	ACCEPT	Summary: IEA annotation from ARBA machine learning. Perlecan plays roles in blood-brain barrier integrity, neural stem cell niches, and brain vascular development. Deep research documents perlecan's role in maintaining blood-brain barrier basement membrane and promoting angiogenic repair following stroke. Reason: Well-supported role. Perlecan is essential for brain vascular development and blood-brain barrier function. While not as central as its skeletal roles, this represents an important developmental function.
GO:0030154 cell differentiation	IEA GO_REF:0000117	KEEP AS NON CORE	Summary: IEA annotation from ARBA machine learning. Perlecan influences chondrocyte differentiation and hypertrophic maturation in growth plates, and affects endothelial cell behavior. This is a very broad term that could apply to many pleiotropic effects. Reason: Too general. While perlecan does influence differentiation of multiple cell types (chondrocytes, endothelial cells, osteoprogenitors), this extremely broad term does not capture perlecan's specific functions. More specific terms for chondrocyte differentiation or endochondral ossification would be preferable.
GO:0046872 metal ion binding	IEA GO_REF:0000043	MARK AS OVER ANNOTATED	Summary: IEA annotation from UniProtKB keyword mapping. This is an extremely generic molecular function term. While calcium ion binding annotation exists from EGF domains, metal ion binding is not a characterized activity of perlecan. Reason: Overly generic term providing no useful functional information. Not a characterized molecular function of perlecan. This represents computational over-annotation without functional significance.
GO:0072359 circulatory system development	IEA GO_REF:0000117	ACCEPT	Summary: IEA annotation from ARBA machine learning. Perlecan is essential for vascular development as demonstrated in knockout mice and zebrafish morphants showing severe vascular defects. Perlecan regulates angiogenesis through growth factor presentation and direct receptor interactions. Reason: Core developmental function. Perlecan is essential for normal vascular development, with knockout causing cardiovascular defects and embryonic lethality. Well-supported by genetic and developmental studies. Supporting Evidence: file:human/HSPG2/HSPG2-deep-research-falcon.md Perlecan modulates VEGFA/VEGFR2 signaling by localizing VEGF and stabilizing receptor-ligand complexes; supports FGF2-FGFR co-receptor functions via HS; engages integrins and dystroglycan to influence adhesion and downstream kinases. Hspg2-null mice exhibit embryonic lethality with severe cardiac and cartilaginous defects, emphasizing perlecan's nonredundant role in BM integrity and morphogenesis.
GO:0005515 protein binding	IPI PMID:12900424 A novel interaction between perlecan protein core and progra...	MODIFY	Summary: IPI annotation showing interaction with progranulin (P28799). This is uninformative as a molecular function term. Reason: Protein binding is uninformative. Perlecan interacts with numerous proteins (laminin, collagen IV, nidogens, fibrillin-1, growth factors, integrins, etc.). Better terms would be specific molecular functions like "extracellular matrix structural constituent" or "growth factor binding". Proposed replacements: extracellular matrix structural constituent growth factor binding Supporting Evidence: PMID:12900424 2003 Aug 4. A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth.
GO:0005515 protein binding	IPI PMID:21596751 Endorepellin, the angiostatic module of perlecan, interacts ...	MODIFY	Summary: IPI annotation showing interaction with VEGFR2/KDR (P35968). This paper demonstrates endorepellin binds VEGFR2 and α2β1 integrin with dual receptor antagonism for anti-angiogenic activity. While the interaction is real, "protein binding" is uninformative. Reason: Protein binding is uninformative. The interaction with VEGFR2 represents a specific receptor-ligand interaction that antagonizes VEGF signaling. Better terms would capture the specific molecular function. Proposed replacements: signaling receptor binding Supporting Evidence: PMID:21596751 perlecan and endorepellin bind directly and with high affinity to both vegf receptors
GO:0005515 protein binding	IPI PMID:23374253 Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of...	MODIFY	Summary: IPI annotation showing interaction with VEGFR2/KDR (P35968). This paper demonstrates that endorepellin LG1/2 domains bind Ig3-5 of VEGFR2 and block VEGFA signaling. While technically correct, "protein binding" is uninformative. Reason: Protein binding is uninformative. The VEGFR2 interaction represents a specific antagonistic receptor binding activity. Better terms would capture this specific molecular function. Proposed replacements: signaling receptor binding Supporting Evidence: PMID:23374253 LG1/2 did not bind Ig1-3, but did bind with high affinity to Ig3-5
GO:0031594 neuromuscular junction	IC PMID:14702351 C-terminal and heparin-binding domains of collagenic tail su...	ACCEPT	Summary: IC annotation with experimental evidence. PMID:14702351 demonstrates that perlecan anchors acetylcholinesterase at the neuromuscular junction through interaction with ColQ. Perlecan-null mice lack AChE at the NMJ. This is a well-characterized and essential localization. Reason: Core localization supported by strong experimental evidence. Perlecan plays an essential structural role at the neuromuscular junction where it anchors acetylcholinesterase. Loss of perlecan causes myotonia in Schwartz-Jampel syndrome due to altered neuromuscular function. Supporting Evidence: PMID:14702351 The collagen-tailed form of acetylcholinesterase (A(12)-AChE) appears to be localized at the neuromuscular junction in association with the transmembrane dystroglycan complex through binding of its collagenic tail (ColQ) to the proteoglycan perlecan. file:human/HSPG2/HSPG2-deep-research-perplexity.md Perlecan plays a critical role at the neuromuscular junction. Perlecan localizes acetylcholinesterase in the neuromuscular junction and is of functional significance in neuromuscular control; in perlecan-null mice, acetylcholinesterase is absent at the neuromuscular junction. A reduced amount of functional perlecan at the neuromuscular junction likely alters the balance of other molecules that signal when muscles should contract and when they should relax.
GO:0032223 negative regulation of synaptic transmission, cholinergic	ISS GO_REF:0000024	UNDECIDED	Summary: ISS annotation based on sequence similarity to mouse orthologs. This term suggests perlecan negatively regulates cholinergic transmission. Perlecan localizes acetylcholinesterase which terminates cholinergic signaling, but this is enabling proper termination rather than negative regulation of transmission itself. Reason: The relationship between perlecan and cholinergic transmission regulation is complex. Perlecan anchors AChE which breaks down acetylcholine, but whether this constitutes "negative regulation" of transmission or proper homeostatic control is unclear. Would need access to the mouse orthologue studies to evaluate this annotation properly.
GO:0035418 protein localization to synapse	ISS GO_REF:0000024	ACCEPT	Summary: ISS annotation based on mouse ortholog. Perlecan localizes acetylcholinesterase to the neuromuscular synapse. This is well-documented experimentally. Reason: Well-supported function. Perlecan serves as an anchor/scaffold that localizes acetylcholinesterase to the neuromuscular synapse, representing a core function at this site. Supporting Evidence: PMID:14702351 The collagen-tailed form of acetylcholinesterase (A(12)-AChE) appears to be localized at the neuromuscular junction in association with the transmembrane dystroglycan complex through binding of its collagenic tail (ColQ) to the proteoglycan perlecan.
GO:0060090 molecular adaptor activity	ISS GO_REF:0000024	ACCEPT	Summary: ISS annotation based on mouse ortholog. Perlecan functions as a molecular scaffold/adaptor that links multiple ECM components (laminin, collagen IV, nidogens) and localizes proteins like acetylcholinesterase. This is an appropriate molecular function term. Reason: Accurate molecular function. Perlecan serves as a molecular adaptor/scaffold in basement membranes, cross-linking laminin and collagen IV networks and localizing proteins like acetylcholinesterase. This is more informative than generic "protein binding".
GO:0005515 protein binding	IPI PMID:14702351 C-terminal and heparin-binding domains of collagenic tail su...	MODIFY	Summary: IPI annotation showing interaction with ACHE/acetylcholinesterase (Q9Y215). While the interaction is real and important, "protein binding" is uninformative. Reason: Protein binding is uninformative. Better captured by "molecular adaptor activity" term which describes perlecan's role in localizing acetylcholinesterase to the synapse. Proposed replacements: molecular adaptor activity Supporting Evidence: PMID:14702351 2003 Dec 31. C-terminal and heparin-binding domains of collagenic tail subunit are both essential for anchoring acetylcholinesterase at the synapse.
GO:0031012 extracellular matrix	HDA PMID:23658023 Comparative proteomic analysis of supportive and unsupportiv...	ACCEPT	Summary: HDA annotation from proteomics study of extracellular matrix. Perlecan is a major structural component of extracellular matrix and basement membranes. This is a core localization. Reason: Core localization. Perlecan is one of the major heparan sulfate proteoglycans of extracellular matrix and basement membranes throughout the body. Supporting Evidence: PMID:23658023 2013 May 8. Comparative proteomic analysis of supportive and unsupportive extracellular matrix substrates for human embryonic stem cell maintenance.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-9940993	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway for heparan sulfate biosynthesis (PXYLP1 dephosphorylates Xyl moiety). Perlecan transits through the Golgi during biosynthesis where heparan sulfate chains undergo extensive modifications. This is a transient biosynthetic localization. Reason: Accurate but non-core. All heparan sulfate proteoglycans transit through the Golgi for glycosaminoglycan chain synthesis and modification. This is a biosynthetic compartment, not where perlecan carries out its biological functions.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-9941039	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway for heparan sulfate biosynthesis (FAM20B phosphorylates Xyl moiety). Perlecan transits through the Golgi during biosynthesis where heparan sulfate chains undergo enzymatic modifications. Transient biosynthetic localization. Reason: Accurate but non-core. Golgi transit is required for all secreted proteoglycans but does not represent functional localization. The numerous Reactome annotations document biosynthetic machinery but not core function.
GO:0030021 extracellular matrix structural constituent conferring compression resistance	ISS GO_REF:0000024	ACCEPT	Summary: ISS annotation based on sequence similarity to mouse ortholog. Perlecan is a major structural constituent of basement membranes and cartilage ECM. Its high negative charge density from heparan sulfate chains attracts water and cations, providing compression resistance particularly important in cartilage and glomerular basement membrane. Reason: Core molecular function. Perlecan's proteoglycan structure with extended heparan sulfate chains provides hydration and compressive resilience to ECM, representing an essential biophysical function especially in cartilage where it enables load-bearing properties.
GO:0031012 extracellular matrix	ISS GO_REF:0000024	ACCEPT	Summary: ISS annotation based on mouse ortholog. Perlecan is a major heparan sulfate proteoglycan component of extracellular matrix and basement membranes throughout the body. Core localization. Reason: Core localization. Perlecan is one of the major structural and regulatory components of extracellular matrix, essential for ECM organization and function.
GO:0005576 extracellular region	TAS Reactome:R-HSA-1592314	ACCEPT	Summary: TAS annotation from Reactome pathway "HSPG2 (perlecan) degradation by MMP3, plasmin, (MMP12)". This documents perlecan degradation by matrix metalloproteinases and plasmin in the extracellular region, which is perlecan's native location. Reason: Core localization. Perlecan functions entirely in the extracellular region including basement membranes, extracellular matrix, and extracellular space. This annotation is accurate and supported by all evidence.
GO:0005576 extracellular region	TAS Reactome:R-HSA-2534240	ACCEPT	Summary: TAS annotation from Reactome pathway "HSPG2 (perlecan) degradation by MMP14, MMP15". This documents perlecan degradation by additional matrix metalloproteinases in the extracellular region. Reason: Core localization. Perlecan is secreted and functions entirely in the extracellular region, where it is subject to proteolytic processing by metalloproteinases.
GO:0005576 extracellular region	TAS Reactome:R-HSA-4088220	ACCEPT	Summary: TAS annotation from Reactome pathway "Endorepellin binds alpha2beta1 integrin". This documents the binding of endorepellin (perlecan domain V fragment) to integrin α2β1, which occurs in the extracellular region. Reason: Core localization. Endorepellin is generated by proteolytic cleavage in the extracellular space and exerts its anti-angiogenic effects through receptor binding in the extracellular region.
GO:0005576 extracellular region	TAS Reactome:R-HSA-4088281	ACCEPT	Summary: TAS annotation from Reactome pathway "Endorepellin binds KDR (VEGFR2)". This documents the binding of endorepellin to VEGFR2, a critical interaction for endorepellin's anti-angiogenic activity occurring in the extracellular region. Reason: Core localization. Endorepellin functions in the extracellular region where it binds VEGFR2 and α2β1 integrin to exert dual receptor antagonism and anti-angiogenic effects.
GO:0005576 extracellular region	TAS Reactome:R-NUL-2534170	ACCEPT	Summary: TAS annotation from Reactome pathway "Degradation of HSPG2 by Mmp13 and Ctss". This documents perlecan degradation by MMP13 and cathepsin S in the extracellular region. Reason: Core localization. Perlecan is subject to proteolytic processing by multiple proteases including MMP13 and cathepsin S in its native extracellular location.
GO:0006629 lipid metabolic process	TAS PMID:21289173 Heparan sulphate proteoglycan and the low-density lipoprotei...	KEEP AS NON CORE	Summary: TAS annotation from PMID:21289173 describing perlecan's role in neuronal amyloid-beta uptake through cooperation with LRP1 (low-density lipoprotein receptor-related protein 1). The paper demonstrates that perlecan (as HSPG) cooperates with LRP1 in cellular uptake processes that include lipid metabolism. However, this is not a core function of perlecan. Reason: Peripheral function. While perlecan can cooperate with LRP1 in receptor-mediated endocytosis processes that involve lipid metabolism, this is not a primary or core function of perlecan. Perlecan's main functions are structural organization of basement membranes and growth factor sequestration/presentation, not lipid metabolism per se. Supporting Evidence: PMID:21289173 In addition, LRP1 and HSPG are part of an immunoprecipitable complex at the cell surface to mediate lipid metabolism ( Wilsie and Orlando, 2003 )
GO:0050750 low-density lipoprotein particle receptor binding	TAS PMID:21289173 Heparan sulphate proteoglycan and the low-density lipoprotei...	ACCEPT	Summary: TAS annotation from PMID:21289173 demonstrating that HSPG (including perlecan) forms a complex with LRP1 and participates in receptor-mediated processes. Domain II of perlecan contains LDL receptor-like repeats, providing structural basis for potential interactions with LDL receptor pathway components. Reason: Well-supported molecular function. Perlecan domain II contains four LDL receptor-like repeats, and perlecan cooperates with LRP1 (LDL receptor-related protein 1) in cellular uptake processes. This represents a legitimate molecular function of perlecan's core protein domains. Supporting Evidence: PMID:21289173 Our findings demonstrate that LRP1 and HSPG function in a cooperative manner to mediate cellular Aβ uptake and define a major pathway through which Aβ gains entry to neuronal cells
GO:0001540 amyloid-beta binding	IC PMID:21289173 Heparan sulphate proteoglycan and the low-density lipoprotei...	ACCEPT	Summary: IC annotation from PMID:21289173 demonstrating that perlecan (as HSPG) binds amyloid-beta peptide. The paper shows that heparan sulfate chains of perlecan mediate Aβ binding to cell surfaces, with HSPG being more important for Aβ binding than LRP1. Heparan sulfate binds the HHQK (amino acids 13-16) region of Aβ. Reason: Well-characterized molecular function relevant to Alzheimer's disease pathology. Perlecan's heparan sulfate chains bind amyloid-beta with functional consequences for Aβ aggregation, plaque formation, and neuronal uptake. This is a specific and important molecular function, though not a core developmental/structural function. Supporting Evidence: PMID:21289173 HSPG is more important for the binding of Aβ to the cell surface than LRP1.
GO:0030021 extracellular matrix structural constituent conferring compression resistance	RCA PMID:28327460 Comprehensive proteomic characterization of stem cell-derive...	ACCEPT	Summary: RCA annotation from proteomics study of stem cell-derived extracellular matrices. Perlecan's heparan sulfate chains create high negative charge density that attracts water and cations, providing hydration and compression resistance essential for ECM mechanical properties. Reason: Core molecular function. Perlecan's proteoglycan structure with extended heparan sulfate chains provides hydration and compressive resilience to ECM, representing an essential biophysical function especially important in cartilage and glomerular basement membrane. Supporting Evidence: PMID:28327460 Epub 2017 Mar 7. Comprehensive proteomic characterization of stem cell-derived extracellular matrices.
GO:0031012 extracellular matrix	HDA PMID:28327460 Comprehensive proteomic characterization of stem cell-derive...	ACCEPT	Summary: HDA annotation from proteomics analysis of stem cell-derived extracellular matrices. Perlecan identified as a component of ECM by mass spectrometry. Reason: Core localization. Perlecan is a major structural component of extracellular matrix identified in multiple proteomics studies across diverse tissue types. Supporting Evidence: PMID:28327460 Epub 2017 Mar 7. Comprehensive proteomic characterization of stem cell-derived extracellular matrices.
GO:0030021 extracellular matrix structural constituent conferring compression resistance	RCA PMID:28675934 Characterization of the Extracellular Matrix of Normal and D...	ACCEPT	Summary: RCA annotation from proteomics characterization of ECM from normal and diseased tissues. Perlecan provides compression resistance through its hydrated heparan sulfate chains. Reason: Core molecular function. Perlecan's high negative charge density from heparan sulfate provides essential compression resistance in tissues including cartilage, basement membranes, and vascular ECM. Supporting Evidence: PMID:28675934 Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.
GO:0031012 extracellular matrix	HDA PMID:28675934 Characterization of the Extracellular Matrix of Normal and D...	ACCEPT	Summary: HDA annotation from proteomics study characterizing ECM of normal and diseased tissues. Perlecan detected as ECM component by mass spectrometry. Reason: Core localization confirmed by proteomics. Perlecan is consistently identified as a major ECM component across multiple tissue types and disease states. Supporting Evidence: PMID:28675934 Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.
GO:0030021 extracellular matrix structural constituent conferring compression resistance	RCA PMID:23979707 SILAC-based proteomics of human primary endothelial cell mor...	ACCEPT	Summary: RCA annotation from SILAC-based proteomics of human endothelial cell morphogenesis. Perlecan identified as structural ECM component conferring compression resistance. Reason: Core molecular function. Perlecan's structural properties provide compression resistance essential for ECM mechanical function in vascular and other tissues. Supporting Evidence: PMID:23979707 Epub 2013 Aug 26. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers.
GO:0030021 extracellular matrix structural constituent conferring compression resistance	RCA PMID:20551380 Proteomics characterization of extracellular space component...	ACCEPT	Summary: RCA annotation from proteomics characterization of human aorta extracellular space components. Perlecan provides structural support and compression resistance in vascular ECM. Reason: Core molecular function. Perlecan's compression resistance properties are essential for vascular ECM integrity and function in large vessels like the aorta. Supporting Evidence: PMID:20551380 2010 Jun 15. Proteomics characterization of extracellular space components in the human aorta.
GO:0030021 extracellular matrix structural constituent conferring compression resistance	RCA PMID:25037231 Extracellular matrix signatures of human primary metastatic ...	ACCEPT	Summary: RCA annotation from proteomics of primary metastatic colon cancers. Perlecan identified as ECM structural component even in tumor microenvironments. Reason: Core molecular function maintained even in pathological contexts. Perlecan provides compression resistance in both normal and tumor ECM. Supporting Evidence: PMID:25037231 Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.
GO:0030021 extracellular matrix structural constituent conferring compression resistance	RCA PMID:27559042 Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin...	ACCEPT	Summary: RCA annotation from glycoproteomics study in human atrial fibrillation. Perlecan provides structural ECM function including compression resistance in cardiac tissues. Reason: Core molecular function. Perlecan's compression resistance properties are important in cardiac ECM and basement membranes. Supporting Evidence: PMID:27559042 Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation.
GO:0031012 extracellular matrix	HDA PMID:25037231 Extracellular matrix signatures of human primary metastatic ...	ACCEPT	Summary: HDA annotation from proteomics of colon cancer and liver metastases ECM. Perlecan detected in tumor-associated ECM. Reason: Core localization. Perlecan is present in ECM even in pathological tumor microenvironments, confirming its fundamental ECM localization. Supporting Evidence: PMID:25037231 Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.
GO:0005576 extracellular region	HDA PMID:27068509 Extracellular matrix remodelling in response to venous hyper...	ACCEPT	Summary: HDA annotation from proteomics of extracellular matrix remodeling in venous hypertension and varicose veins. Perlecan detected in remodeling vascular ECM. Reason: Core localization. Perlecan functions in the extracellular region including vascular basement membranes and ECM. Supporting Evidence: PMID:27068509 Apr 11. Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins.
GO:0031012 extracellular matrix	HDA PMID:27559042 Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin...	ACCEPT	Summary: HDA annotation from glycoproteomics in atrial fibrillation. Perlecan detected in cardiac ECM. Reason: Core localization. Perlecan is present in cardiac extracellular matrix and basement membranes. Supporting Evidence: PMID:27559042 Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation.
GO:0005615 extracellular space	HDA PMID:20551380 Proteomics characterization of extracellular space component...	ACCEPT	Summary: HDA annotation from proteomics of human aorta extracellular space. Perlecan identified as a component of extracellular space in vascular tissues. Reason: Core localization. Perlecan is secreted into the extracellular space where it functions in basement membranes and ECM. Supporting Evidence: PMID:20551380 2010 Jun 15. Proteomics characterization of extracellular space components in the human aorta.
GO:0031012 extracellular matrix	HDA PMID:20551380 Proteomics characterization of extracellular space component...	ACCEPT	Summary: HDA annotation from proteomics characterization of aorta extracellular matrix. Perlecan is a major ECM component in vascular tissues. Reason: Core localization. Perlecan is essential for vascular ECM organization and function. Supporting Evidence: PMID:20551380 2010 Jun 15. Proteomics characterization of extracellular space components in the human aorta.
GO:0031012 extracellular matrix	HDA PMID:23979707 SILAC-based proteomics of human primary endothelial cell mor...	ACCEPT	Summary: HDA annotation from SILAC proteomics of endothelial cell morphogenesis. Perlecan detected as ECM component during endothelial tube formation. Reason: Core localization. Perlecan is a key ECM component in angiogenesis and vascular development. Supporting Evidence: PMID:23979707 Epub 2013 Aug 26. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers.
GO:0005604 basement membrane	TAS PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β ne...	ACCEPT	Summary: TAS annotation from PMID:21126803 on endorepellin (perlecan domain V) and α2 integrin-mediated amyloid-beta neurotoxicity. While the study focuses on endorepellin function, it acknowledges perlecan's primary basement membrane localization. Reason: Core localization. Basement membrane is perlecan's primary and canonical localization where it performs essential structural and signaling functions. Supporting Evidence: PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.
GO:0006954 inflammatory response	TAS PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β ne...	KEEP AS NON CORE	Summary: TAS annotation from PMID:21126803. The study examines endorepellin's protective effects against Aβ neurotoxicity, which has inflammatory components. However, inflammatory response is not a core function of perlecan. Reason: Peripheral function. While perlecan and endorepellin may modulate inflammatory processes indirectly through Aβ binding and effects on integrin signaling, inflammatory response is not a primary or core function of perlecan. The main functions are structural ECM organization and growth factor signaling. Supporting Evidence: PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.
GO:0007420 brain development	TAS PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β ne...	ACCEPT	Summary: TAS annotation from PMID:21126803 on endorepellin and amyloid-beta. While this study focuses on Alzheimer's disease pathology rather than development, perlecan does play roles in blood-brain barrier formation and neural tissue development as documented in the deep research. Reason: Well-supported developmental function. Perlecan is essential for blood-brain barrier integrity, neural stem cell niches, and brain vascular development. Though not as central as skeletal functions, brain development represents an important role for perlecan. Supporting Evidence: PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.
GO:0016525 negative regulation of angiogenesis	TAS PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β ne...	ACCEPT	Summary: TAS annotation from PMID:21126803 on endorepellin. Endorepellin (perlecan domain V) exhibits potent anti-angiogenic activity through dual antagonism of VEGFR2 and α2β1 integrin, opposing the pro-angiogenic function of full-length perlecan. Reason: Well-characterized function of endorepellin. While full-length perlecan promotes angiogenesis, proteolytic cleavage generates endorepellin which negatively regulates angiogenesis. This represents an important biological switch in perlecan function and is a core activity of the endorepellin fragment. Supporting Evidence: file:human/HSPG2/HSPG2-deep-research-perplexity.md Endorepellin functions as a potent mediator of angiogenesis repression both in vitro and in vivo, exerting this effect through dual receptor antagonism by simultaneously engaging VEGFR2 and alpha2beta1 integrin at sites independent of the VEGFA binding site. Signaling through the alpha2beta1 integrin leads to actin disassembly and blockade of endothelial cell migration, which is necessary for capillary morphogenesis. PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.
GO:0030154 cell differentiation	TAS PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β ne...	KEEP AS NON CORE	Summary: TAS annotation from PMID:21126803. This study does not directly address cell differentiation. While perlecan influences chondrocyte differentiation in growth plates, this very broad term does not capture specific functions. Reason: Too general. While perlecan influences differentiation of multiple cell types (chondrocytes, endothelial cells, osteoprogenitors), this extremely broad term does not usefully describe perlecan's specific functions. More specific terms for chondrocyte differentiation or endochondral ossification would be preferable. Supporting Evidence: PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.
GO:0072359 circulatory system development	TAS PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β ne...	ACCEPT	Summary: TAS annotation from PMID:21126803. While this paper focuses on Alzheimer's pathology, perlecan is essential for vascular development as extensively documented in the deep research, with knockout mice showing cardiovascular defects. Reason: Core developmental function. Perlecan is essential for normal circulatory system development, with genetic ablation causing severe vascular defects and embryonic lethality. Well-supported by developmental studies in multiple model organisms. Supporting Evidence: PMID:21126803 Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.
GO:0006898 receptor-mediated endocytosis	ISS GO_REF:0000024	KEEP AS NON CORE	Summary: ISS annotation based on sequence similarity to mouse ortholog. PMID:21289173 demonstrates that perlecan cooperates with LRP1 in receptor-mediated endocytosis of amyloid-beta, with HSPG acting as a coreceptor for LRP1-mediated uptake. Reason: Non-core function. While perlecan participates in receptor-mediated endocytosis as a coreceptor for LRP1, particularly for amyloid-beta uptake, this is not a primary structural or signaling function. This represents a specialized role in Alzheimer's disease pathology rather than a core developmental or ECM function. Supporting Evidence: PMID:21289173 First, HSPG may function as a coreceptor for LRP1
GO:0098797 plasma membrane protein complex	TAS PMID:21289173 Heparan sulphate proteoglycan and the low-density lipoprotei...	KEEP AS NON CORE	Summary: TAS annotation from PMID:21289173 describing perlecan as part of an HSPG-LRP1 complex at the plasma membrane. The study shows that "LRP1 and HSPG are part of an immunoprecipitable complex at the cell surface." Reason: Non-core localization. While perlecan can be part of a plasma membrane protein complex with LRP1 for receptor-mediated endocytosis, this is not perlecan's primary localization. Perlecan's core locations are basement membranes and extracellular matrix, not plasma membrane complexes. This represents a specialized interaction in specific contexts (e.g., Aβ uptake). Supporting Evidence: PMID:21289173 In addition, LRP1 and HSPG are part of an immunoprecipitable complex at the cell surface to mediate lipid metabolism ( Wilsie and Orlando, 2003 )
GO:0005604 basement membrane	TAS PMID:8621634 Perlecan and basement membrane-chondroitin sulfate proteogly...	ACCEPT	Summary: TAS annotation from PMID:8621634 identifying perlecan as a basement membrane component in the Engelbreth-Holm-Swarm tumor matrix, which is a classical source of basement membrane proteins. Reason: Core localization. This paper characterizes perlecan as "basement membrane-specific heparan sulfate proteoglycan" and demonstrates its basement membrane localization by immunohistochemistry. Basement membrane is perlecan's primary and defining localization. Supporting Evidence: PMID:8621634 Both are, however, basement membrane components, although there are tissue-specific differences in their distribution
GO:0005925 focal adhesion	HDA PMID:21423176 Analysis of the myosin-II-responsive focal adhesion proteome...	KEEP AS NON CORE	Summary: HDA annotation from proteomics analysis of focal adhesion complexes during myosin-II-responsive adhesion maturation. Perlecan detected in focal adhesion proteome. Reason: Non-core localization. While perlecan may be present in or near focal adhesions where ECM interacts with integrin-based cell adhesion complexes, this is not a primary or characteristic localization for perlecan. Perlecan's core localizations are basement membranes and extracellular matrix. Focal adhesion presence likely reflects ECM-integrin interactions rather than a specific functional role at focal adhesions. Supporting Evidence: PMID:21423176 Analysis of the myosin-II-responsive focal adhesion proteome reveals a role for β-Pix in negative regulation of focal adhesion maturation.
GO:0070062 extracellular exosome	HDA PMID:23533145 In-depth proteomic analyses of exosomes isolated from expres...	KEEP AS NON CORE	Summary: HDA annotation from proteomics of extracellular exosomes isolated from expressed prostatic secretions in urine. Perlecan detected in exosome preparations. Reason: Non-core localization. Detection of perlecan in exosome preparations likely reflects extracellular contamination or non-specific association rather than a functional role in exosome biology. Perlecan is a massive secreted ECM protein not expected to be packaged into exosomes. This annotation does not represent a core function or localization. Supporting Evidence: PMID:23533145 2013 Apr 23. In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.
GO:0005615 extracellular space	HDA PMID:16502470 Human colostrum: identification of minor proteins in the aqu...	ACCEPT	Summary: HDA annotation from proteomics identification of proteins in human colostrum aqueous phase. Perlecan detected in extracellular fluids. Reason: Core localization. Perlecan is secreted into the extracellular space where it functions in basement membranes and ECM. Detection in biological fluids like colostrum confirms its extracellular localization. Supporting Evidence: PMID:16502470 Human colostrum: identification of minor proteins in the aqueous phase by proteomics.
GO:0070062 extracellular exosome	HDA PMID:19199708 Proteomic analysis of human parotid gland exosomes by multid...	KEEP AS NON CORE	Summary: HDA annotation from proteomics of human parotid gland exosomes. Perlecan detected in exosome preparations. Reason: Non-core localization. Similar to other exosome annotations, detection of this massive ECM protein in exosome preparations likely reflects contamination or non-specific association rather than true exosomal packaging. Not a functional or core localization for perlecan. Supporting Evidence: PMID:19199708 Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).
GO:0070062 extracellular exosome	HDA PMID:19056867 Large-scale proteomics and phosphoproteomics of urinary exos...	KEEP AS NON CORE	Summary: HDA annotation from large-scale proteomics of urinary exosomes. Perlecan detected in exosome preparations. Reason: Non-core localization. Detection in exosome preparations does not represent a core function. Given perlecan's size (468 kDa) and role as an ECM structural protein, presence in exosomes likely reflects extracellular contamination rather than functional exosomal packaging. Supporting Evidence: PMID:19056867 2008 Dec 3. Large-scale proteomics and phosphoproteomics of urinary exosomes.
GO:0005576 extracellular region	TAS Reactome:R-HSA-3814820	ACCEPT	Summary: TAS annotation from Reactome pathway "HSPG2 (perlecan) is cleaved by BMP1, TLL1, TLL2, Cathepsin L1". Documents proteolytic processing of perlecan in the extracellular region by BMP1-tolloid metalloproteinases and cathepsin L to generate endorepellin. Reason: Core localization and function. Proteolytic cleavage of perlecan to generate endorepellin is a key regulatory mechanism occurring in the extracellular region.
GO:0005576 extracellular region	TAS Reactome:R-HSA-2396337	ACCEPT	Summary: TAS annotation from Reactome pathway "HSPG2 binds FGF2(10-155), Fibronectin matrix, Transthyretin tetramer, PDGFA homodimer, PDGFB homodimer". Documents perlecan's binding interactions with growth factors and ECM proteins occurring in the extracellular region. Reason: Core localization and function. Perlecan's binding of growth factors (FGF-2, PDGF) and ECM proteins (fibronectin) in the extracellular region represents core functions.
GO:0005576 extracellular region	TAS Reactome:R-HSA-2396395	ACCEPT	Summary: TAS annotation from Reactome pathway "HSPG2 (perlecan) binds alpha-dystroglycan". Documents perlecan's interaction with dystroglycan, which occurs in the extracellular region at sites like the neuromuscular junction. Reason: Core localization. Perlecan interacts with dystroglycan in basement membranes, particularly at the neuromuscular junction, representing a key structural interaction in the extracellular region.
GO:0005576 extracellular region	TAS Reactome:R-HSA-4084505	ACCEPT	Summary: TAS annotation from Reactome pathway "Laminins bind HSPG2". Documents perlecan's binding to laminins, critical basement membrane proteins, occurring in the extracellular region. Reason: Core localization and function. Perlecan-laminin interactions are essential for basement membrane assembly and function in the extracellular region.
GO:0005576 extracellular region	TAS Reactome:R-HSA-976734	ACCEPT	Summary: TAS annotation from Reactome pathway "Amyloid fibrils have additional components". Documents perlecan as a component of amyloid plaques in Alzheimer's disease, which form in the extracellular region. Reason: Valid localization. While not a core function, perlecan's presence in amyloid plaques in the extracellular region is well-documented and relevant to Alzheimer's disease pathology.
GO:0005576 extracellular region	TAS Reactome:R-HSA-9914537	ACCEPT	Summary: TAS annotation from Reactome pathway "DGC complex binds AGRN and HSPG2". Documents perlecan's binding to the dystroglycan complex (DGC) and agrin in the extracellular region at the neuromuscular junction. Reason: Core localization. Perlecan functions in the extracellular region at the neuromuscular junction where it interacts with the dystroglycan complex.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-1878002	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "XYLTs transfer Xyl to core protein". This documents the first step of heparan sulfate tetrasaccharide linker synthesis in the Golgi, where perlecan transits during biosynthesis. Reason: Non-core biosynthetic localization. All heparan sulfate proteoglycans transit through the Golgi for glycosaminoglycan chain synthesis and modification. This is a required biosynthetic compartment but not where perlecan carries out its biological functions.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-1889981	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "B4GALT7 transfers Gal group to xylosyl-unit of the tetrasaccharide linker". Documents heparan sulfate linker biosynthesis in Golgi during perlecan glycosylation. Reason: Non-core biosynthetic localization. Golgi transit is required for all secreted proteoglycans but represents a transient biosynthetic step, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-3560804	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective B4GALT7 does not transfer Gal to xylosyl-unit of the tetrasaccharide linker". Documents disease pathway affecting perlecan glycosylation in Golgi. Reason: Non-core biosynthetic localization. This documents biosynthetic machinery defects, not core perlecan function. Golgi is a transient biosynthetic compartment.
GO:0070062 extracellular exosome	HDA PMID:21362503 Protein profile of exosomes from trabecular meshwork cells.	KEEP AS NON CORE	Summary: HDA annotation from proteomics of exosomes from trabecular meshwork cells. Perlecan detected in exosome preparations. Reason: Non-core localization. Similar to other exosome annotations, detection of this large ECM structural protein in exosome preparations likely reflects contamination. Not a functional localization. Supporting Evidence: PMID:21362503 Epub 2011 Mar 8. Protein profile of exosomes from trabecular meshwork cells.
GO:0043202 lysosomal lumen	TAS Reactome:R-HSA-1667005	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Heparanase (HPSE) cleaves heparan sulfate from its proteoglycan (lysosome)". Documents degradation of perlecan's heparan sulfate chains by heparanase in lysosomes during turnover. Reason: Non-core degradation localization. While perlecan can be taken up and degraded in lysosomes, this represents a catabolic endpoint rather than a functional localization. Perlecan's functions occur in the extracellular space, not in lysosomes.
GO:0043202 lysosomal lumen	TAS Reactome:R-HSA-2024084	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "HS-GAGs translocate to the lysosome for degradation". Documents transport of heparan sulfate proteoglycans including perlecan to lysosomes for degradation. Reason: Non-core degradation localization. Lysosomal degradation is a catabolic process, not a site where perlecan performs its biological functions. This is a terminal degradation pathway.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2022851	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "EXT1:EXT2 transfers GlcNAc to the heparan chain". Documents heparan sulfate chain elongation in Golgi during perlecan biosynthesis. Reason: Non-core biosynthetic localization. Golgi transit for heparan sulfate synthesis is required but represents transient biosynthetic processing, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2022856	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "EXT1:EXT2 transfers GlcA to heparan". Documents heparan sulfate chain elongation in Golgi. Reason: Non-core biosynthetic localization. Golgi transit for HS synthesis is required but represents transient biosynthetic processing, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2022860	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "NDST1-4 can sulfate a glucosamine residue in heparan to form heparan sulfate". Documents HS sulfation in Golgi. Reason: Non-core biosynthetic localization. HS modifications occur in Golgi during biosynthesis but not where perlecan functions biologically.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2022887	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "NDST1-4 N-deacetylates GlcNAc residues in heparan". Documents HS modification in Golgi. Reason: Non-core biosynthetic localization. Golgi modifications of HS are biosynthetic steps, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2024108	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Some HSPGs are secreted to the plasma membrane". Documents trafficking of perlecan through Golgi to secretion. Reason: Non-core biosynthetic localization. Golgi is a transient biosynthetic and trafficking compartment, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2076383	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "HS3ST1 sulfates GlcN at C3 in heparan sulfate". Documents HS sulfation in Golgi. Reason: Non-core biosynthetic localization. HS sulfation is a biosynthetic modification step in Golgi, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2076392	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "EXT1:EXT2 transfers GlcA to heparan". Documents HS chain elongation in Golgi. Reason: Non-core biosynthetic localization. Golgi HS biosynthesis is transient, not where perlecan functions.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2076419	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "HS6STs sulfate GlcN at C6 in heparan sulfate/heparin". Documents HS sulfation in Golgi. Reason: Non-core biosynthetic localization. HS sulfation in Golgi is biosynthetic processing, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2076508	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "HS2ST1 trimer sulfates IdoA at C2 in heparan sulfate". Documents HS sulfation in Golgi. Reason: Non-core biosynthetic localization. Golgi HS modifications are biosynthetic steps, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-2076611	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "HS3ST2-6 sulfate GlcN at C3 in heparan sulfate". Documents HS sulfation in Golgi. Reason: Non-core biosynthetic localization. HS sulfation is biosynthetic processing in Golgi, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-3656254	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective EXT2 does not transfer GlcNAc to heparan chain". Documents disease mutations affecting HS biosynthesis. Reason: Non-core biosynthetic localization. Documents disease mutations in HS biosynthesis enzymes, not core perlecan function. Golgi is transient biosynthetic compartment.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-3656257	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective EXT1 does not transfer GlcA to heparan". Documents disease mutations affecting HS biosynthesis. Reason: Non-core biosynthetic localization. Documents disease mutations in HS biosynthesis, not core perlecan function. Golgi is transient biosynthetic compartment.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-3656261	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective EXT1 does not transfer GlcNAc to heparan chain". Documents disease mutations affecting HS biosynthesis. Reason: Non-core biosynthetic localization. Documents disease mutations in HS biosynthesis enzymes, not core perlecan function.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-3656267	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective EXT2 does not transfer GlcA to heparan". Documents disease mutations affecting HS biosynthesis. Reason: Non-core biosynthetic localization. Documents disease mutations in HS biosynthesis, not core perlecan function.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-9036285	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective EXT1 does not transfer GlcA to heparan". Documents disease mutations affecting HS biosynthesis. Reason: Non-core biosynthetic localization. Documents disease mutations in HS biosynthesis, not core perlecan function.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-9036289	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective EXT2 does not transfer GlcA to heparan". Documents disease mutations affecting HS biosynthesis. Reason: Non-core biosynthetic localization. Documents disease mutations in HS biosynthesis, not core perlecan function.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-9953259	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "EXTL3 dimer transfers GlcNAc to the GAG linker". Documents HS linker synthesis in Golgi. Reason: Non-core biosynthetic localization. Golgi HS linker synthesis is biosynthetic processing, not functional localization.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-1678694	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Heparanase 2 (HPSE2) binds heparan sulfate proteoglycans". Documents HPSE2 binding to HSPGs including perlecan. Reason: Non-core localization. While heparanase 2 binds perlecan's heparan sulfate chains, this interaction occurs wherever perlecan is localized (primarily ECM/basement membranes). The pathway annotation implies plasma membrane localization, but this is not a characteristic or primary localization for perlecan.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-2024084	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "HS-GAGs translocate to the lysosome for degradation". Documents trafficking of HSPGs from plasma membrane to lysosomes. Reason: Non-core localization. This documents a degradative trafficking pathway. While perlecan may transit through or near the plasma membrane during internalization, this is not a primary functional localization. Perlecan's core functions occur in basement membranes and ECM, not at the plasma membrane.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-2024108	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Some HSPGs are secreted to the plasma membrane". Documents secretion of HSPGs. Reason: Non-core localization. While perlecan is secreted and some HSPGs associate with plasma membranes, perlecan's primary destination is the extracellular matrix and basement membranes, not the plasma membrane. This annotation likely reflects general HSPG secretion pathways rather than perlecan-specific localization.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-2404131	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "LRPs transport extracellular CR:atREs:HSPG:apoE to cytosol". Documents lipoprotein uptake involving HSPGs and LRP receptors at the plasma membrane. Reason: Non-core localization. While perlecan can participate in LRP-mediated endocytosis processes at the cell surface, this is not a primary localization. Perlecan's core functions occur in basement membranes and ECM, not at the plasma membrane.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-2423785	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "CR:atREs binds apoE and HSPG". Documents carotenoid-retinoid complexes binding apoE and HSPGs. Reason: Non-core localization and function. This documents a specialized lipoprotein metabolism interaction at the cell surface. While perlecan can interact with apoE-containing complexes, this is not a core function and plasma membrane is not a primary perlecan localization.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-2429643	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "NREH hydrolyses atREs (HSPG:apoE) to atROL and FAs". Documents metabolism of internalized lipids involving HSPGs. Reason: Non-core localization and function. This documents a metabolic pathway involving HSPGs as coreceptors. Plasma membrane is not a primary perlecan localization, and this represents a peripheral function.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-9694579	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Spike glycoprotein of SARS-CoV-2 binds ACE2 on host cell". Documents SARS-CoV-2 interaction with cell surface HSPGs during viral entry. Reason: Non-core and non-physiological. While HSPGs including perlecan may facilitate SARS-CoV-2 attachment to cells, this is pathogen exploitation of cell surface glycans, not a physiological function. This does not represent a core function or characteristic localization of perlecan.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-9694661	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "TMPRSS2 Mediated SARS-CoV-2 Spike Protein Cleavage and Endocytosis". Documents SARS-CoV-2 viral entry involving HSPGs. Reason: Non-core and non-physiological. SARS-CoV-2 exploitation of HSPGs is not a physiological perlecan function. Plasma membrane is not a characteristic perlecan localization.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-9698988	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Direct Host Cell Membrane Fusion and Release of SARS-CoV-2 Nucleocapsid". Documents SARS-CoV-2 viral entry. Reason: Non-core and non-physiological. Viral exploitation of HSPGs is not a physiological perlecan function. Plasma membrane is not a characteristic perlecan localization.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-9699007	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "FURIN Mediated SARS-CoV-2 Spike Protein Cleavage and Endocytosis". Documents SARS-CoV-2 viral entry involving HSPGs. Reason: Non-core and non-physiological. SARS-CoV-2 exploitation of HSPGs is not a physiological perlecan function. Plasma membrane is not a characteristic perlecan localization.
GO:0005886 plasma membrane	TAS Reactome:R-HSA-9836899	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "sG binds to HSPGs". Documents viral glycoprotein (sG) binding to heparan sulfate proteoglycans. Reason: Non-core and likely non-physiological. Viral protein exploitation of HSPGs is not a physiological perlecan function. Plasma membrane is not a characteristic perlecan localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-1667005	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Heparanase (HPSE) cleaves heparan sulfate from its proteoglycan (lysosome)". Actually documents lysosomal degradation, not Golgi localization. Reason: Non-core degradation localization. Despite Golgi annotation, this pathway actually describes lysosomal heparanase activity. Both Golgi biosynthesis and lysosomal degradation are non-core localizations representing biosynthetic/catabolic endpoints rather than functional sites.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-1889955	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "B3GAT dimers transfer GlcA to tetrasaccharide linker". Documents HS linker biosynthesis in Golgi. Reason: Non-core biosynthetic localization. Golgi HS linker synthesis is transient biosynthetic processing, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-1889978	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "B3GALT6 transfers Gal to the tetrasaccharide linker". Documents HS linker biosynthesis in Golgi. Reason: Non-core biosynthetic localization. Golgi HS linker synthesis is transient biosynthetic processing, not functional localization.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-3560802	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective B3GAT3 does not transfer GlcA to tetrasaccharide linker". Documents disease mutations affecting HS biosynthesis. Reason: Non-core biosynthetic localization. Documents disease mutations in HS biosynthesis enzymes, not core perlecan function. Golgi is transient biosynthetic compartment.
GO:0005796 Golgi lumen	TAS Reactome:R-HSA-4420365	KEEP AS NON CORE	Summary: TAS annotation from Reactome pathway "Defective B3GALT6 does not transfer Gal to the tetrasaccharide linker". Documents disease mutations affecting HS biosynthesis. Reason: Non-core biosynthetic localization. Documents disease mutations in HS biosynthesis enzymes, not core perlecan function. Golgi is transient biosynthetic compartment.
GO:0005515 protein binding	IPI PMID:12604605 Perlecan protein core interacts with extracellular matrix pr...	MODIFY	Summary: IPI annotation showing interaction with ECM1 (Q16610). PMID:12604605 demonstrates perlecan C-terminus interacts with ECM1 C-terminus, a glycoprotein involved in bone formation and angiogenesis. Reason: Protein binding is uninformative. Better terms would capture perlecan's specific molecular functions such as "extracellular matrix structural constituent" or molecular adaptor activity for organizing ECM components. Proposed replacements: extracellular matrix structural constituent molecular adaptor activity Supporting Evidence: PMID:12604605 Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis.
GO:0005515 protein binding	IPI PMID:11956183 The type XIII collagen ectodomain is a 150-nm rod and capabl...	MODIFY	Summary: IPI annotation showing interaction with COL13A1 (Q5TAT6). PMID:11956183 demonstrates type XIII collagen ectodomain binds perlecan along with fibronectin, nidogen-2, and heparin. Reason: Protein binding is uninformative. Better terms would capture perlecan's specific role in extracellular matrix organization through binding multiple ECM components including collagens. Proposed replacements: extracellular matrix structural constituent molecular adaptor activity Supporting Evidence: PMID:11956183 The type XIII collagen ectodomain is a 150-nm rod and capable of binding to fibronectin, nidogen-2, perlecan, and heparin.

Core Functions

Cross-linking basement membrane proteins (laminin, collagen IV, nidogens, fibrillin-1) and providing compression resistance through negatively charged heparan sulfate chains that attract water and cations

Molecular Function:

extracellular matrix structural constituent conferring compression resistance

Cellular Locations:

basement membrane extracellular matrix

Sequestering and presenting growth factors (FGF-2, FGF-18, VEGF, BMP-2, PDGF) to their cognate receptors via heparan sulfate chains (domain I, domain V) and core protein domains (domain III), forming ternary signaling complexes that activate downstream pathways

Molecular Function:

growth factor binding

Directly Involved In:

angiogenesis circulatory system development brain development

Cellular Locations:

basement membrane extracellular matrix

Substrates:

FGF-2 FGF-18 VEGFA BMP-2 PDGFB

Bridging laminin and collagen IV networks through multivalent interactions that organize basement membrane architecture

Molecular Function:

molecular adaptor activity

Cellular Locations:

basement membrane

Supporting Evidence:

file:human/HSPG2/HSPG2-deep-research-perplexity.md
Perlecan functions as a critical cross-linking component of basement membranes, interacting with and stabilizing the major basement membrane proteins including laminin, type IV collagen, and nidogens. Through its multiple binding partners, perlecan bridges and stabilizes the laminin network with the type IV collagen network within basement membranes.

Localizing acetylcholinesterase to neuromuscular junctions through binding interactions that anchor the synaptic enzyme for proper neurotransmission

Molecular Function:

molecular adaptor activity

Directly Involved In:

protein localization to synapse

Cellular Locations:

neuromuscular junction neuron projection

Supporting Evidence:

PMID:14702351
The collagen-tailed form of acetylcholinesterase (A(12)-AChE) appears to be localized at the neuromuscular junction in association with the transmembrane dystroglycan complex through binding of its collagenic tail (ColQ) to the proteoglycan perlecan.

Antagonizing VEGF-mediated angiogenesis through dual receptor blockade (endorepellin fragment binds VEGFR2 and α2β1 integrin at sites distinct from VEGFA binding, inducing VEGFR2 dephosphorylation and suppressing pro-angiogenic signaling)

Molecular Function:

signaling receptor binding

Directly Involved In:

negative regulation of angiogenesis

Cellular Locations:

extracellular region

Supporting Evidence:

PMID:21596751
Here, we show that both perlecan and endorepellin bind directly and with high affinity to both VEGF receptors 1 and 2, in a region that differs from VEGFA-binding site. In both human and porcine endothelial cells, this interaction evokes a physical down-regulation of both the α2β1 integrin and VEGFR2.
PMID:23374253
Indeed, we found that LG1/2 did not bind Ig1-3, but did bind with high affinity to Ig3-5, distal to the known VEGFA binding site, i.e., Ig2-3. Moreover, we found that LG1/2 blocked the rapid VEGFA activation of VEGFR2 at Tyr1175 in endothelial cells.

References

GO_REF:0000002

Gene Ontology annotation through association of InterPro records with GO terms.

GO_REF:0000024

Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity.

GO_REF:0000033

Annotation inferences using phylogenetic trees

GO_REF:0000043

Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping

GO_REF:0000044

Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt.

GO_REF:0000117

Electronic Gene Ontology annotations created by ARBA machine learning models

GO_REF:0000120

Combined Automated Annotation using Multiple IEA Methods.

PMID:11956183

The type XIII collagen ectodomain is a 150-nm rod and capable of binding to fibronectin, nidogen-2, perlecan, and heparin.

PMID:12604605

Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis.

PMID:12900424

A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth.

PMID:14702351

C-terminal and heparin-binding domains of collagenic tail subunit are both essential for anchoring acetylcholinesterase at the synapse.

PMID:16502470

Human colostrum: identification of minor proteins in the aqueous phase by proteomics.

PMID:19056867

Large-scale proteomics and phosphoproteomics of urinary exosomes.

PMID:19199708

Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).

PMID:20551380

Proteomics characterization of extracellular space components in the human aorta.

PMID:21126803

Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.

PMID:21289173

Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake.

PMID:21362503

Protein profile of exosomes from trabecular meshwork cells.

PMID:21423176

Analysis of the myosin-II-responsive focal adhesion proteome reveals a role for β-Pix in negative regulation of focal adhesion maturation.

PMID:21596751

Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

PMID:23374253

Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells.

PMID:23533145

In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

PMID:23658023

Comparative proteomic analysis of supportive and unsupportive extracellular matrix substrates for human embryonic stem cell maintenance.

PMID:23979707

SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers.

PMID:25037231

Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.

PMID:27068509

Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins.

PMID:27559042

Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation.

PMID:28327460

Comprehensive proteomic characterization of stem cell-derived extracellular matrices.

PMID:28675934

Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.

PMID:8621634

Perlecan and basement membrane-chondroitin sulfate proteoglycan (bamacan) are two basement membrane chondroitin/dermatan sulfate proteoglycans in the Engelbreth-Holm-Swarm tumor matrix.

Reactome:R-HSA-1592314

HSPG2 (perlecan) degradation by MMP3, plasmin, (MMP12)

Reactome:R-HSA-1667005

Heparanase (HPSE) cleaves heparan sulfate from its proteoglycan (lysosome)

Reactome:R-HSA-1678694

Heparanase 2 (HPSE2) binds heparan sulfate proteoglycans

Reactome:R-HSA-1878002

XYLTs transfer Xyl to core protein

Reactome:R-HSA-1889955

B3GAT dimers transfer GlcA to tetrasaccharide linker

Reactome:R-HSA-1889978

B3GALT6 transfers Gal to the tetrasaccharide linker

Reactome:R-HSA-1889981

B4GALT7 transfers Gal group to xylosyl-unit of the tetrasaccharide linker

Reactome:R-HSA-2022851

EXT1:EXT2 transfers GlcNAc to the heparan chain

Reactome:R-HSA-2022856

EXT1:EXT2 transfers GlcA to heparan

Reactome:R-HSA-2022860

NDST1-4 can sulfate a glucosamine residue in heparan to form heparan sulfate (HS)

Reactome:R-HSA-2022887

NDST1-4 N-deacetylates GlcNAc residues in heparan

Reactome:R-HSA-2024084

HS-GAGs translocate to the lysosome for degradation

Reactome:R-HSA-2024108

Some HSPGs are secreted to the plasma membrane

Reactome:R-HSA-2076383

HS3ST1 sulfates GlcN at C3 in heparan sulfate

Reactome:R-HSA-2076392

EXT1:EXT2 transfers GlcA to heparan

Reactome:R-HSA-2076419

HS6STs sulfate GlcN at C6 in heparan sulfate/heparin

Reactome:R-HSA-2076508

HS2ST1 trimer sulfates IdoA at C2 in heparan sulfate

Reactome:R-HSA-2076611

HS3ST2-6 sulfate GlcN at C3 in heparan sulfate

Reactome:R-HSA-2396337

HSPG2 binds FGF2(10-155), Fibronectn matrix, Transthyretin tetramer, PDGFA homodimer, PDGFB homodimer

Reactome:R-HSA-2396395

HSPG2 (perlecan) binds alpha-dystroglycan

Reactome:R-HSA-2404131

LRPs transport extracellular CR:atREs:HSPG:apoE to cytosol

Reactome:R-HSA-2423785

CR:atREs binds apoE and HSPG

Reactome:R-HSA-2429643

NREH hydrolyses atREs (HSPG:apoE) to atROL and FAs

Reactome:R-HSA-2534240

HSPG2 (perlecan) degradation by MMP14, MMP15

Reactome:R-HSA-3560802

Defective B3GAT3 does not transfer GlcA to tetrasaccharide linker

Reactome:R-HSA-3560804

Defective B4GALT7 does not transfer Gal to xylosyl-unit of the tetrasaccharide linker

Reactome:R-HSA-3656254

Defective EXT2 (in EXT1:EXT2) does not transfer GlcNAc to the heparan chain

Reactome:R-HSA-3656257

Defective EXT1 (in EXT1:EXT2) does not transfer GlcA to heparan

Reactome:R-HSA-3656261

Defective EXT1 (in EXT1:EXT2) does not transfer GlcNAc to the heparan chain

Reactome:R-HSA-3656267

Defective EXT2 (in EXT1:EXT2) does not transfer GlcA to heparan

Reactome:R-HSA-3814820

HSPG2 (perlecan) is cleaved by BMP1, TLL1, TLL2, Cathepsin L1

Reactome:R-HSA-4084505

Laminins bind HSPG2

Reactome:R-HSA-4088220

Endorepellin binds alpha2beta1 integrin

Reactome:R-HSA-4088281

Endorepellin binds KDR (VEGFR2)

Reactome:R-HSA-4420365

Defective B3GALT6 does not transfer Gal to the tetrasaccharide linker

Reactome:R-HSA-9036285

Defective EXT1 (in EXT1:EXT2) does not transfer GlcA to heparan

Reactome:R-HSA-9036289

Defective EXT2 (in EXT1:EXT2) does not transfer GlcA to heparan

Reactome:R-HSA-9694579

Spike glycoprotein of SARS-CoV-2 binds ACE2 on host cell

Reactome:R-HSA-9694661

TMPRSS2 Mediated SARS-CoV-2 Spike Protein Cleavage and Endocytosis

Reactome:R-HSA-9698988

Direct Host Cell Membrane Membrane Fusion and Release of SARS-CoV-2 Nucleocapsid

Reactome:R-HSA-9699007

FURIN Mediated SARS-CoV-2 Spike Protein Cleavage and Endocytosis

Reactome:R-HSA-976734

Amyloid fibrils have additional components

Reactome:R-HSA-9836899

sG binds to HSPGs

Reactome:R-HSA-9914537

DGC complex binds AGRN and HSPG2

Reactome:R-HSA-9940993

PXYLP1 dephosphorylates Xyl moiety

Reactome:R-HSA-9941039

FAM20B phosphorylates Xyl moiety

Reactome:R-HSA-9953259

EXTL3 dimer transfers GlcNAc to the GAG linker

Reactome:R-NUL-2534170

Degradation of HSPG2 by Mmp13 and Ctss

📚 Additional Documentation

Deep Research Falcon

(HSPG2-deep-research-falcon.md)

provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:11:58.822722'
end_time: '2025-12-14T17:20:08.851208'
duration_seconds: 490.03
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: HSPG2
gene_symbol: HSPG2
uniprot_accession: P98160
protein_description: 'RecName: Full=Basement membrane-specific heparan sulfate proteoglycan
core protein; Short=HSPG; AltName: Full=Perlecan; Short=PLC; Contains: RecName:
Full=Endorepellin; Contains: RecName: Full=LG3 peptide; Flags: Precursor;'
gene_info: Name=HSPG2;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881);
EGF-like_dom. (IPR000742); Ig-like_dom. (IPR007110); Ig-like_dom_sf. (IPR036179)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 24

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

UniProt Accession: P98160
Protein Description: RecName: Full=Basement membrane-specific heparan sulfate proteoglycan core protein; Short=HSPG; AltName: Full=Perlecan; Short=PLC; Contains: RecName: Full=Endorepellin; Contains: RecName: Full=LG3 peptide; Flags: Precursor;
Gene Information: Name=HSPG2;
Organism (full): Homo sapiens (Human).
Protein Family: Not specified in UniProt
Key Domains: ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881); EGF-like_dom. (IPR000742); Ig-like_dom. (IPR007110); Ig-like_dom_sf. (IPR036179)

MANDATORY VERIFICATION STEPS:

Check if the gene symbol "HSPG2" matches the protein description above
Verify the organism is correct: Homo sapiens (Human).
Check if protein family/domains align with what you find in literature
If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'HSPG2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene HSPG2 (gene ID: HSPG2, UniProt: P98160) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

UniProt Accession: P98160
Protein Description: RecName: Full=Basement membrane-specific heparan sulfate proteoglycan core protein; Short=HSPG; AltName: Full=Perlecan; Short=PLC; Contains: RecName: Full=Endorepellin; Contains: RecName: Full=LG3 peptide; Flags: Precursor;
Gene Information: Name=HSPG2;
Organism (full): Homo sapiens (Human).
Protein Family: Not specified in UniProt
Key Domains: ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881); EGF-like_dom. (IPR000742); Ig-like_dom. (IPR007110); Ig-like_dom_sf. (IPR036179)

MANDATORY VERIFICATION STEPS:

Check if the gene symbol "HSPG2" matches the protein description above
Verify the organism is correct: Homo sapiens (Human).
Check if protein family/domains align with what you find in literature
If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

Research Target:

Please provide a comprehensive research report on the gene HSPG2 (gene ID: HSPG2, UniProt: P98160) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Research plan and verification
- Identity confirmed: HSPG2 encodes perlecan (UniProt P98160), a very large basement membrane heparan sulfate proteoglycan with five modular domains and N‑terminal HS chains; the C‑terminus corresponds to domain V, also called endorepellin, which contains laminin G (LG) modules including LG3. Organism: Homo sapiens. Reported domains and modular organization (EGF-like, Ig-like, ConA-like folds) align with recent domain-centric reviews of human perlecan structure and function (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, melrose2024diverseandmultifunctional pages 1-2).

HSPG2/perlecan: key concepts and definitions
- Definition and architecture: Perlecan is a ~470–500 kDa basement membrane-specific proteoglycan with five protein domains (I–V). It bears three HS chains at the N-terminus (domain I), with occasional CS substitutions, and undergoes proteolytic processing that yields bioactive C-terminal fragments, notably endorepellin (domain V) and its LG3 sub-fragment (Jun 2024; https://doi.org/10.1002/pgr2.22; Jul 2024; https://doi.org/10.1002/jsp2.1362) (mongiat2024proteoglycansofbasement pages 3-4, mongiat2024proteoglycansofbasement pages 4-6, melrose2024diverseandmultifunctional pages 1-2).
- Localization: Perlecan is a core scaffold of basement membranes across vasculature and epithelia, and a key component of the pericellular matrix in cartilage, meniscus, tendon/ligament, and intervertebral disc (IVD) (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, melrose2024diverseandmultifunctional pages 1-2).
- Primary molecular functions: (i) structural basement membrane scaffold and PCM stabilizer; (ii) HS-mediated sequestration and presentation of morphogens/growth factors (e.g., FGF family, VEGF, PDGF, BMPs); (iii) regulation of mechanotransduction and mechano‑osmotic signaling in weight‑bearing tissues; (iv) anti‑angiogenic signaling via the processed C‑terminal endorepellin (Jun 2024; https://doi.org/10.1002/pgr2.22; Jul 2024; https://doi.org/10.1002/jsp2.1362) (mongiat2024proteoglycansofbasement pages 4-6, melrose2024diverseandmultifunctional pages 1-2).

Structure, domains, processing, and interactions
- Domain organization: Domain I (HS attachment) drives growth-factor binding/delivery; domain II includes LDL receptor-like features; domain III interacts with select FGFs; domain IV contains multiple Ig-like repeats supporting adhesion and cytoskeletal signaling; domain V (endorepellin) is composed of three LG modules interspersed with EGF-like repeats (Jul 2024; https://doi.org/10.1002/jsp2.1362; Jun 2024; https://doi.org/10.1002/pgr2.22) (melrose2024diverseandmultifunctional pages 1-2, mongiat2024proteoglycansofbasement pages 3-4).
- HS chain biology: The N-terminal HS chains govern high-affinity binding and spatial presentation of HS-binding cytokines and growth factors, modulating their gradients and signaling competence in tissues (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 1-3).
- Proteolytic processing to endorepellin/LG3: Perlecan is proteolytically processed to release endorepellin (domain V) and further to LG3. Endorepellin is an angiostatic matricryptin; LG3 is the principal angiostatic module. BMP‑1/Tolloid-like metalloproteases (and cathepsin L downstream of caspase‑3) mediate cleavage, with a reported specific site between Asn4196 and Asp4197 that yields intact LG3 (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 6-7).

Cellular/extracellular localization and pathway context
- Basement membrane and pericellular niches: Perlecan assembles into vascular/endothelial BMs and avascular cartilaginous PCM, where it stabilizes ECM networks, coordinates receptor signaling, and buffers mechanical loads (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, melrose2024diverseandmultifunctional pages 1-2).
- Receptor and pathway interactions: Perlecan modulates VEGFA/VEGFR2 signaling by localizing VEGF and stabilizing receptor-ligand complexes; supports FGF2–FGFR co‑receptor functions via HS; engages integrins (α2β1, α5β1) and dystroglycan to influence adhesion and downstream kinases; in bone/cartilage/muscle, perlecan contributes to mechanosensing and mechanoresponsive gene programs (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 4-6, mongiat2024proteoglycansofbasement pages 1-3).
- Anti‑angiogenic signaling of endorepellin: Endorepellin exerts dual receptor antagonism by engaging integrin α2β1 and VEGFR2 in endothelial cells, triggering focal adhesion and actin cytoskeleton disassembly and inducing angiostasis at nanomolar concentrations (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 6-7).

Mechanobiology roles and tissue contexts
- Mechanotransduction: In IVD, cartilage, tendon/ligament and other weight-bearing tissues, perlecan’s HS-rich PCM confers mechano‑osmotic transduction that supports cell viability, metabolic buffering in acidic/hypoxic milieus, and remodeling during chondroid metaplasia associated with repair (Jul 2024; https://doi.org/10.1002/jsp2.1362; Jan 2023; https://doi.org/10.1016/j.lfs.2022.121190) (melrose2024diverseandmultifunctional pages 1-2, zhao2023perlecanrolesin pages 1-2).
- Developmental essentiality: Hspg2-null mice exhibit embryonic lethality with severe cardiac and cartilaginous defects, emphasizing perlecan’s nonredundant role in BM integrity and morphogenesis (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731) (lavorgna2023perlecanareview pages 1-2).

Genetics and human disease (2023–2024 updates prioritized)
- Allelic spectrum: Biallelic HSPG2 variants underlie a continuum from Schwartz–Jampel syndrome (SJS; myotonia, chondrodysplasia) through dyssegmental dysplasia (DDSH; lethal neonatal form) to Rolland–Desbuquois-type dyssegmental dysplasia (DDRD; nonlethal). Counts summarized: 44 SJS and 8 DDSH HSPG2 pathogenic variants reported; a 2024 DDRD study identified four pathogenic variants—c.9970G>A (p.G3324R), c.559C>T (p.R187X), c.7006+1G>A, c.11562+2T>G—and a shared founder haplotype of 85,973 bp across five patients, supporting allelism of SJS/DDSH/DDRD and genotype–phenotype correlations (Feb 2024; https://doi.org/10.1038/s10038-024-01229-6) (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2).
- Neuromusculoskeletal and vascular implications: Clinical and experimental syntheses highlight perlecan’s roles in angiogenesis, BBB stability, neuromuscular function, cartilage/bone homeostasis, and sarcopenia/OA associations, with therapeutic exploration of domain V in CNS models (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731) (lavorgna2023perlecanareview pages 1-2).

Cancer biology and endothelial contexts
- Tumor microenvironment: Perlecan’s HS chains can trap and present pro‑angiogenic factors (e.g., FGF2), sustaining endothelial signaling; in contrast, proteolytic remodeling releases endorepellin, which disrupts angiogenic signaling and can reduce tumor neovascularization and growth (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 4-6, mongiat2024proteoglycansofbasement pages 1-3, mongiat2024proteoglycansofbasement pages 6-7).

Cardiovascular and renal findings
- Endothelial dysfunction signature: Secretome profiling under calciprotein particle exposure reports diminished extracellular release of BM components including perlecan/HSPG2 and fibronectin, supporting the use of soluble BM proteins as markers of endothelial stress; these changes co-occur with increased soluble CD59 (Oct 2024; https://doi.org/10.3390/ijms252111382) (melrose2025glycosaminoglycansinstructivebiomolecules pages 10-12).

Applications and real‑world implementations
- Regenerative medicine and biomaterials: Recombinant perlecan domain V/endorepellin is explored as an anti‑angiogenic and pro‑homeostatic additive to biomaterials; perlecan’s domain-specific growth factor–binding and mechano‑osmotic properties are being leveraged in disc and cartilage repair strategies and in vascular biomaterials to modulate endothelial behavior (Jul 2024; https://doi.org/10.1002/jsp2.1362; Jun 2024; https://doi.org/10.1002/pgr2.22) (melrose2024diverseandmultifunctional pages 1-2, mongiat2024proteoglycansofbasement pages 4-6).

Expert opinions and synthesis
- Consensus from 2023–2024 reviews places perlecan as a central BM/PCM hub that integrates structural scaffolding with growth factor presentation and mechanobiology. Its processed C‑terminal endorepellin provides a tunable, context‑dependent switch that counters angiogenic drive by dual targeting VEGFR2 and α2β1 integrin, while N‑terminal HS chains potentiate morphogen signaling. Genetic data in rare skeletal dysplasias provide human evidence for dosage‑sensitive requirements in BM integrity and skeletal development (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jun 2024; https://doi.org/10.1002/pgr2.22; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, mongiat2024proteoglycansofbasement pages 1-3, mongiat2024proteoglycansofbasement pages 4-6, melrose2024diverseandmultifunctional pages 1-2).

Relevant statistics and data
- Variant counts in HSPG2-related disorders: 44 SJS and 8 DDSH pathogenic variants reported; DDRD founder cohort (n=5) sharing an ~86 kb haplotype with four pathogenic variants identified (Feb 2024; https://doi.org/10.1038/s10038-024-01229-6) (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2).
- Endorepellin potency: Recombinant endorepellin exhibits angiostatic activity at nanomolar concentrations and accumulates perivascularly in tumors; LG3 is the principal anti‑angiogenic effector module (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 6-7).

Structured summary table
| Category | Key points | Recent sources (Year; DOI/URL) |
|---|---|---|
| Identity / structure | - Five modular domains (I–V)
- N-terminal heparan sulfate (HS) chains; occasional CS
- C-terminal domain V = endorepellin containing LG modules (LG3) | 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2); 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2) |
| Localization | - Basement membranes (vascular BMs)
- Pericellular matrix of cartilage, IVD, tendon
- Vascular endothelium/perivascular regions | 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2); 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2) |
| Functions | - Structural BM scaffold and PCM stabilizer
- Sequestration/presentation of HS-binding growth factors (FGFs, VEGF, PDGF)
- Mechanotransduction / mechano-osmotic regulation | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6); 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2) |
| Angiogenesis | - Endorepellin (domain V) exerts angiostatic activity via dual antagonism of VEGFR2 and integrin α2β1
- LG3 module is primary angiostatic effector; active at nanomolar ranges | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 6-7) |
| Processing | - Proteolytic release of endorepellin fragments (LG1-2 and LG3)
- BMP-1 / Tolloid-like metalloproteases (and other proteases) mediate cleavage; reported cleavage site near Asn4196–Asp4197 | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 6-7); 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6) |
| Pathways | - VEGFA → VEGFR2 axis (HS modulates VEGF localization/activity)
- Integrins: α2β1, α5β1 mediate cell adhesion/signaling
- Dystroglycan and FGF2–FGFR interactions for morphogen delivery | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6); 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2) |
| Genetics & disease | - Allelic disorders: Schwartz–Jampel syndrome (SJS), Silverman–Handmaker DDSH, DDRD (Rolland–Desbuquois)
- Reported: ~44 pathogenic variants for SJS; 8 for DDSH; 2024 study identified DDRD HSPG2 variants and a shared 85,973 bp founder haplotype | 2024; https://doi.org/10.1038/s10038-024-01229-6 (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2); 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2) |
| Cancer | - Perlecan/HSPG2 modulates tumor angiogenesis and microenvironmental growth-factor availability
- Fragmentation (endorepellin) can be angiostatic; intact HS can promote growth-factor signaling | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6); 2023; https://doi.org/10.1016/j.lfs.2022.121190 (zhao2023perlecanrolesin pages 1-2) |
| Cardiovascular / renal | - Perlecan essential for BM integrity in cardiac development and vascular stability
- Altered perlecan levels linked to vascular/BM dysfunction and disease contexts | 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2); 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6) |
| Musculoskeletal | - Critical in PCM of cartilage/IVD for osmotic/mechanical buffering
- HS-dependent binding/presentation of FGFs and other morphogens supports chondrogenesis and repair | 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2); 2023; https://doi.org/10.1016/j.lfs.2022.121190 (zhao2023perlecanrolesin pages 1-2) |
| Applications | - Recombinant perlecan domain V / endorepellin explored for anti-angiogenic and regenerative biomaterials
- Perlecan-functionalized scaffolds for vascular and cartilage tissue engineering under investigation | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6); 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2) |

Table: Concise summary table of perlecan (HSPG2) identity, functions, processing, disease links, pathways, and recent sources (2023–2024) to support deeper review and citation.

Compliance with identification safeguards
- Symbol disambiguation: HSPG2 uniquely corresponds to human perlecan; all cited articles explicitly discuss human perlecan/HSPG2 or mammalian orthologs in the context of human-relevant biology. Domain descriptions (EGF-like, Ig-like, ConA-like folds) align with UniProt and recent domain-centric reviews (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, melrose2024diverseandmultifunctional pages 1-2).

Cited sources (selection; URLs and dates)
- Lavorgna TR et al., Frontiers in Physiology, May 30, 2023. Perlecan: a review of its role in neurologic and musculoskeletal disease. https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2).
- Melrose J & Guilak F., JOR Spine, Jul 2024. Diverse and multifunctional roles for perlecan (HSPG2) in repair of the intervertebral disc. https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2).
- Mongiat M. et al., Proteoglycan Research, Jun 2024. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6, mongiat2024proteoglycansofbasement pages 3-4, mongiat2024proteoglycansofbasement pages 6-7, mongiat2024proteoglycansofbasement pages 1-3).
- Zhao XX et al., Life Sciences, Jan 2023. Perlecan: roles in osteoarthritis and potential treating target. https://doi.org/10.1016/j.lfs.2022.121190 (zhao2023perlecanrolesin pages 1-2).
- Farshadyeganeh P. et al., Journal of Human Genetics, Feb 2024. Dyssegmental dysplasia Rolland–Desbuquois type is caused by pathogenic variants in HSPG2. https://doi.org/10.1038/s10038-024-01229-6 (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2).
- Melrose J., International Journal of Molecular Sciences, Mar 2025. Glycosaminoglycans… https://doi.org/10.3390/ijms26062554 (mechanobiology context; includes statements on perlecan in vascular/cartilage; use cautiously). (melrose2025glycosaminoglycansinstructivebiomolecules pages 10-12)

Limitations
- Some clinically focused 2024–2025 primary data (e.g., specific cancer radioresistance mechanisms; additional cardiovascular/renal genetics) were not available in the present evidence extraction and thus are summarized at pathway level from recent reviews. Where detailed study-level statistics were not present in the extracted evidence, claims are restricted to review-supported mechanistic consensus and explicitly dated/cited (mongiat2024proteoglycansofbasement pages 4-6, mongiat2024proteoglycansofbasement pages 1-3).

References

(lavorgna2023perlecanareview pages 1-2): Tessa R. Lavorgna, Timothy E. Gressett, Wesley H. Chastain, and Gregory J. Bix. Perlecan: a review of its role in neurologic and musculoskeletal disease. Frontiers in Physiology, May 2023. URL: https://doi.org/10.3389/fphys.2023.1189731, doi:10.3389/fphys.2023.1189731. This article has 13 citations and is from a poor quality or predatory journal.
(melrose2024diverseandmultifunctional pages 1-2): James Melrose and Farshid Guilak. Diverse and multifunctional roles for perlecan (hspg2) in repair of the intervertebral disc. JOR Spine, Jul 2024. URL: https://doi.org/10.1002/jsp2.1362, doi:10.1002/jsp2.1362. This article has 7 citations and is from a peer-reviewed journal.
(mongiat2024proteoglycansofbasement pages 3-4): Maurizio Mongiat, Gabriel Pascal, Evelina Poletto, Davion M. Williams, and Renato V. Iozzo. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. Proteoglycan research, Jun 2024. URL: https://doi.org/10.1002/pgr2.22, doi:10.1002/pgr2.22. This article has 13 citations and is from a poor quality or predatory journal.
(mongiat2024proteoglycansofbasement pages 4-6): Maurizio Mongiat, Gabriel Pascal, Evelina Poletto, Davion M. Williams, and Renato V. Iozzo. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. Proteoglycan research, Jun 2024. URL: https://doi.org/10.1002/pgr2.22, doi:10.1002/pgr2.22. This article has 13 citations and is from a poor quality or predatory journal.
(mongiat2024proteoglycansofbasement pages 1-3): Maurizio Mongiat, Gabriel Pascal, Evelina Poletto, Davion M. Williams, and Renato V. Iozzo. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. Proteoglycan research, Jun 2024. URL: https://doi.org/10.1002/pgr2.22, doi:10.1002/pgr2.22. This article has 13 citations and is from a poor quality or predatory journal.
(mongiat2024proteoglycansofbasement pages 6-7): Maurizio Mongiat, Gabriel Pascal, Evelina Poletto, Davion M. Williams, and Renato V. Iozzo. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. Proteoglycan research, Jun 2024. URL: https://doi.org/10.1002/pgr2.22, doi:10.1002/pgr2.22. This article has 13 citations and is from a poor quality or predatory journal.
(zhao2023perlecanrolesin pages 1-2): Xiao-Xuan Zhao, Wen-Qing Xie, Wen-Feng Xiao, Heng-Zhen Li, Shinen Naranmandakh, Olivier Bruyere, Jean-Yves Reginster, and Yu-Sheng Li. Perlecan: roles in osteoarthritis and potential treating target. Life Sciences, 312:121190, Jan 2023. URL: https://doi.org/10.1016/j.lfs.2022.121190, doi:10.1016/j.lfs.2022.121190. This article has 7 citations and is from a peer-reviewed journal.
(farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2): Paniz Farshadyeganeh, Takahiro Yamada, Hirofumi Ohashi, Gen Nishimura, Hiroki Fujita, Yuriko Oishi, Misa Nunode, Shuku Ishikawa, Jun Murotsuki, Yuri Yamashita, Shiro Ikegawa, Tomoo Ogi, Eri Arikawa-Hirasawa, and Kinji Ohno. Dyssegmental dysplasia rolland–desbuquois type is caused by pathogenic variants in hspg2 - a founder haplotype shared in five patients. Journal of Human Genetics, 69:235-244, Feb 2024. URL: https://doi.org/10.1038/s10038-024-01229-6, doi:10.1038/s10038-024-01229-6. This article has 2 citations and is from a peer-reviewed journal.
(melrose2025glycosaminoglycansinstructivebiomolecules pages 10-12): James Melrose. Glycosaminoglycans, instructive biomolecules that regulate cellular activity and synaptic neuronal control of specific tissue functional properties. International Journal of Molecular Sciences, Mar 2025. URL: https://doi.org/10.3390/ijms26062554, doi:10.3390/ijms26062554. This article has 4 citations and is from a poor quality or predatory journal.

Citations

mongiat2024proteoglycansofbasement pages 1-3
mongiat2024proteoglycansofbasement pages 6-7
lavorgna2023perlecanareview pages 1-2
melrose2025glycosaminoglycansinstructivebiomolecules pages 10-12
melrose2024diverseandmultifunctional pages 1-2
mongiat2024proteoglycansofbasement pages 4-6
zhao2023perlecanrolesin pages 1-2
mongiat2024proteoglycansofbasement pages 3-4
https://doi.org/10.3389/fphys.2023.1189731;
https://doi.org/10.1002/jsp2.1362
https://doi.org/10.1002/pgr2.22;
https://doi.org/10.1002/jsp2.1362;
https://doi.org/10.1002/pgr2.22
https://doi.org/10.1016/j.lfs.2022.121190
https://doi.org/10.3389/fphys.2023.1189731
https://doi.org/10.1038/s10038-024-01229-6
https://doi.org/10.3390/ijms252111382
https://doi.org/10.3390/ijms26062554
https://doi.org/10.3389/fphys.2023.1189731,
https://doi.org/10.1002/jsp2.1362,
https://doi.org/10.1002/pgr2.22,
https://doi.org/10.1016/j.lfs.2022.121190,
https://doi.org/10.1038/s10038-024-01229-6,
https://doi.org/10.3390/ijms26062554,

Deep Research Perplexity

(HSPG2-deep-research-perplexity.md)

provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2025-11-10T17:08:21.439515'
end_time: '2025-11-10T17:10:49.839046'
duration_seconds: 148.4
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: HSPG2
gene_symbol: HSPG2
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
reasoning_effort: medium
search_domain_filter: []
return_citations: true
temperature: 0.0
citation_count: 45

Question

Gene Research for Functional Annotation

Please provide a comprehensive research report on the gene HSPG2 (HSPG2) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Output

Let me analyze the provided search results to create a comprehensive research report on HSPG2 (the gene encoding perlecan).

Key information to organize:
1. Gene basics and structure
2. Protein structure and domains
3. Primary functions
4. Molecular mechanisms
5. Expression patterns
6. Disease associations
7. Evolutionary aspects
8. Recent research developments

Major themes I need to cover:
- HSPG2 encodes perlecan, a massive heparan sulfate proteoglycan
- Located in basement membranes and extracellular matrix
- Five distinct domains with different functions
- Involved in growth factor signaling, cell adhesion, angiogenesis
- Critical for cartilage and bone development
- Role at neuromuscular junctions
- Disease associations: Schwartz-Jampel syndrome, dyssegmental dysplasia
- Recent applications in cancer biology and tissue repair

Let me structure this as:
1. Title
2. Overview paragraph with key findings
3. Gene structure and protein architecture
4. Biochemical properties and domain functions
5. Role in growth factor signaling
6. Extracellular matrix organization and barrier function
7. Developmental processes and tissue-specific functions
8. Disease implications
9. Evolutionary conservation
10. Contemporary research and therapeutic applications
11. Conclusion

Now I'll write this comprehensively with proper citations.

Comprehensive Research Report on HSPG2: The Heparan Sulfate Proteoglycan Perlecan and Its Multifunctional Role in Basement Membrane Organization and Cell Signaling

Executive Summary

The HSPG2 gene encodes perlecan, one of the largest known human proteins with a molecular weight of approximately 468,829 daltons and consisting of 4,391 amino acids, making it one of the most massive proteins encoded in the human genome[1][7]. This multidomain heparan sulfate proteoglycan serves as a critical structural and regulatory component of basement membranes and extracellular matrices throughout the body, where it functions as a molecular hub coordinating cell signaling, tissue development, and barrier formation[1][2]. The protein's distinctive "string of pearls" appearance in electron microscopy reflects its modular architecture comprising five structurally and functionally distinct domains that interact with a vast array of extracellular matrix components, cell surface receptors, and bioactive molecules including growth factors[1][7]. Perlecan's essential role in normal physiology is underscored by the severe pathological consequences of HSPG2 mutations, which range from the relatively mild Schwartz-Jampel syndrome characterized by myotonia and chondrodysplasia to the perinatally lethal dyssegmental dysplasia, Silverman-Handmaker type[1][2][10]. Recent research has revealed perlecan's emerging importance in cancer biology, tissue repair mechanisms, and its dual capacity to both promote and inhibit angiogenesis depending on its proteolytic state, establishing it as a promising therapeutic target across multiple disease contexts[6][9][14][31][34].

Molecular Architecture and Structural Organization of HSPG2/Perlecan

Gene Structure and Protein Synthesis

The HSPG2 gene, located on chromosome 1, spans substantial genomic sequence and produces a cDNA encoding approximately 13.2 kilobases of open reading frame[5]. The mature protein core, excluding its 21-amino acid signal peptide, achieves a molecular weight of approximately 466,564 daltons, making perlecan substantially larger than typical extracellular matrix proteins[5]. The protein undergoes extensive post-translational modification through the covalent attachment of glycosaminoglycan side chains, primarily heparan sulfate but also potentially chondroitin sulfate or other sulfated glycosaminoglycans depending on the cell type of origin[13][27]. Perlecan domain I contains three attachment sites for these bulky glycosaminoglycan chains located at serines 65, 71, and 76, with each chain typically measuring 70-100 kilodaltons, while additional attachment sites have been identified on domain V[1][13][27]. This extensive glycosaminoglycan substitution not only dramatically increases the effective molecular weight of secreted perlecan but also imparts the property of high negative charge density through sulfate and carboxyl groups, fundamentally altering the protein's biochemical properties and biological activities[1][7].

Multidomain Architecture and Structural Homologies

Perlecan's core protein structure comprises five distinct modular domains, each with unique structural motifs and functional capabilities, reflecting evolution through gene duplication and exon shuffling from ancient ancestral proteins[1][7]. Domain I, occupying approximately amino acids 1-195, presents a structure unique among proteoglycans and serves as the attachment site for the three major heparan sulfate chains; notably, while these glycosaminoglycan chains are not strictly required for correct protein folding and secretion, their absence or reduced sulfation substantially decreases perlecan's ability to interact with matrix proteins[1][7]. Domain II consists of four repeats highly homologous to the ligand-binding region of the low-density lipoprotein receptor, each containing six conserved cysteine residues and a pentapeptide motif DGSDE that mediates ligand binding, with additional isolated immunoglobulin-like fold structures providing further structural stability through disulfide bonding[1][7][26]. Domain III exhibits structural homology to domains IVa and IVb of laminin, forming an inflexible rod-like structure maintained by disulfide linkages within laminin-EGF domains, and has been identified as a binding site for specific fibroblast growth factors such as FGF-7 and FGF-18[1][7][22]. Domain IV comprises the largest module of perlecan with greater than 2,000 residues, containing 21 immunoglobulin-type repeats similar to those found in neural cell adhesion molecules, with an early segment comprising approximately 29 hydrophobic amino acids potentially enabling interaction with plasma membranes[5][7]. Domain V, homologous to the carboxyl-terminal G-domain of laminin and related merosin proteins, contains three globular regions interspersed with four epidermal growth factor-like repeats and is responsible for self-assembly interactions critical to basement membrane formation; notably, this domain can also be modified by glycosaminoglycan attachment and when proteolytically cleaved generates the biologically distinct fragment known as endorepellin[5][7][13][14].

Heparan Sulfate Side Chains and Their Biochemical Significance

Structure and Enzymatic Modification of Heparan Sulfate

The heparan sulfate chains attached to perlecan represent highly modified linear polysaccharides composed of repeating disaccharide units of glucuronic acid or iduronic acid linked to N-acetylglucosamine or N-sulfoglucosamine[8][11]. These chains undergo extensive enzymatic modification after synthesis, including N-sulfation, O-sulfation at multiple positions on uronic acid and glucosamine residues, and epimerization of glucuronic acid to iduronic acid, creating a vast structural diversity of heparan sulfate sequences within single molecules and between different cell sources[11][19][33]. This heterogeneous sulfation pattern directly determines the biological activity of heparan sulfate, with higher levels of sulfation generally facilitating interactions with growth factors and their receptors; oligosaccharide sequences containing eight or more sugar residues demonstrate optimal activity in facilitating ternary complex formation with growth factors and growth factor receptors[11]. The biologic importance of this sulfation pattern is illustrated by studies examining perlecan glycosaminoglycan sulfation levels, which revealed that puromycin treatment of human glomerular endothelial cells alters sulfation of perlecan's heparan sulfate chains through decreased expression of sulfate transferase enzymes, thereby reducing glycosaminoglycan chain stability without affecting core protein expression[1].

Functional Consequences of Glycosaminoglycan Composition

The specific glycosaminoglycan substitution pattern of perlecan exhibits remarkable cell-type specificity, with endothelial cells characteristically synthesizing a monosubstituted heparan sulfate glycoform, while keratinocytes produce perlecan substituted with the unusual combination of keratan sulfate, heparan sulfate, and chondroitin sulfate chains[13][27]. Mouse perlecan contains additional attachment sites on domain V at serine 3593 or serine 3250 depending on the isoform, expanding the potential for glycosaminoglycan substitution beyond the domain I sites[27]. The substitution of perlecan with chondroitin sulfate rather than heparan sulfate creates profound functional consequences; in mice engineered to lack heparan sulfate attachment sites on perlecan (Hspg2Δ3/Δ3), approximately 40% of synthesized perlecan is substituted with heparin sulfate while 60% receives chondroitin sulfate substitution, compared to the 100% heparin sulfate substitution in wild-type perlecan, with dramatic effects on protein function despite normal core protein synthesis[39].

Perlecan's Role in Growth Factor Sequestration and Presentation

Fibroblast Growth Factor Binding and Signaling

Perlecan functions as a critical regulator of fibroblast growth factor signaling through multiple mechanisms coordinated by its heparan sulfate chains and specific protein domains. Perlecan isolated from developing growth plates has been demonstrated to bind FGF-2 via its heparan sulfate side chains and FGF-18 via domain III of its core protein, with these interactions mediating the action of growth factors on FGF receptors[1][7][8]. The structural basis of FGF-heparan sulfate interactions involves recognition of FGF binding sites comprising the β1-β2 loop and extended β10-β12 region, with each FGF ligand demonstrating discrete binding affinity for heparan sulfate chains, thereby generating FGF-specific morphogenetic gradients essential for cell specification during development and regeneration[8]. During endochondral ossification, perlecan likely plays a critical role in sequestration and controlled delivery of FGF-2 and FGF-18, ensuring appropriate temporal and spatial availability of these mitogens for chondrocyte proliferation and differentiation[1][7]. The mechanistic basis for FGF-HSPG-FGFR signaling involves formation of a 2:2:2 ternary dimer complex, wherein heparan sulfate chains promote formation of the 2:2:2 structure through engagement of ligand and receptors bound within the dimer, leading to conformational changes that stabilize FGFR dimerization and enable juxtaposition and activation of the intracellular tyrosine kinase domains[8][11].

Vascular Endothelial Growth Factor Signaling in Angiogenesis

Perlecan exerts pro-angiogenic activity principally through modulation of the FGF-2 pathway via its heparan sulfate side chains, which present this ligand to its receptor and induce complex downstream signaling cascades promoting cell proliferation, motility, and adhesion[31]. Additionally, perlecan positively affects angiogenesis through modulation of the VEGFR2-Neuropilin-1 signaling axis, achieved by directly presenting heparan sulfate-bound VEGFA to VEGFR2 or indirectly delivering VEGFA to its receptor following heparanase-mediated cleavage[31]. In growth plate formation, perlecan in cartilage plays a critical role in promoting VEGF signaling essential for endochondral bone formation by promoting angiogenesis required for cartilage matrix remodeling; in perlecan-deficient mice, despite significantly elevated VEGFA mRNA and protein expression in hypertrophic chondrocytes, vascular invasion into the hypertrophic zone is severely impaired due to absent perlecan-mediated VEGFR activation[21][37][40]. This paradox demonstrates that elevated growth factor availability cannot compensate for the absence of perlecan's structural and signaling functions, indicating that cartilage perlecan specifically activates VEGF/VEGFR signaling on endothelial cells and facilitates osteoblast migration into the growth plate[21][40]. Research employing hind-limb ischemia models has further demonstrated that the heparan sulfate side chains of perlecan constitute important mediators of the angiogenic response to ischemia through a mechanism involving upregulation of VEGF expression, with perlecan heparan sulfate-deficient mice exhibiting significantly decreased VEGF mRNA and protein expression with impaired endothelial cell density in ischemic muscle[24].

Bone Morphogenetic Protein and Other Growth Factor Interactions

Perlecan domain I, through its attached heparan sulfate chains, binds not only fibroblast and vascular endothelial growth factors but also bone morphogenetic proteins and platelet-derived growth factor, promoting cellular proliferation, differentiation, and tissue development[41][27]. Perlecan domain III specifically binds platelet-derived growth factor, with the highest binding affinity for PDGF-BB mapped to domain III-2 at nanomolar concentrations, with lower binding affinities evident for domains I, IV-1, and V, while PDGF-AA binds preferentially to domain III-2[41]. Perlecan's ability to sequester and present these diverse growth factors to their cognate receptors explains both its essential role in normal tissue development and its potential pathological effects when absent, as demonstrated by the severe skeletal abnormalities observed in perlecan null mice.

Basement Membrane Organization and Barrier Function

Structural Role in Basement Membrane Assembly

Perlecan functions as a critical cross-linking component of basement membranes, interacting with and stabilizing the major basement membrane proteins including laminin, type IV collagen, and nidogens. The core protein of perlecan contains multiple domains with capacity to interact with these structural proteins; domain IV contains tandem immunoglobulin repeats capable of interacting with other proteins containing similar repeats in zipper-like fashion, including cell surface ectodomains and other immunoglobulin superfamily members[33]. Perlecan's domains I and II interact with central regions of fibrillin-1, a critical component of elastic fiber architecture[33]. Notably, through its multiple binding partners, perlecan bridges and stabilizes the laminin network with the type IV collagen network within basement membranes; perlecan can self-interact and further stabilize these protein networks through homophilic binding[33][28]. The contribution of perlecan to basement membrane stabilization is particularly evident in the glomerular basement membrane of the kidney, where perlecan, along with agrin, laminin, type IV collagen, and nidogens, comprises the specialized filtration barrier; mature glomerular basement membranes contain primarily agrin as their primary heparan sulfate proteoglycan component, although during glomerulogenesis both perlecan and agrin demonstrate co-distribution followed by redistribution of perlecan to the mesangial matrix[42].

Hydration and Charge Density Properties

Through its abundant heparan sulfate side chains bearing high negative charge density from sulfate and carboxyl moieties, perlecan regulates the hydration of basement membranes by providing charged surfaces that attract cations and osmotically active water molecules[25][42]. This hydration capacity contributes to the basement membrane's physical properties and its ability to restrict diffusion of large molecules including plasma proteins[25]. Studies examining glomerular filtration have demonstrated that the heparan sulfate chains of perlecan play important roles in glomerular filtration, particularly for larger protein quantities; mice whose perlecan lacks heparan sulfate attachment sites (Hspg2Δ3/Δ3) exhibit proteinuria when administered bovine serum albumin intraperitoneally, indicating that heparan sulfate chains of perlecan contribute essentially to charge-based filtration in the glomerular basement membrane[39].

Endothelial Barrier Function in Vascular Tissues

In vascular tissues, perlecan serves as a key component of the vascular extracellular matrix, where it interacts with various other matrix components and helps maintain endothelial barrier function[1][7]. Perlecan simultaneously exerts opposing effects on vascular homeostasis: while promoting growth factor activity and stimulating endothelial growth and regeneration through FGF-2 interactions[1][7], perlecan simultaneously functions as a potent inhibitor of smooth muscle cell proliferation and is thus thought to help maintain vascular homeostasis by preventing inappropriate smooth muscle expansion[1][7][43]. This balance between endothelial growth promotion and smooth muscle inhibition appears critical for maintaining normal vascular function, and perturbations in perlecan expression or function are associated with pathological vascular remodeling.

Perlecan's Critical Functions in Skeletal Development and Growth Plate Biology

Growth Plate Development and Endochondral Ossification

Perlecan represents a key component of the extracellular matrix of cartilage where it is essential for normal growth plate development and long bone growth[1][7]. The dwarfism exhibited by perlecan null mice closely resembles the phenotype produced by activating mutations in the gene for FGFR3, a receptor for fibroblast growth factors, suggesting that perlecan's primary skeletal effect operates through modulation of FGF receptor signaling[1][7]. Perlecan's absence dramatically alters growth plate architecture; in perlecan-deficient mice, the growth plate is significantly wider but shorter due to severely impaired endochondral bone formation, despite hypertrophic chondrocyte differentiation occurring normally[21][40]. However, the crucial pathologic finding in perlecan-deficient mice is that removal of the hypertrophic matrix and calcified cartilage is inhibited, resulting in severely impaired vascular invasion into the hypertrophic zone and almost complete lack of bone marrow and trabecular bone formation[21][40]. This indicates that perlecan's role extends beyond growth factor presentation to include critical functions in vascular invasion and matrix remodeling essential for the transition from cartilage to bone.

Chondrocyte Regulation and Mechanotransduction

In articular cartilage, perlecan binds FGF-2 in the pericellular matrix and acts as a mechanotransducer, converting mechanical stimuli into biochemical signals that regulate chondrocyte behavior[8]. Perlecan's heparan sulfate chains may exert repressive control over chondrocytes in mature cartilage, which explains in part why cartilage has such a poor healing response[27]. In perlecan heparan sulfate-deficient mice (Hspg2 exon 3 null), chondrocytes display increased hypertrophic maturational changes and proliferative rates both in vitro and in vivo, with accelerated growth plate maturation, elevated glycosaminoglycan deposition, and exostosis formation in the intervertebral disc[27]. These findings indicate that perlecan heparan sulfate normally acts as a brake on chondrocyte maturation and matrix synthesis, and its absence leads to acceleration of these processes.

Bone Formation and Mineralization

Perlecan's role in bone formation is complex and appears to involve sequestration of heparin-binding growth factors; in osteoprogenitors from perlecan-deficient embryos, absence of perlecan leads to increased potential to differentiate, which appears to result from unleashing of heparin-binding growth factors normally sequestered by perlecan's heparan sulfate chains in the extracellular space[15]. During endochondral ossification, the altered organization of the chondrocyte territorial matrix in the absence of perlecan allows increased diffusion of heparin-binding growth factors from the periosteal compartment, a signal associated with enhanced bone formation and mineral apposition[15]. This mechanism is consistent with the established function of heparan sulfate proteoglycans in establishing heparin-binding growth factor gradients and perlecan's preferential expression at interfaces where a barrier is required, such as the chondro-osseous junction in the growth plate[15]. The enhanced mineralization observed in perlecan-deficient bones may further result from the protective role of perlecan and its heparan sulfate chains in preventing tissue mineralization through direct interaction with calcium phosphate mineral[15].

Perlecan at the Neuromuscular Junction

Organization and Function in Synaptic Architecture

Perlecan plays a critical role at the neuromuscular junction, the specialized synaptic region between nerve terminals and muscle fibers where signals are relayed to trigger muscle contraction[2][18]. At the neuromuscular junction, perlecan functions to maintain the stability of the extracellular matrix surrounding nerve bundles; loss of the protein results in axonal breakage and degeneration followed by synaptic retraction in the Drosophila larval neuromuscular junction model[3]. Perlecan localizes acetylcholinesterase in the neuromuscular junction and is of functional significance in neuromuscular control; in perlecan-null mice, acetylcholinesterase is absent at the neuromuscular junction[13]. A reduced amount of functional perlecan at the neuromuscular junction likely alters the balance of other molecules that signal when muscles should contract and when they should relax[2][18]. This altered balance results in continuous muscle contraction, leading to myotonia as observed in patients with Schwartz-Jampel syndrome[2][18].

Signaling Pathways in NMJ Development and Maintenance

In the Drosophila system, the perlecan homolog encoded by the trol gene has been suggested to play a signaling role at neuromuscular junctions by regulating Wingless diffusion, and recent research indicates that synaptic retraction observed with perlecan loss is independent of this role in Wingless signaling[3]. Instead, perlecan's primary role appears to be maintaining the stability of the extracellular matrix surrounding nerve bundles through its structural properties. The Wnt signaling pathway is also regulated by Trol and is important for formation of pre- and postsynaptic structures of the neuromuscular junction[22]. Perlecan interactions with various ECM proteins and receptors at the neuromuscular junction create a specialized microenvironment essential for both the development and maintenance of synaptic transmission.

Perlecan's Roles in Neural Tissues and Regeneration

Blood-Brain Barrier Integrity and Repair

Perlecan has critical roles in maintaining the structural integrity of the blood-brain barrier basement membrane, which serves to protect the central nervous system while controlling molecular transport between blood and neural tissue[44][47]. Perlecan domain V demonstrates neuroprotective and anti-inflammatory properties, making it a candidate for treatment of Alzheimer's disease and stroke[44]. Following cerebral artery occlusion stroke in animal models, perlecan domain V promotes angiogenic repair of the blood-brain barrier by facilitating pericyte recruitment through upregulation of PDGFRβ, which drives pericyte migration required for pericyte-endothelial tube repair interactions in the neurovascular unit[44]. Recombinant perlecan domain V is now available for blood-brain barrier repair strategies and, when decorated with heparan sulfate and chondroitin sulfate chains, functions as a vascular proteoglycan in its own right, supporting endothelial cell interactions equivalent to full-length perlecan[44].

Neural Stem Cell Niches and Neurogenesis

Perlecan-FGF-2 interactions in the neural stem cell niche (referred to as a fractone) regulate the survival, proliferation, and differentiation of neuroprogenitor stem cell populations in the subventricular zone and dentate gyrus of the hippocampus[44]. This function is particularly important for maintaining the capacity for adult neurogenesis throughout life. Recent studies have demonstrated that loss of perlecan or impaired FGF-2 signaling through heparan sulfate chains results in reduced neuroprogenitor populations and diminished adult neurogenesis[44].

Peripheral Nerve Regeneration

In peripheral nerve regeneration following injury, perlecan is present in basement membranes including the Schwann cell basal lamina and can bind fibronectin and appear in fibrillar matrices deposited by Schwann cells[47]. Through its covalently bonded heparan sulfate chains, perlecan binds other extracellular matrix proteins including laminin and various collagens[47]. Perlecan regulates many cell signaling events through interactions with fibroblast growth factor and vascular endothelial growth factor families to regulate vascularization, which is essential for nerve regeneration[47]. However, detailed roles of perlecan in peripheral nerve regeneration remain to be fully characterized[47].

Endorepellin: The Angiostatic C-Terminal Fragment of Perlecan

Proteolytic Generation and Structural Organization

The C-terminal domain V of perlecan, also known as endorepellin to signify its anti-endothelial and angiostatic properties, represents a biologically distinct fragment distinct from the intact parent molecule[9][14][31][34]. Endorepellin is an 85-kiloDalton glycoprotein consisting of three laminin-like globular repeats separated by two epidermal growth factor-like module doublets, organized in the sequence LG1-EGF1-EGF2-LG2-EGF3-EGF4-LG3[14][31][34]. The crystal structure of human perlecan LG3 has been solved at high resolution, revealing a 200-amino acid structure constructed as a 15-stranded anti-parallel β sandwich forming a jellyroll fold characteristic of laminin globular domains[14]. Endorepellin is not produced alone but must be proteolytically cleaved from secreted perlecan; generation of bioactive endorepellin is mediated by the activity of cathepsin L, the same enzyme involved in generation of endostatin, another anti-angiogenic protein[9][14][34]. The C-terminal LG3 domain is highly sensitive to proteolysis by the BMP1-Tolloid-like family of matrix metalloproteinases, which can further liberate the isolated LG3 fragment[9][14][34]. Once cleaved, endorepellin is found in similar regions as intact perlecan, primarily within the basement membrane of epithelial-lining organs and along the cardiovascular system, and notably increased levels of endorepellin have been identified in sarcopenia, the age-related loss of skeletal muscle mass and function[14][34].

Dual Receptor Antagonism and Signaling Mechanisms

Despite being a key region within the pro-angiogenic parent molecule perlecan, endorepellin functions as a potent mediator of angiogenesis repression both in vitro and in vivo, exerting this effect through dual receptor antagonism by simultaneously engaging VEGFR2 and α2β1 integrin at sites independent of the VEGFA binding site[9][14][31][34]. Endorepellin binds with similar affinity to both VEGFR1 and VEGFR2 as VEGFA itself; in competition binding assays, highly purified human recombinant endorepellin cannot be displaced from either receptor by molar excesses of recombinant VEGFA, demonstrating that endorepellin binds to a discrete region of VEGFR2 ectodomain that does not overlap with the VEGF ligand binding site[14]. Signaling through the α2β1 integrin leads to actin disassembly and blockade of endothelial cell migration, which is necessary for capillary morphogenesis[34]. Signaling through VEGFR2 induces dephosphorylation of the receptor via activation of Src homology protein phosphatase-1 and suppression of downstream pro-angiogenic effectors, especially attenuating VEGFA expression[9][14][34]. Endorepellin suppresses HIF-1α levels in endothelial cells and transcriptionally downregulates HIF1A and VEGFA mRNA expression, inhibiting VEGFA secretion under hypoxic conditions[9].

Autophagy Induction and Emerging Therapeutic Roles

A novel and emerging role of endorepellin is its ability to evoke autophagy by activating Peg3 and various canonical autophagic markers in endothelial cells[9][14]. This effect is specific for endothelial cells as these are the primary cells expressing both VEGFR2 and α2β1 integrin, the receptors mediating endorepellin's effects[34]. The biological properties of this natural endogenous protein establish endorepellin as a potential therapeutic agent against cancer and other diseases where angiogenesis is prominent[9][14][34]. Recombinant domain V and its fragments are now being explored as therapeutic agents for treatment of cancer, stroke, and tissue repair applications[17].

HSPG2 Mutations and Associated Genetic Diseases

Schwartz-Jampel Syndrome

More than 30 mutations in the HSPG2 gene have been identified in patients with Schwartz-Jampel syndrome, a rare autosomal recessive skeletal dysplasia characterized by varying degrees of myotonia (continuous involuntary muscle contraction) and chondrodysplasia[2][10]. Most mutations identified in Schwartz-Jampel syndrome patients reduce the amount of perlecan that is produced, while other mutations lead to a version of perlecan that is only partially functional[2][18]. In contrast to the severe dyssegmental dysplasia mutations, Schwartz-Jampel syndrome mutations result in different forms of perlecan in reduced levels that are secreted to the extracellular matrix and are likely partially functional[10]. A reduction in the amount or function of perlecan disrupts the normal development of cartilage and bone tissue, which underlies the chondrodysplasia observed in affected individuals[2][18]. The molecular basis of myotonia appears distinct from that of chondrodysplasia; a reduced amount of functional perlecan at the neuromuscular junction likely alters the balance of molecules that signal when muscles should contract and when they should relax, resulting in muscle contraction being triggered continuously[2][18].

Dyssegmental Dysplasia, Silverman-Handmaker Type

Mutations in the HSPG2 gene can cause dyssegmental dysplasia, Silverman-Handmaker type, a much more severe form of chondrodysplasia that is typically perinatally lethal[2][10]. Because of the very severe abnormalities associated with this condition, most affected individuals die before birth, are stillborn, or live only into early infancy[2][18]. At least seven HSPG2 gene mutations have been identified in people with this condition[2]. These mutations prevent the production or transport of any functional perlecan; a total lack of this protein significantly disrupts the development of cartilage and bone tissue, causing this very severe type of chondrodysplasia[2][10]. Unlike Schwartz-Jampel syndrome mutations which result in reduced levels of partially functional perlecan secreted into the extracellular matrix, dyssegmental dysplasia mutations result in truncated perlecan molecules that are not secreted into the extracellular matrix[10]. The degree of severity inversely correlates with the amount of perlecan being deposited into the extracellular matrix, with functional null mutations producing the most severe phenotype[48]. Clinical features of dyssegmental dysplasia, Silverman-Handmaker type include severe dwarfism, short and bowed limbs, flat facial features, anisospondyly, and encephalocele[48]. Mice with perlecan null mutations develop severe chondrodysplasia and typically die just after birth from respiratory failure, serving as excellent models for studying perlecan function[10].

Recent Findings on Splicing Variants and Evolutionary Changes

Recent large-scale functional screening studies have identified genetic variants with effects on exon inclusion in the HSPG2 gene; notably, a variant rs12737091 in the HSPG2 gene has an MaPSy function score of -4.95 and a SpliceAI donor gain score of 0.98, consistent with creation of a canonical splice donor motif, with RT-PCR validation confirming that this variant disrupts inclusion of the wild-type HSPG2 exon in favor of a truncated exon[55]. This variant is fixed in all three Neanderthal genomes and is found at low frequencies in non-African modern humans, suggesting differential selection between modern humans and archaic hominins[55].

Role of Perlecan in Tumor Biology and Cancer Metastasis

Dual Pro- and Anti-Tumorigenic Functions

Perlecan can either prevent or promote the progression of cancers to metastatic disease depending on its state and proteolytic processing in the tumor microenvironment[50][53]. Breast, prostate, lung, and renal cancers all preferentially metastasize to bone, which is characteristically a dense, perlecan-rich environment that is initially a "hostile" niche for cancer cells[50]. Driven by inflammation and cancer-associated fibroblast activity, production of perlecan and its enzymatic modifiers, which include matrix metalloproteinases, sulfatases, and heparanase, increases substantially in the reactive stroma surrounding growing and invading tumors[50][53]. These enzymatic modifiers promote degradation of the perlecan-rich stroma, which "flips the molecular switch" and converts the initially hostile stroma into a welcoming microenvironment that supports cancer dissemination and metastasis[50][53].

Radiotherapy Resistance in Prostate Cancer

Recent proteomic analysis of prostate cancer cells and their radioresistant derivatives has identified perlecan/HSPG2 as a critical regulator of cancer cell radiosensitivity[6][30][54]. In radioresistant prostate cancer cell lines, perlecan is upregulated compared to parental cells, and knockdown of perlecan/HSPG2 specifically sensitizes radioresistant cells to irradiation while the sensitivity of parental cells does not change[6][30][54]. This differential effect indicates a potential role for perlecan in suppressing tumor radioresistance through extracellular matrix remodeling mechanisms[6][30]. Validation in both androgen-independent DU145 cells and androgen-sensitive LNCaP cells supports perlecan/HSPG2 as a regulator of cell radiosensitivity and signposts it as a potential therapeutic target and biomarker for prostate cancer[6][30][54].

Cell Dormancy in Perivascular Niches

Vascular endothelial cell secretion of perlecan influences lung cancer cell dormancy in the perivascular niche, suggesting that perlecan contributes to maintaining tumor cells in a quiescent state before metastatic outgrowth[53]. Perlecan has recently been shown to be upregulated in cancer-associated fibroblasts in pancreatic cancer through secretion of TNFα from p53 gain-of-function cancer cells, with cancer cell education of cancer-associated fibroblasts and elevated perlecan secretion being responsible for generation of a prometastatic microenvironment[53].

Expression Patterns and Developmental Regulation

Tissue Distribution and Cell-Type Specific Expression

Perlecan exhibits ubiquitous distribution throughout the body, occurring in vascular, cartilaginous, fibro-cartilaginous, adipose, lymphoreticular systems, neural, bone and bone marrow stromal tissues[27]. HSPG2 expression begins in the early stages of embryogenesis, with perlecan detected along the cell surface of blastomeres at the two-cell stage and during the attachment phase of implantation at the exterior surface of the trophectoderm[48]. Following implantation, perlecan accumulates throughout the developing cardiovascular system and at sites of cartilage primordia[48]. At embryonic day 10.5, perlecan is found in vascularized tissues such as the heart, pericardium, blood vessel walls, and in cartilage primordia[48]. The highest deposition of perlecan occurs in cartilage undergoing endochondral ossification, such as the primordium of vertebral bodies and rib cartilage[48]. At later developmental stages, perlecan is expressed throughout the basal lamina of the embryo and organs such as the lung, kidney, liver, gastrointestinal tract, and brain[48].

Regulation of HSPG2 Promoter Activity

The HSPG2 gene promoter regulating perlecan expression contains multiple transcription factor binding sites, including conserved NFκB binding elements located more than 2.4 kilobases upstream of the transcriptional start site[57]. In response to TNF-α signaling, NFκB is translocated to the nucleus and binds to these distal NFκB elements in the HSPG2 promoter, upregulating perlecan expression in multiple cell types including stromal cells and cancer cell lines[57]. The HSPG2 promoter also contains conserved SMAD3 binding sites, indicating that transforming growth factor-beta signaling contributes to regulation of perlecan expression[57]. This regulation allows cells to respond to inflammatory stimuli and growth factor signaling by upregulating perlecan expression, which has profound implications for wound healing, tissue repair, and tumor microenvironment remodeling.

Evolutionary Conservation and Ancient Origins

Conservation Across Animal Phyla

Perlecan is highly conserved across species, and available data indicate that it has evolved from ancient ancestors through gene duplication and exon shuffling[1][7]. Phylogenetic analysis of HSPG2/perl transcripts reveals that the perlecan homologs from simple placozoans (Trichoplax adhaerens) and cnidarians (Nematostella vectensis) are most closely related to one another, in agreement with the commonly accepted view of basal metazoans' place on the metazoan evolutionary tree[56]. The T. adhaerens perl gene serves as a good proxy for the ancestral perl, suggesting that perlecan evolved before the divergence of most modern animal phyla[56]. The major finding from evolutionary studies is that HSPG2/perlecan first appears in the common ancestor of placozoans, cnidarians, and bilaterians, predating the metazoan ancestor as previously commonly thought[56]. Perlecan homologs have been identified in poriferan sponges, demonstrating that the gene's origins trace to the earliest multicellular animals[56]. Perl is expressed in both placozoans and the cnidarian N. vectensis, and is activated during regeneration of lost tissue in cnidarians[56]. The evolutionary conservation of perlecan's structure and function across more than 550 million years of animal evolution underscores its fundamental importance in basement membrane biology and tissue organization[51].

Contemporary Applications and Therapeutic Development

Recombinant Perlecan Fragments in Tissue Engineering

Recombinant fragments of perlecan, particularly domain I and domain V, have been proposed as therapeutic agents for multiple applications[17][27]. The protein component of perlecan domain I contains three glycosaminoglycan attachment sites that can be decorated with heparan sulfate, and recombinant perlecan domain I decorated with heparan sulfate has been incorporated into three-dimensional scaffolds for multiple therapeutic applications[27]. The incorporation of perlecan domain I into three-dimensional structures has resulted in increased retention of FGF-2 and BMP2 for cartilage repair and regeneration[27]. More recently, advances in fabrication and microfluidics have enabled production of growth factor gradients, an approach that has been utilized to generate chemotactic gradients with FGF-2 for directed tissue repair[27]. Recombinant perlecan domain V has been explored for stroke treatment and blood-brain barrier repair, and these approaches demonstrate significant potential in tissue repair and regeneration[44][17].

Perlecan in Wound Healing and Vascular Repair

Perlecan promotes angiogenic repair of skin wounds through FGF-2 sequestered by its domain I heparan sulfate chains[41]. In vascular repair, heparin-binding growth factors including FGF-2 bind to perlecan's heparan sulfate chains at sites of tissue injury, where heparanase released by inflammatory cells cleaves these chains to release heparin-binding growth factors directly at the site of injury[27][41]. Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxia-induced pulmonary hypertension through impaired FGF-2/FGFR1 interactions[41]. These findings establish perlecan as critical mediator of wound healing and angiogenic repair processes through growth factor sequestration and presentation.

Single Molecule Measurements and Mechanosensing

Atomic force microscopy-based single molecule force measurements have revealed that the core protein of purified full-length human perlecan is of suitable size to span the pericellular space of the lacunar canalicular system in bone, with a measured end-to-end length of 170 ± 20 nanometers and diameter of 2-4 nanometers[51]. Force pulling revealed a strong protein core that can withstand over 100 piconewtons of tension, well above the drag forces estimated to be exerted on individual osteocyte tethers[51]. Data fitting with an extensible worm-like chain model showed that the perlecan protein core has a mean elastic constant of 890 piconewtons and corresponding Young's modulus of 71 megapascals[51]. These biophysical properties establish perlecan as a strong but elastic tether in the lacunar canalicular system that can function as a mechanosensing element transmitting fluid flow information to osteocytes[51].

Molecular Degradation and Proteolytic Processing

Proteolytic Enzymes Acting on Perlecan

Cells can modify their extracellular matrix and basement membranes in response to signals or stress through the action of specific proteases on proteins in the extracellular environment[1]. Cathepsin S, a cysteine protease, moderately attenuates binding of FGF-positive cells to perlecan-positive substrates and is a potential protease acting on the core protein of perlecan in the basement membrane or stroma[1]. Release of heparan sulfate-bound basic FGF in culture can be achieved through treatment with stromelysin, heparitinase I, rat collagenase, and plasmin, indicating multiple proteolytic pathways capable of liberating growth factors from perlecan's heparan sulfate chains[1]. Heparanase is responsible for cleavage of the heparan sulfate chains of perlecan in the extracellular matrix, releasing growth factors bound to heparan sulfate[1]. Addition of heparanase to cell culture of epithelia in basement membrane causes an increase in epithelial cell proliferation due to FGF-10 release, demonstrating the functional consequences of heparan sulfate chain degradation[1].

Heparanase Activity in Pathological Contexts

Heparanase is a multitasking protein that exhibits enzymatic activity towards heparan sulfate chains, contributing to degradation and remodeling of extracellular matrix and basement membranes[32]. Through its enzymatic activity, heparanase catalyzes the cutting of side chains of heparan sulfate proteoglycans including perlecan, thereby promoting release and diffusion of various heparan sulfate-linked molecules including growth factors, cytokines, and enzymes[32]. In normal tissue and physiological conditions, heparanase exhibits only low levels of expression restricted to keratinocytes, trophoblasts, platelets, mast cells, and leukocytes[32]. In contrast, in pathological conditions such as tumor progression and metastasis, inflammation, and fibrosis, heparanase is substantially overexpressed[32]. The overexpression of heparanase in multiple cancer types contributes to the molecular switch that converts the perlecan-rich hostile stroma into a welcoming environment for metastatic progression[50][53].

Conclusion

The HSPG2 gene product, perlecan, represents one of the most multifunctional and structurally complex proteins in the human genome, serving as a critical architectural component of basement membranes while simultaneously functioning as a sophisticated molecular hub coordinating growth factor signaling, cell adhesion, angiogenesis, and developmental patterning. The protein's five distinct domains, each with unique structural features and binding capabilities, provide enormous biological versatility, enabling perlecan to interact with an extensive network of extracellular matrix components, cell surface receptors, and bioactive molecules. The absolute essentiality of perlecan for normal development is starkly illustrated by the severity of HSPG2 mutations, ranging from the inherited chondrodysplasias to perinatally lethal skeletal disorders. The discovery of endorepellin, a proteolytically cleaved fragment of perlecan with entirely opposite biological activities from the intact parent molecule, reveals how proteolytic processing can fundamentally reprogram the function of extracellular matrix components, with implications for understanding both physiological tissue remodeling and pathological processes including cancer progression. Emerging research has established perlecan as a critical regulator of tumor microenvironment composition and cancer radioresistance, positioning it as a promising therapeutic target in oncology. Furthermore, recent advances in recombinant protein technologies and biomaterial engineering have enabled development of perlecan domain-based therapeutics for tissue repair and regeneration, particularly for blood-brain barrier restoration following stroke and for guided tissue regeneration in orthopedic applications. The evolutionary conservation of perlecan's structure and function across more than half a billion years of animal evolution underscores its fundamental and irreplaceable role in the biology of multicellular organisms. Continued investigation of perlecan's molecular mechanisms, its proteolytic processing, and its interactions with other matrix components and signaling pathways will undoubtedly yield new insights into developmental biology, tissue homeostasis, and disease pathogenesis while revealing new therapeutic opportunities for conditions ranging from skeletal dysplasias to cancer and neurodegenerative diseases.

Citations

https://en.wikipedia.org/wiki/Perlecan
https://medlineplus.gov/genetics/gene/hspg2/
https://elifesciences.org/reviewed-preprints/88273
https://www.ncbi.nlm.nih.gov/gene/3339
https://pubmed.ncbi.nlm.nih.gov/1569102/
https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1452463/full
https://www.nature.com/articles/s41392-020-00222-7
https://pmc.ncbi.nlm.nih.gov/articles/PMC4769797/
https://pmc.ncbi.nlm.nih.gov/articles/PMC447613/
https://pmc.ncbi.nlm.nih.gov/articles/PMC4393358/
https://pmc.ncbi.nlm.nih.gov/articles/PMC3957550/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9010944/
https://pmc.ncbi.nlm.nih.gov/articles/PMC4137566/
https://journals.physiology.org/doi/pdf/10.1152/ajpcell.00113.2022
https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/biot.201700196
https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00631/full
https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2019.00018/full
https://pubmed.ncbi.nlm.nih.gov/22421594/
https://pmc.ncbi.nlm.nih.gov/articles/PMC6266596/
https://pmc.ncbi.nlm.nih.gov/articles/PMC2826543/
https://pubmed.ncbi.nlm.nih.gov/25249499/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9243345/
https://pubmed.ncbi.nlm.nih.gov/1744087/
https://www.aging-us.com/article/202789/text
https://anatomypubs.onlinelibrary.wiley.com/doi/full/10.1002/dvdy.274
https://pmc.ncbi.nlm.nih.gov/articles/PMC4753091/
https://pmc.ncbi.nlm.nih.gov/articles/PMC6316874/
https://pmc.ncbi.nlm.nih.gov/articles/PMC11115568/
https://onlinelibrary.wiley.com/doi/10.1002/jsp2.1362
https://journals.physiology.org/doi/full/10.1152/ajpcell.00018.2022?doi=10.1152%2Fajpcell.00018.2022
https://pmc.ncbi.nlm.nih.gov/articles/PMC3340529/
https://pubmed.ncbi.nlm.nih.gov/34405137/
https://pubmed.ncbi.nlm.nih.gov/15872080/
https://pmc.ncbi.nlm.nih.gov/articles/PMC3108006/
https://journals.biologists.com/dev/article/148/5/dev191320/237489/The-ECM-as-a-driver-of-heart-development-and
https://pmc.ncbi.nlm.nih.gov/articles/PMC12583040/
https://pmc.ncbi.nlm.nih.gov/articles/PMC4508384/
https://pubmed.ncbi.nlm.nih.gov/32266656/
https://pmc.ncbi.nlm.nih.gov/articles/PMC4808358/
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01482/full
https://www.pnas.org/doi/10.1073/pnas.2218308120
https://pmc.ncbi.nlm.nih.gov/articles/PMC4398486/
https://pmc.ncbi.nlm.nih.gov/articles/PMC4091977/
https://onlinelibrary.wiley.com/doi/10.1111/dgd.12741
https://www.proteinatlas.org/ENSG00000142798-HSPG2/tissue

📄 View Raw YAML

id: P98160
gene_symbol: HSPG2
aliases:
  - Perlecan
  - PLC
  - HSPG
  - SJS
  - SJS1
product_type: PROTEIN
status: COMPLETE
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: Perlecan is a massive heparan sulfate proteoglycan (468 kDa, 4391 
  amino acids) that functions as a critical structural organizer and signaling 
  hub of basement membranes throughout the body. The protein contains five 
  structurally distinct domains that enable diverse functions through 
  interactions with extracellular matrix components (laminin, type IV collagen, 
  nidogens, fibrillin-1) and cell surface receptors. Heparan sulfate chains 
  attached primarily to domain I (at serines 65, 71, 76) and domain V create 
  high negative charge density essential for basement membrane hydration and 
  charge-based filtration, particularly in the glomerular basement membrane. 
  These heparan sulfate chains sequester and present growth factors (FGF-2, 
  FGF-18, VEGF, BMP, PDGF) to their cognate receptors, forming ternary complexes
  that activate downstream signaling cascades regulating cell proliferation, 
  differentiation, and angiogenesis. Domain III binds FGF-18 and PDGF through 
  its core protein. Perlecan plays essential roles in growth plate development 
  and endochondral ossification by modulating FGF receptor signaling and 
  enabling vascular invasion required for bone formation. At neuromuscular 
  junctions, perlecan localizes acetylcholinesterase and maintains synaptic 
  stability. Proteolytic cleavage by cathepsin L and BMP1-tolloid 
  metalloproteinases generates endorepellin (domain V fragment) and LG3 peptide,
  which exhibit anti-angiogenic activity opposing the pro-angiogenic function of
  full-length perlecan through dual antagonism of VEGFR2 and α2β1 integrin. 
  Loss-of-function mutations cause dyssegmental dysplasia (Silverman-Handmaker 
  type, typically perinatally lethal), while hypomorphic mutations cause 
  Schwartz-Jampel syndrome characterized by chondrodysplasia and myotonia.
core_functions:
  - description: Cross-linking basement membrane proteins (laminin, collagen IV,
      nidogens, fibrillin-1) and providing compression resistance through 
      negatively charged heparan sulfate chains that attract water and cations
    molecular_function:
      id: GO:0030021
      label: extracellular matrix structural constituent conferring compression 
        resistance
    locations:
      - id: GO:0005604
        label: basement membrane
      - id: GO:0031012
        label: extracellular matrix
  - description: Sequestering and presenting growth factors (FGF-2, FGF-18, 
      VEGF, BMP-2, PDGF) to their cognate receptors via heparan sulfate chains 
      (domain I, domain V) and core protein domains (domain III), forming 
      ternary signaling complexes that activate downstream pathways
    molecular_function:
      id: GO:0019838
      label: growth factor binding
    directly_involved_in:
      - id: GO:0001525
        label: angiogenesis
      - id: GO:0072359
        label: circulatory system development
      - id: GO:0007420
        label: brain development
    locations:
      - id: GO:0005604
        label: basement membrane
      - id: GO:0031012
        label: extracellular matrix
    substrates:
      - id: UniProtKB:P09038
        label: FGF-2
      - id: UniProtKB:O76093
        label: FGF-18
      - id: UniProtKB:P15692
        label: VEGFA
      - id: UniProtKB:P12643
        label: BMP-2
      - id: UniProtKB:P01127
        label: PDGFB
  - description: Bridging laminin and collagen IV networks through multivalent 
      interactions that organize basement membrane architecture
    molecular_function:
      id: GO:0060090
      label: molecular adaptor activity
    locations:
      - id: GO:0005604
        label: basement membrane
    supported_by:
      - reference_id: file:human/HSPG2/HSPG2-deep-research-perplexity.md
        supporting_text: "Perlecan functions as a critical cross-linking component
          of basement membranes, interacting with and stabilizing the major basement
          membrane proteins including laminin, type IV collagen, and nidogens. Through
          its multiple binding partners, perlecan bridges and stabilizes the laminin
          network with the type IV collagen network within basement membranes."
  - description: Localizing acetylcholinesterase to neuromuscular junctions 
      through binding interactions that anchor the synaptic enzyme for proper 
      neurotransmission
    molecular_function:
      id: GO:0060090
      label: molecular adaptor activity
    directly_involved_in:
      - id: GO:0035418
        label: protein localization to synapse
    locations:
      - id: GO:0031594
        label: neuromuscular junction
      - id: GO:0043005
        label: neuron projection
    supported_by:
      - reference_id: PMID:14702351
        supporting_text: "The collagen-tailed form of acetylcholinesterase (A(12)-AChE)
          appears to be localized at the neuromuscular junction in association with
          the transmembrane dystroglycan complex through binding of its collagenic
          tail (ColQ) to the proteoglycan perlecan."
  - description: Antagonizing VEGF-mediated angiogenesis through dual receptor 
      blockade (endorepellin fragment binds VEGFR2 and α2β1 integrin at sites 
      distinct from VEGFA binding, inducing VEGFR2 dephosphorylation and 
      suppressing pro-angiogenic signaling)
    molecular_function:
      id: GO:0005102
      label: signaling receptor binding
    directly_involved_in:
      - id: GO:0016525
        label: negative regulation of angiogenesis
    locations:
      - id: GO:0005576
        label: extracellular region
    supported_by:
      - reference_id: PMID:21596751
        supporting_text: "Here, we show that both perlecan and endorepellin bind directly
          and with high affinity to both VEGF receptors 1 and 2, in a region that
          differs from VEGFA-binding site. In both human and porcine endothelial cells,
          this interaction evokes a physical down-regulation of both the α2β1 integrin
          and VEGFR2."
      - reference_id: PMID:23374253
        supporting_text: "Indeed, we found that LG1/2 did not bind Ig1-3, but did
          bind with high affinity to Ig3-5, distal to the known VEGFA binding site,
          i.e., Ig2-3. Moreover, we found that LG1/2 blocked the rapid VEGFA activation
          of VEGFR2 at Tyr1175 in endothelial cells."
existing_annotations:
  - term:
      id: GO:0043005
      label: neuron projection
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: IBA annotation based on phylogenetic analysis. Perlecan localizes
        at neuromuscular junctions where it anchors acetylcholinesterase and 
        maintains synaptic stability. The deep research document confirms 
        perlecan's role at neuromuscular junctions and in neural tissues 
        including blood-brain barrier basement membranes. UniProt features list 
        "Interaction with PRPH" (peripherin) suggesting neuron projection 
        localization.
      action: ACCEPT
      reason: Well-supported by both phylogenetic inference and experimental 
        evidence. Perlecan is present at neuromuscular junctions (a specialized 
        neuron projection) and in neural basement membranes. This represents a 
        core function of perlecan in neural tissues.
      supported_by:
        - reference_id: PMID:14702351
          supporting_text: "The collagen-tailed form of acetylcholinesterase (A(12)-AChE)
            appears to be localized at the neuromuscular junction in association with
            the transmembrane dystroglycan complex through binding of its collagenic
            tail (ColQ) to the proteoglycan perlecan."
  - term:
      id: GO:0001525
      label: angiogenesis
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: IEA annotation from UniProtKB keyword mapping. Perlecan has dual 
        pro- and anti-angiogenic roles. Full-length perlecan promotes 
        angiogenesis through its heparan sulfate chains that bind and present 
        VEGF and FGF-2 to their receptors. Proteolytically cleaved endorepellin 
        (domain V) exhibits potent anti-angiogenic activity through dual 
        antagonism of VEGFR2 and α2β1 integrin. Deep research extensively 
        documents both activities.
      action: ACCEPT
      reason: Core function of perlecan. Despite the dual nature (both pro- and 
        anti-angiogenic depending on proteolytic state), perlecan is 
        fundamentally involved in angiogenesis regulation. The term captures the
        biological process without specifying direction, which is appropriate 
        given perlecan's context-dependent activities.
      supported_by:
        - reference_id: PMID:21596751
          supporting_text: "Endorepellin, the C-terminal module of perlecan, negatively
            regulates angiogenesis counter to its proangiogenic parental molecule."
        - reference_id: file:human/HSPG2/HSPG2-deep-research-perplexity.md
          supporting_text: "Perlecan exerts pro-angiogenic activity principally through
            modulation of the FGF-2 pathway via its heparan sulfate side chains, which
            present this ligand to its receptor and induce complex downstream signaling
            cascades promoting cell proliferation, motility, and adhesion. Additionally,
            perlecan positively affects angiogenesis through modulation of the VEGFR2-Neuropilin-1
            signaling axis."
  - term:
      id: GO:0005509
      label: calcium ion binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000002
    review:
      summary: IEA annotation from InterPro domain IPR001881 (EGF-like 
        calcium-binding domain). Perlecan domain V contains multiple EGF-like 
        repeats that may have calcium-binding capacity. However, calcium binding
        is not a characterized or functionally important activity for perlecan. 
        UniProt does not list calcium as a cofactor.
      action: MARK_AS_OVER_ANNOTATED
      reason: While perlecan contains EGF-like domains that structurally may 
        bind calcium, this is not a characterized molecular function of perlecan
        and does not contribute to its known biological activities. This 
        represents computational over-annotation based on domain presence 
        without functional validation.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: IEA
    original_reference_id: GO_REF:0000044
    review:
      summary: IEA annotation from UniProtKB subcellular location. Perlecan is 
        secreted and localized to extracellular spaces including basement 
        membranes, extracellular matrix, and extracellular space. This is 
        universally accepted.
      action: ACCEPT
      reason: Core localization. Perlecan is a secreted protein that functions 
        entirely in the extracellular space. The term is appropriately general 
        for this widely distributed ECM protein.
  - term:
      id: GO:0005604
      label: basement membrane
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: IEA annotation combining ARBA and UniProtKB subcellular location.
        Perlecan is the major heparan sulfate proteoglycan of basement membranes
        throughout the body. This is perlecan's canonical and most important 
        localization, critical for basement membrane structural integrity, 
        growth factor sequestration, and barrier function.
      action: ACCEPT
      reason: Core localization representing perlecan's primary and most 
        important site of action. Basement membrane is where perlecan carries 
        out its essential structural and signaling functions.
      supported_by:
        - reference_id: file:human/HSPG2/HSPG2-deep-research-perplexity.md
          supporting_text: "Perlecan functions as a critical cross-linking component
            of basement membranes, interacting with and stabilizing the major basement
            membrane proteins including laminin, type IV collagen, and nidogens. Through
            its multiple binding partners, perlecan bridges and stabilizes the laminin
            network with the type IV collagen network within basement membranes."
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: IEA annotation from ARBA machine learning. Perlecan transits 
        through the Golgi during biosynthesis where heparan sulfate chains are 
        added and modified. This is a transient biosynthetic localization, not a
        functional site.
      action: KEEP_AS_NON_CORE
      reason: Accurate but non-core annotation. All secreted proteoglycans 
        transit through the Golgi for glycosylation. This does not represent a 
        functional localization where perlecan carries out its biological 
        activities, merely a biosynthetic transit point.
  - term:
      id: GO:0007420
      label: brain development
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: IEA annotation from ARBA machine learning. Perlecan plays roles 
        in blood-brain barrier integrity, neural stem cell niches, and brain 
        vascular development. Deep research documents perlecan's role in 
        maintaining blood-brain barrier basement membrane and promoting 
        angiogenic repair following stroke.
      action: ACCEPT
      reason: Well-supported role. Perlecan is essential for brain vascular 
        development and blood-brain barrier function. While not as central as 
        its skeletal roles, this represents an important developmental function.
  - term:
      id: GO:0030154
      label: cell differentiation
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: IEA annotation from ARBA machine learning. Perlecan influences 
        chondrocyte differentiation and hypertrophic maturation in growth 
        plates, and affects endothelial cell behavior. This is a very broad term
        that could apply to many pleiotropic effects.
      action: KEEP_AS_NON_CORE
      reason: Too general. While perlecan does influence differentiation of 
        multiple cell types (chondrocytes, endothelial cells, osteoprogenitors),
        this extremely broad term does not capture perlecan's specific 
        functions. More specific terms for chondrocyte differentiation or 
        endochondral ossification would be preferable.
  - term:
      id: GO:0046872
      label: metal ion binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: IEA annotation from UniProtKB keyword mapping. This is an 
        extremely generic molecular function term. While calcium ion binding 
        annotation exists from EGF domains, metal ion binding is not a 
        characterized activity of perlecan.
      action: MARK_AS_OVER_ANNOTATED
      reason: Overly generic term providing no useful functional information. 
        Not a characterized molecular function of perlecan. This represents 
        computational over-annotation without functional significance.
  - term:
      id: GO:0072359
      label: circulatory system development
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: IEA annotation from ARBA machine learning. Perlecan is essential 
        for vascular development as demonstrated in knockout mice and zebrafish 
        morphants showing severe vascular defects. Perlecan regulates 
        angiogenesis through growth factor presentation and direct receptor 
        interactions.
      action: ACCEPT
      reason: Core developmental function. Perlecan is essential for normal 
        vascular development, with knockout causing cardiovascular defects and 
        embryonic lethality. Well-supported by genetic and developmental 
        studies.
      supported_by:
        - reference_id: file:human/HSPG2/HSPG2-deep-research-falcon.md
          supporting_text: "Perlecan modulates VEGFA/VEGFR2 signaling by localizing
            VEGF and stabilizing receptor-ligand complexes; supports FGF2-FGFR co-receptor
            functions via HS; engages integrins and dystroglycan to influence adhesion
            and downstream kinases. Hspg2-null mice exhibit embryonic lethality with
            severe cardiac and cartilaginous defects, emphasizing perlecan's nonredundant
            role in BM integrity and morphogenesis."
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:12900424
    review:
      summary: IPI annotation showing interaction with progranulin (P28799). 
        This is uninformative as a molecular function term.
      action: MODIFY
      reason: Protein binding is uninformative. Perlecan interacts with numerous
        proteins (laminin, collagen IV, nidogens, fibrillin-1, growth factors, 
        integrins, etc.). Better terms would be specific molecular functions 
        like "extracellular matrix structural constituent" or "growth factor 
        binding".
      proposed_replacement_terms:
        - id: GO:0005201
          label: extracellular matrix structural constituent
        - id: GO:0019838
          label: growth factor binding
      supported_by:
        - reference_id: PMID:12900424
          supporting_text: '2003 Aug 4. A novel interaction between perlecan protein
            core and progranulin: potential effects on tumor growth.'
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:21596751
    review:
      summary: IPI annotation showing interaction with VEGFR2/KDR (P35968). This
        paper demonstrates endorepellin binds VEGFR2 and α2β1 integrin with dual
        receptor antagonism for anti-angiogenic activity. While the interaction 
        is real, "protein binding" is uninformative.
      action: MODIFY
      reason: Protein binding is uninformative. The interaction with VEGFR2 
        represents a specific receptor-ligand interaction that antagonizes VEGF 
        signaling. Better terms would capture the specific molecular function.
      proposed_replacement_terms:
        - id: GO:0005102
          label: signaling receptor binding
      supported_by:
        - reference_id: PMID:21596751
          supporting_text: "perlecan and endorepellin bind directly and with high
            affinity to both vegf receptors"
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:23374253
    review:
      summary: IPI annotation showing interaction with VEGFR2/KDR (P35968). This
        paper demonstrates that endorepellin LG1/2 domains bind Ig3-5 of VEGFR2 
        and block VEGFA signaling. While technically correct, "protein binding" 
        is uninformative.
      action: MODIFY
      reason: Protein binding is uninformative. The VEGFR2 interaction 
        represents a specific antagonistic receptor binding activity. Better 
        terms would capture this specific molecular function.
      proposed_replacement_terms:
        - id: GO:0005102
          label: signaling receptor binding
      supported_by:
        - reference_id: PMID:23374253
          supporting_text: "LG1/2 did not bind Ig1-3, but did bind with high affinity
            to Ig3-5"
  - term:
      id: GO:0031594
      label: neuromuscular junction
    evidence_type: IC
    original_reference_id: PMID:14702351
    review:
      summary: IC annotation with experimental evidence. PMID:14702351 
        demonstrates that perlecan anchors acetylcholinesterase at the 
        neuromuscular junction through interaction with ColQ. Perlecan-null mice
        lack AChE at the NMJ. This is a well-characterized and essential 
        localization.
      action: ACCEPT
      reason: Core localization supported by strong experimental evidence. 
        Perlecan plays an essential structural role at the neuromuscular 
        junction where it anchors acetylcholinesterase. Loss of perlecan causes 
        myotonia in Schwartz-Jampel syndrome due to altered neuromuscular 
        function.
      supported_by:
        - reference_id: PMID:14702351
          supporting_text: "The collagen-tailed form of acetylcholinesterase (A(12)-AChE)
            appears to be localized at the neuromuscular junction in association with
            the transmembrane dystroglycan complex through binding of its collagenic
            tail (ColQ) to the proteoglycan perlecan."
        - reference_id: file:human/HSPG2/HSPG2-deep-research-perplexity.md
          supporting_text: "Perlecan plays a critical role at the neuromuscular junction.
            Perlecan localizes acetylcholinesterase in the neuromuscular junction
            and is of functional significance in neuromuscular control; in perlecan-null
            mice, acetylcholinesterase is absent at the neuromuscular junction. A
            reduced amount of functional perlecan at the neuromuscular junction likely
            alters the balance of other molecules that signal when muscles should
            contract and when they should relax."
  - term:
      id: GO:0032223
      label: negative regulation of synaptic transmission, cholinergic
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: ISS annotation based on sequence similarity to mouse orthologs. 
        This term suggests perlecan negatively regulates cholinergic 
        transmission. Perlecan localizes acetylcholinesterase which terminates 
        cholinergic signaling, but this is enabling proper termination rather 
        than negative regulation of transmission itself.
      action: UNDECIDED
      reason: The relationship between perlecan and cholinergic transmission 
        regulation is complex. Perlecan anchors AChE which breaks down 
        acetylcholine, but whether this constitutes "negative regulation" of 
        transmission or proper homeostatic control is unclear. Would need access
        to the mouse orthologue studies to evaluate this annotation properly.
  - term:
      id: GO:0035418
      label: protein localization to synapse
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: ISS annotation based on mouse ortholog. Perlecan localizes 
        acetylcholinesterase to the neuromuscular synapse. This is 
        well-documented experimentally.
      action: ACCEPT
      reason: Well-supported function. Perlecan serves as an anchor/scaffold 
        that localizes acetylcholinesterase to the neuromuscular synapse, 
        representing a core function at this site.
      supported_by:
        - reference_id: PMID:14702351
          supporting_text: "The collagen-tailed form of acetylcholinesterase (A(12)-AChE)
            appears to be localized at the neuromuscular junction in association with
            the transmembrane dystroglycan complex through binding of its collagenic
            tail (ColQ) to the proteoglycan perlecan."
  - term:
      id: GO:0060090
      label: molecular adaptor activity
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: ISS annotation based on mouse ortholog. Perlecan functions as a 
        molecular scaffold/adaptor that links multiple ECM components (laminin, 
        collagen IV, nidogens) and localizes proteins like acetylcholinesterase.
        This is an appropriate molecular function term.
      action: ACCEPT
      reason: Accurate molecular function. Perlecan serves as a molecular 
        adaptor/scaffold in basement membranes, cross-linking laminin and 
        collagen IV networks and localizing proteins like acetylcholinesterase. 
        This is more informative than generic "protein binding".
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:14702351
    review:
      summary: IPI annotation showing interaction with ACHE/acetylcholinesterase
        (Q9Y215). While the interaction is real and important, "protein binding"
        is uninformative.
      action: MODIFY
      reason: Protein binding is uninformative. Better captured by "molecular 
        adaptor activity" term which describes perlecan's role in localizing 
        acetylcholinesterase to the synapse.
      proposed_replacement_terms:
        - id: GO:0060090
          label: molecular adaptor activity
      supported_by:
        - reference_id: PMID:14702351
          supporting_text: 2003 Dec 31. C-terminal and heparin-binding domains 
            of collagenic tail subunit are both essential for anchoring 
            acetylcholinesterase at the synapse.
  - term:
      id: GO:0031012
      label: extracellular matrix
    evidence_type: HDA
    original_reference_id: PMID:23658023
    review:
      summary: HDA annotation from proteomics study of extracellular matrix. 
        Perlecan is a major structural component of extracellular matrix and 
        basement membranes. This is a core localization.
      action: ACCEPT
      reason: Core localization. Perlecan is one of the major heparan sulfate 
        proteoglycans of extracellular matrix and basement membranes throughout 
        the body.
      supported_by:
        - reference_id: PMID:23658023
          supporting_text: 2013 May 8. Comparative proteomic analysis of 
            supportive and unsupportive extracellular matrix substrates for 
            human embryonic stem cell maintenance.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9940993
    review:
      summary: TAS annotation from Reactome pathway for heparan sulfate 
        biosynthesis (PXYLP1 dephosphorylates Xyl moiety). Perlecan transits 
        through the Golgi during biosynthesis where heparan sulfate chains 
        undergo extensive modifications. This is a transient biosynthetic 
        localization.
      action: KEEP_AS_NON_CORE
      reason: Accurate but non-core. All heparan sulfate proteoglycans transit 
        through the Golgi for glycosaminoglycan chain synthesis and 
        modification. This is a biosynthetic compartment, not where perlecan 
        carries out its biological functions.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9941039
    review:
      summary: TAS annotation from Reactome pathway for heparan sulfate 
        biosynthesis (FAM20B phosphorylates Xyl moiety). Perlecan transits 
        through the Golgi during biosynthesis where heparan sulfate chains 
        undergo enzymatic modifications. Transient biosynthetic localization.
      action: KEEP_AS_NON_CORE
      reason: Accurate but non-core. Golgi transit is required for all secreted 
        proteoglycans but does not represent functional localization. The 
        numerous Reactome annotations document biosynthetic machinery but not 
        core function.
  - term:
      id: GO:0030021
      label: extracellular matrix structural constituent conferring compression 
        resistance
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: ISS annotation based on sequence similarity to mouse ortholog. 
        Perlecan is a major structural constituent of basement membranes and 
        cartilage ECM. Its high negative charge density from heparan sulfate 
        chains attracts water and cations, providing compression resistance 
        particularly important in cartilage and glomerular basement membrane.
      action: ACCEPT
      reason: Core molecular function. Perlecan's proteoglycan structure with 
        extended heparan sulfate chains provides hydration and compressive 
        resilience to ECM, representing an essential biophysical function 
        especially in cartilage where it enables load-bearing properties.
  - term:
      id: GO:0031012
      label: extracellular matrix
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: ISS annotation based on mouse ortholog. Perlecan is a major 
        heparan sulfate proteoglycan component of extracellular matrix and 
        basement membranes throughout the body. Core localization.
      action: ACCEPT
      reason: Core localization. Perlecan is one of the major structural and 
        regulatory components of extracellular matrix, essential for ECM 
        organization and function.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-1592314
    review:
      summary: TAS annotation from Reactome pathway "HSPG2 (perlecan) 
        degradation by MMP3, plasmin, (MMP12)". This documents perlecan 
        degradation by matrix metalloproteinases and plasmin in the 
        extracellular region, which is perlecan's native location.
      action: ACCEPT
      reason: Core localization. Perlecan functions entirely in the 
        extracellular region including basement membranes, extracellular matrix,
        and extracellular space. This annotation is accurate and supported by 
        all evidence.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2534240
    review:
      summary: TAS annotation from Reactome pathway "HSPG2 (perlecan) 
        degradation by MMP14, MMP15". This documents perlecan degradation by 
        additional matrix metalloproteinases in the extracellular region.
      action: ACCEPT
      reason: Core localization. Perlecan is secreted and functions entirely in 
        the extracellular region, where it is subject to proteolytic processing 
        by metalloproteinases.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-4088220
    review:
      summary: TAS annotation from Reactome pathway "Endorepellin binds 
        alpha2beta1 integrin". This documents the binding of endorepellin 
        (perlecan domain V fragment) to integrin α2β1, which occurs in the 
        extracellular region.
      action: ACCEPT
      reason: Core localization. Endorepellin is generated by proteolytic 
        cleavage in the extracellular space and exerts its anti-angiogenic 
        effects through receptor binding in the extracellular region.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-4088281
    review:
      summary: TAS annotation from Reactome pathway "Endorepellin binds KDR 
        (VEGFR2)". This documents the binding of endorepellin to VEGFR2, a 
        critical interaction for endorepellin's anti-angiogenic activity 
        occurring in the extracellular region.
      action: ACCEPT
      reason: Core localization. Endorepellin functions in the extracellular 
        region where it binds VEGFR2 and α2β1 integrin to exert dual receptor 
        antagonism and anti-angiogenic effects.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-NUL-2534170
    review:
      summary: TAS annotation from Reactome pathway "Degradation of HSPG2 by 
        Mmp13 and Ctss". This documents perlecan degradation by MMP13 and 
        cathepsin S in the extracellular region.
      action: ACCEPT
      reason: Core localization. Perlecan is subject to proteolytic processing 
        by multiple proteases including MMP13 and cathepsin S in its native 
        extracellular location.
  - term:
      id: GO:0006629
      label: lipid metabolic process
    evidence_type: TAS
    original_reference_id: PMID:21289173
    review:
      summary: TAS annotation from PMID:21289173 describing perlecan's role in 
        neuronal amyloid-beta uptake through cooperation with LRP1 (low-density 
        lipoprotein receptor-related protein 1). The paper demonstrates that 
        perlecan (as HSPG) cooperates with LRP1 in cellular uptake processes 
        that include lipid metabolism. However, this is not a core function of 
        perlecan.
      action: KEEP_AS_NON_CORE
      reason: Peripheral function. While perlecan can cooperate with LRP1 in 
        receptor-mediated endocytosis processes that involve lipid metabolism, 
        this is not a primary or core function of perlecan. Perlecan's main 
        functions are structural organization of basement membranes and growth 
        factor sequestration/presentation, not lipid metabolism per se.
      supported_by:
        - reference_id: PMID:21289173
          supporting_text: "In addition, LRP1 and HSPG are part of an immunoprecipitable
            complex at the cell surface to mediate lipid metabolism ( Wilsie and Orlando,
            2003 )"
  - term:
      id: GO:0050750
      label: low-density lipoprotein particle receptor binding
    evidence_type: TAS
    original_reference_id: PMID:21289173
    review:
      summary: TAS annotation from PMID:21289173 demonstrating that HSPG 
        (including perlecan) forms a complex with LRP1 and participates in 
        receptor-mediated processes. Domain II of perlecan contains LDL 
        receptor-like repeats, providing structural basis for potential 
        interactions with LDL receptor pathway components.
      action: ACCEPT
      reason: Well-supported molecular function. Perlecan domain II contains 
        four LDL receptor-like repeats, and perlecan cooperates with LRP1 (LDL 
        receptor-related protein 1) in cellular uptake processes. This 
        represents a legitimate molecular function of perlecan's core protein 
        domains.
      supported_by:
        - reference_id: PMID:21289173
          supporting_text: Our findings demonstrate that LRP1 and HSPG function 
            in a cooperative manner to mediate cellular Aβ uptake and define a 
            major pathway through which Aβ gains entry to neuronal cells
  - term:
      id: GO:0001540
      label: amyloid-beta binding
    evidence_type: IC
    original_reference_id: PMID:21289173
    review:
      summary: IC annotation from PMID:21289173 demonstrating that perlecan (as 
        HSPG) binds amyloid-beta peptide. The paper shows that heparan sulfate 
        chains of perlecan mediate Aβ binding to cell surfaces, with HSPG being 
        more important for Aβ binding than LRP1. Heparan sulfate binds the HHQK 
        (amino acids 13-16) region of Aβ.
      action: ACCEPT
      reason: Well-characterized molecular function relevant to Alzheimer's 
        disease pathology. Perlecan's heparan sulfate chains bind amyloid-beta 
        with functional consequences for Aβ aggregation, plaque formation, and 
        neuronal uptake. This is a specific and important molecular function, 
        though not a core developmental/structural function.
      supported_by:
        - reference_id: PMID:21289173
          supporting_text: "HSPG is more important for the binding of Aβ to the cell
            surface than LRP1."
  - term:
      id: GO:0030021
      label: extracellular matrix structural constituent conferring compression 
        resistance
    evidence_type: RCA
    original_reference_id: PMID:28327460
    review:
      summary: RCA annotation from proteomics study of stem cell-derived 
        extracellular matrices. Perlecan's heparan sulfate chains create high 
        negative charge density that attracts water and cations, providing 
        hydration and compression resistance essential for ECM mechanical 
        properties.
      action: ACCEPT
      reason: Core molecular function. Perlecan's proteoglycan structure with 
        extended heparan sulfate chains provides hydration and compressive 
        resilience to ECM, representing an essential biophysical function 
        especially important in cartilage and glomerular basement membrane.
      supported_by:
        - reference_id: PMID:28327460
          supporting_text: Epub 2017 Mar 7. Comprehensive proteomic 
            characterization of stem cell-derived extracellular matrices.
  - term:
      id: GO:0031012
      label: extracellular matrix
    evidence_type: HDA
    original_reference_id: PMID:28327460
    review:
      summary: HDA annotation from proteomics analysis of stem cell-derived 
        extracellular matrices. Perlecan identified as a component of ECM by 
        mass spectrometry.
      action: ACCEPT
      reason: Core localization. Perlecan is a major structural component of 
        extracellular matrix identified in multiple proteomics studies across 
        diverse tissue types.
      supported_by:
        - reference_id: PMID:28327460
          supporting_text: Epub 2017 Mar 7. Comprehensive proteomic 
            characterization of stem cell-derived extracellular matrices.
  - term:
      id: GO:0030021
      label: extracellular matrix structural constituent conferring compression 
        resistance
    evidence_type: RCA
    original_reference_id: PMID:28675934
    review:
      summary: RCA annotation from proteomics characterization of ECM from 
        normal and diseased tissues. Perlecan provides compression resistance 
        through its hydrated heparan sulfate chains.
      action: ACCEPT
      reason: Core molecular function. Perlecan's high negative charge density 
        from heparan sulfate provides essential compression resistance in 
        tissues including cartilage, basement membranes, and vascular ECM.
      supported_by:
        - reference_id: PMID:28675934
          supporting_text: Characterization of the Extracellular Matrix of 
            Normal and Diseased Tissues Using Proteomics.
  - term:
      id: GO:0031012
      label: extracellular matrix
    evidence_type: HDA
    original_reference_id: PMID:28675934
    review:
      summary: HDA annotation from proteomics study characterizing ECM of normal
        and diseased tissues. Perlecan detected as ECM component by mass 
        spectrometry.
      action: ACCEPT
      reason: Core localization confirmed by proteomics. Perlecan is 
        consistently identified as a major ECM component across multiple tissue 
        types and disease states.
      supported_by:
        - reference_id: PMID:28675934
          supporting_text: Characterization of the Extracellular Matrix of 
            Normal and Diseased Tissues Using Proteomics.
  - term:
      id: GO:0030021
      label: extracellular matrix structural constituent conferring compression 
        resistance
    evidence_type: RCA
    original_reference_id: PMID:23979707
    review:
      summary: RCA annotation from SILAC-based proteomics of human endothelial 
        cell morphogenesis. Perlecan identified as structural ECM component 
        conferring compression resistance.
      action: ACCEPT
      reason: Core molecular function. Perlecan's structural properties provide 
        compression resistance essential for ECM mechanical function in vascular
        and other tissues.
      supported_by:
        - reference_id: PMID:23979707
          supporting_text: Epub 2013 Aug 26. SILAC-based proteomics of human 
            primary endothelial cell morphogenesis unveils tumor angiogenic 
            markers.
  - term:
      id: GO:0030021
      label: extracellular matrix structural constituent conferring compression 
        resistance
    evidence_type: RCA
    original_reference_id: PMID:20551380
    review:
      summary: RCA annotation from proteomics characterization of human aorta 
        extracellular space components. Perlecan provides structural support and
        compression resistance in vascular ECM.
      action: ACCEPT
      reason: Core molecular function. Perlecan's compression resistance 
        properties are essential for vascular ECM integrity and function in 
        large vessels like the aorta.
      supported_by:
        - reference_id: PMID:20551380
          supporting_text: 2010 Jun 15. Proteomics characterization of 
            extracellular space components in the human aorta.
  - term:
      id: GO:0030021
      label: extracellular matrix structural constituent conferring compression 
        resistance
    evidence_type: RCA
    original_reference_id: PMID:25037231
    review:
      summary: RCA annotation from proteomics of primary metastatic colon 
        cancers. Perlecan identified as ECM structural component even in tumor 
        microenvironments.
      action: ACCEPT
      reason: Core molecular function maintained even in pathological contexts. 
        Perlecan provides compression resistance in both normal and tumor ECM.
      supported_by:
        - reference_id: PMID:25037231
          supporting_text: Extracellular matrix signatures of human primary 
            metastatic colon cancers and their metastases to liver.
  - term:
      id: GO:0030021
      label: extracellular matrix structural constituent conferring compression 
        resistance
    evidence_type: RCA
    original_reference_id: PMID:27559042
    review:
      summary: RCA annotation from glycoproteomics study in human atrial 
        fibrillation. Perlecan provides structural ECM function including 
        compression resistance in cardiac tissues.
      action: ACCEPT
      reason: Core molecular function. Perlecan's compression resistance 
        properties are important in cardiac ECM and basement membranes.
      supported_by:
        - reference_id: PMID:27559042
          supporting_text: Glycoproteomics Reveals Decorin Peptides With 
            Anti-Myostatin Activity in Human Atrial Fibrillation.
  - term:
      id: GO:0031012
      label: extracellular matrix
    evidence_type: HDA
    original_reference_id: PMID:25037231
    review:
      summary: HDA annotation from proteomics of colon cancer and liver 
        metastases ECM. Perlecan detected in tumor-associated ECM.
      action: ACCEPT
      reason: Core localization. Perlecan is present in ECM even in pathological
        tumor microenvironments, confirming its fundamental ECM localization.
      supported_by:
        - reference_id: PMID:25037231
          supporting_text: Extracellular matrix signatures of human primary 
            metastatic colon cancers and their metastases to liver.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: HDA
    original_reference_id: PMID:27068509
    review:
      summary: HDA annotation from proteomics of extracellular matrix remodeling
        in venous hypertension and varicose veins. Perlecan detected in 
        remodeling vascular ECM.
      action: ACCEPT
      reason: Core localization. Perlecan functions in the extracellular region 
        including vascular basement membranes and ECM.
      supported_by:
        - reference_id: PMID:27068509
          supporting_text: 'Apr 11. Extracellular matrix remodelling in response to
            venous hypertension: proteomics of human varicose veins.'
  - term:
      id: GO:0031012
      label: extracellular matrix
    evidence_type: HDA
    original_reference_id: PMID:27559042
    review:
      summary: HDA annotation from glycoproteomics in atrial fibrillation. 
        Perlecan detected in cardiac ECM.
      action: ACCEPT
      reason: Core localization. Perlecan is present in cardiac extracellular 
        matrix and basement membranes.
      supported_by:
        - reference_id: PMID:27559042
          supporting_text: Glycoproteomics Reveals Decorin Peptides With 
            Anti-Myostatin Activity in Human Atrial Fibrillation.
  - term:
      id: GO:0005615
      label: extracellular space
    evidence_type: HDA
    original_reference_id: PMID:20551380
    review:
      summary: HDA annotation from proteomics of human aorta extracellular 
        space. Perlecan identified as a component of extracellular space in 
        vascular tissues.
      action: ACCEPT
      reason: Core localization. Perlecan is secreted into the extracellular 
        space where it functions in basement membranes and ECM.
      supported_by:
        - reference_id: PMID:20551380
          supporting_text: 2010 Jun 15. Proteomics characterization of 
            extracellular space components in the human aorta.
  - term:
      id: GO:0031012
      label: extracellular matrix
    evidence_type: HDA
    original_reference_id: PMID:20551380
    review:
      summary: HDA annotation from proteomics characterization of aorta 
        extracellular matrix. Perlecan is a major ECM component in vascular 
        tissues.
      action: ACCEPT
      reason: Core localization. Perlecan is essential for vascular ECM 
        organization and function.
      supported_by:
        - reference_id: PMID:20551380
          supporting_text: 2010 Jun 15. Proteomics characterization of 
            extracellular space components in the human aorta.
  - term:
      id: GO:0031012
      label: extracellular matrix
    evidence_type: HDA
    original_reference_id: PMID:23979707
    review:
      summary: HDA annotation from SILAC proteomics of endothelial cell 
        morphogenesis. Perlecan detected as ECM component during endothelial 
        tube formation.
      action: ACCEPT
      reason: Core localization. Perlecan is a key ECM component in angiogenesis
        and vascular development.
      supported_by:
        - reference_id: PMID:23979707
          supporting_text: Epub 2013 Aug 26. SILAC-based proteomics of human 
            primary endothelial cell morphogenesis unveils tumor angiogenic 
            markers.
  - term:
      id: GO:0005604
      label: basement membrane
    evidence_type: TAS
    original_reference_id: PMID:21126803
    review:
      summary: TAS annotation from PMID:21126803 on endorepellin (perlecan 
        domain V) and α2 integrin-mediated amyloid-beta neurotoxicity. While the
        study focuses on endorepellin function, it acknowledges perlecan's 
        primary basement membrane localization.
      action: ACCEPT
      reason: Core localization. Basement membrane is perlecan's primary and 
        canonical localization where it performs essential structural and 
        signaling functions.
      supported_by:
        - reference_id: PMID:21126803
          supporting_text: Perlecan domain V inhibits α2 integrin-mediated 
            amyloid-β neurotoxicity.
  - term:
      id: GO:0006954
      label: inflammatory response
    evidence_type: TAS
    original_reference_id: PMID:21126803
    review:
      summary: TAS annotation from PMID:21126803. The study examines 
        endorepellin's protective effects against Aβ neurotoxicity, which has 
        inflammatory components. However, inflammatory response is not a core 
        function of perlecan.
      action: KEEP_AS_NON_CORE
      reason: Peripheral function. While perlecan and endorepellin may modulate 
        inflammatory processes indirectly through Aβ binding and effects on 
        integrin signaling, inflammatory response is not a primary or core 
        function of perlecan. The main functions are structural ECM organization
        and growth factor signaling.
      supported_by:
        - reference_id: PMID:21126803
          supporting_text: Perlecan domain V inhibits α2 integrin-mediated 
            amyloid-β neurotoxicity.
  - term:
      id: GO:0007420
      label: brain development
    evidence_type: TAS
    original_reference_id: PMID:21126803
    review:
      summary: TAS annotation from PMID:21126803 on endorepellin and 
        amyloid-beta. While this study focuses on Alzheimer's disease pathology 
        rather than development, perlecan does play roles in blood-brain barrier
        formation and neural tissue development as documented in the deep 
        research.
      action: ACCEPT
      reason: Well-supported developmental function. Perlecan is essential for 
        blood-brain barrier integrity, neural stem cell niches, and brain 
        vascular development. Though not as central as skeletal functions, brain
        development represents an important role for perlecan.
      supported_by:
        - reference_id: PMID:21126803
          supporting_text: Perlecan domain V inhibits α2 integrin-mediated 
            amyloid-β neurotoxicity.
  - term:
      id: GO:0016525
      label: negative regulation of angiogenesis
    evidence_type: TAS
    original_reference_id: PMID:21126803
    review:
      summary: TAS annotation from PMID:21126803 on endorepellin. Endorepellin 
        (perlecan domain V) exhibits potent anti-angiogenic activity through 
        dual antagonism of VEGFR2 and α2β1 integrin, opposing the pro-angiogenic
        function of full-length perlecan.
      action: ACCEPT
      reason: Well-characterized function of endorepellin. While full-length 
        perlecan promotes angiogenesis, proteolytic cleavage generates 
        endorepellin which negatively regulates angiogenesis. This represents an
        important biological switch in perlecan function and is a core activity 
        of the endorepellin fragment.
      supported_by:
        - reference_id: file:human/HSPG2/HSPG2-deep-research-perplexity.md
          supporting_text: "Endorepellin functions as a potent mediator of angiogenesis
            repression both in vitro and in vivo, exerting this effect through dual
            receptor antagonism by simultaneously engaging VEGFR2 and alpha2beta1
            integrin at sites independent of the VEGFA binding site. Signaling through
            the alpha2beta1 integrin leads to actin disassembly and blockade of endothelial
            cell migration, which is necessary for capillary morphogenesis."
        - reference_id: PMID:21126803
          supporting_text: Perlecan domain V inhibits α2 integrin-mediated 
            amyloid-β neurotoxicity.
  - term:
      id: GO:0030154
      label: cell differentiation
    evidence_type: TAS
    original_reference_id: PMID:21126803
    review:
      summary: TAS annotation from PMID:21126803. This study does not directly 
        address cell differentiation. While perlecan influences chondrocyte 
        differentiation in growth plates, this very broad term does not capture 
        specific functions.
      action: KEEP_AS_NON_CORE
      reason: Too general. While perlecan influences differentiation of multiple
        cell types (chondrocytes, endothelial cells, osteoprogenitors), this 
        extremely broad term does not usefully describe perlecan's specific 
        functions. More specific terms for chondrocyte differentiation or 
        endochondral ossification would be preferable.
      supported_by:
        - reference_id: PMID:21126803
          supporting_text: Perlecan domain V inhibits α2 integrin-mediated 
            amyloid-β neurotoxicity.
  - term:
      id: GO:0072359
      label: circulatory system development
    evidence_type: TAS
    original_reference_id: PMID:21126803
    review:
      summary: TAS annotation from PMID:21126803. While this paper focuses on 
        Alzheimer's pathology, perlecan is essential for vascular development as
        extensively documented in the deep research, with knockout mice showing 
        cardiovascular defects.
      action: ACCEPT
      reason: Core developmental function. Perlecan is essential for normal 
        circulatory system development, with genetic ablation causing severe 
        vascular defects and embryonic lethality. Well-supported by 
        developmental studies in multiple model organisms.
      supported_by:
        - reference_id: PMID:21126803
          supporting_text: Perlecan domain V inhibits α2 integrin-mediated 
            amyloid-β neurotoxicity.
  - term:
      id: GO:0006898
      label: receptor-mediated endocytosis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: ISS annotation based on sequence similarity to mouse ortholog. 
        PMID:21289173 demonstrates that perlecan cooperates with LRP1 in 
        receptor-mediated endocytosis of amyloid-beta, with HSPG acting as a 
        coreceptor for LRP1-mediated uptake.
      action: KEEP_AS_NON_CORE
      reason: Non-core function. While perlecan participates in 
        receptor-mediated endocytosis as a coreceptor for LRP1, particularly for
        amyloid-beta uptake, this is not a primary structural or signaling 
        function. This represents a specialized role in Alzheimer's disease 
        pathology rather than a core developmental or ECM function.
      supported_by:
        - reference_id: PMID:21289173
          supporting_text: "First, HSPG may function as a coreceptor for LRP1"
  - term:
      id: GO:0098797
      label: plasma membrane protein complex
    evidence_type: TAS
    original_reference_id: PMID:21289173
    review:
      summary: TAS annotation from PMID:21289173 describing perlecan as part of 
        an HSPG-LRP1 complex at the plasma membrane. The study shows that "LRP1 
        and HSPG are part of an immunoprecipitable complex at the cell surface."
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. While perlecan can be part of a plasma 
        membrane protein complex with LRP1 for receptor-mediated endocytosis, 
        this is not perlecan's primary localization. Perlecan's core locations 
        are basement membranes and extracellular matrix, not plasma membrane 
        complexes. This represents a specialized interaction in specific 
        contexts (e.g., Aβ uptake).
      supported_by:
        - reference_id: PMID:21289173
          supporting_text: "In addition, LRP1 and HSPG are part of an immunoprecipitable
            complex at the cell surface to mediate lipid metabolism ( Wilsie and Orlando,
            2003 )"
  - term:
      id: GO:0005604
      label: basement membrane
    evidence_type: TAS
    original_reference_id: PMID:8621634
    review:
      summary: TAS annotation from PMID:8621634 identifying perlecan as a 
        basement membrane component in the Engelbreth-Holm-Swarm tumor matrix, 
        which is a classical source of basement membrane proteins.
      action: ACCEPT
      reason: Core localization. This paper characterizes perlecan as "basement 
        membrane-specific heparan sulfate proteoglycan" and demonstrates its 
        basement membrane localization by immunohistochemistry. Basement 
        membrane is perlecan's primary and defining localization.
      supported_by:
        - reference_id: PMID:8621634
          supporting_text: "Both are, however, basement membrane components, although
            there are tissue-specific differences in their distribution"
  - term:
      id: GO:0005925
      label: focal adhesion
    evidence_type: HDA
    original_reference_id: PMID:21423176
    review:
      summary: HDA annotation from proteomics analysis of focal adhesion 
        complexes during myosin-II-responsive adhesion maturation. Perlecan 
        detected in focal adhesion proteome.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. While perlecan may be present in or near 
        focal adhesions where ECM interacts with integrin-based cell adhesion 
        complexes, this is not a primary or characteristic localization for 
        perlecan. Perlecan's core localizations are basement membranes and 
        extracellular matrix. Focal adhesion presence likely reflects 
        ECM-integrin interactions rather than a specific functional role at 
        focal adhesions.
      supported_by:
        - reference_id: PMID:21423176
          supporting_text: Analysis of the myosin-II-responsive focal adhesion 
            proteome reveals a role for β-Pix in negative regulation of focal 
            adhesion maturation.
  - term:
      id: GO:0070062
      label: extracellular exosome
    evidence_type: HDA
    original_reference_id: PMID:23533145
    review:
      summary: HDA annotation from proteomics of extracellular exosomes isolated
        from expressed prostatic secretions in urine. Perlecan detected in 
        exosome preparations.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. Detection of perlecan in exosome 
        preparations likely reflects extracellular contamination or non-specific
        association rather than a functional role in exosome biology. Perlecan 
        is a massive secreted ECM protein not expected to be packaged into 
        exosomes. This annotation does not represent a core function or 
        localization.
      supported_by:
        - reference_id: PMID:23533145
          supporting_text: 2013 Apr 23. In-depth proteomic analyses of exosomes 
            isolated from expressed prostatic secretions in urine.
  - term:
      id: GO:0005615
      label: extracellular space
    evidence_type: HDA
    original_reference_id: PMID:16502470
    review:
      summary: HDA annotation from proteomics identification of proteins in 
        human colostrum aqueous phase. Perlecan detected in extracellular 
        fluids.
      action: ACCEPT
      reason: Core localization. Perlecan is secreted into the extracellular 
        space where it functions in basement membranes and ECM. Detection in 
        biological fluids like colostrum confirms its extracellular 
        localization.
      supported_by:
        - reference_id: PMID:16502470
          supporting_text: 'Human colostrum: identification of minor proteins in the
            aqueous phase by proteomics.'
  - term:
      id: GO:0070062
      label: extracellular exosome
    evidence_type: HDA
    original_reference_id: PMID:19199708
    review:
      summary: HDA annotation from proteomics of human parotid gland exosomes. 
        Perlecan detected in exosome preparations.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. Similar to other exosome annotations, 
        detection of this massive ECM protein in exosome preparations likely 
        reflects contamination or non-specific association rather than true 
        exosomal packaging. Not a functional or core localization for perlecan.
      supported_by:
        - reference_id: PMID:19199708
          supporting_text: Proteomic analysis of human parotid gland exosomes by
            multidimensional protein identification technology (MudPIT).
  - term:
      id: GO:0070062
      label: extracellular exosome
    evidence_type: HDA
    original_reference_id: PMID:19056867
    review:
      summary: HDA annotation from large-scale proteomics of urinary exosomes. 
        Perlecan detected in exosome preparations.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. Detection in exosome preparations does not 
        represent a core function. Given perlecan's size (468 kDa) and role as 
        an ECM structural protein, presence in exosomes likely reflects 
        extracellular contamination rather than functional exosomal packaging.
      supported_by:
        - reference_id: PMID:19056867
          supporting_text: 2008 Dec 3. Large-scale proteomics and 
            phosphoproteomics of urinary exosomes.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-3814820
    review:
      summary: TAS annotation from Reactome pathway "HSPG2 (perlecan) is cleaved
        by BMP1, TLL1, TLL2, Cathepsin L1". Documents proteolytic processing of 
        perlecan in the extracellular region by BMP1-tolloid metalloproteinases 
        and cathepsin L to generate endorepellin.
      action: ACCEPT
      reason: Core localization and function. Proteolytic cleavage of perlecan 
        to generate endorepellin is a key regulatory mechanism occurring in the 
        extracellular region.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2396337
    review:
      summary: TAS annotation from Reactome pathway "HSPG2 binds FGF2(10-155), 
        Fibronectin matrix, Transthyretin tetramer, PDGFA homodimer, PDGFB 
        homodimer". Documents perlecan's binding interactions with growth 
        factors and ECM proteins occurring in the extracellular region.
      action: ACCEPT
      reason: Core localization and function. Perlecan's binding of growth 
        factors (FGF-2, PDGF) and ECM proteins (fibronectin) in the 
        extracellular region represents core functions.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2396395
    review:
      summary: TAS annotation from Reactome pathway "HSPG2 (perlecan) binds 
        alpha-dystroglycan". Documents perlecan's interaction with dystroglycan,
        which occurs in the extracellular region at sites like the neuromuscular
        junction.
      action: ACCEPT
      reason: Core localization. Perlecan interacts with dystroglycan in 
        basement membranes, particularly at the neuromuscular junction, 
        representing a key structural interaction in the extracellular region.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-4084505
    review:
      summary: TAS annotation from Reactome pathway "Laminins bind HSPG2". 
        Documents perlecan's binding to laminins, critical basement membrane 
        proteins, occurring in the extracellular region.
      action: ACCEPT
      reason: Core localization and function. Perlecan-laminin interactions are 
        essential for basement membrane assembly and function in the 
        extracellular region.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-976734
    review:
      summary: TAS annotation from Reactome pathway "Amyloid fibrils have 
        additional components". Documents perlecan as a component of amyloid 
        plaques in Alzheimer's disease, which form in the extracellular region.
      action: ACCEPT
      reason: Valid localization. While not a core function, perlecan's presence
        in amyloid plaques in the extracellular region is well-documented and 
        relevant to Alzheimer's disease pathology.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9914537
    review:
      summary: TAS annotation from Reactome pathway "DGC complex binds AGRN and 
        HSPG2". Documents perlecan's binding to the dystroglycan complex (DGC) 
        and agrin in the extracellular region at the neuromuscular junction.
      action: ACCEPT
      reason: Core localization. Perlecan functions in the extracellular region 
        at the neuromuscular junction where it interacts with the dystroglycan 
        complex.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-1878002
    review:
      summary: TAS annotation from Reactome pathway "XYLTs transfer Xyl to core 
        protein". This documents the first step of heparan sulfate 
        tetrasaccharide linker synthesis in the Golgi, where perlecan transits 
        during biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. All heparan sulfate 
        proteoglycans transit through the Golgi for glycosaminoglycan chain 
        synthesis and modification. This is a required biosynthetic compartment 
        but not where perlecan carries out its biological functions.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-1889981
    review:
      summary: TAS annotation from Reactome pathway "B4GALT7 transfers Gal group
        to xylosyl-unit of the tetrasaccharide linker". Documents heparan 
        sulfate linker biosynthesis in Golgi during perlecan glycosylation.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi transit is required for 
        all secreted proteoglycans but represents a transient biosynthetic step,
        not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-3560804
    review:
      summary: TAS annotation from Reactome pathway "Defective B4GALT7 does not 
        transfer Gal to xylosyl-unit of the tetrasaccharide linker". Documents 
        disease pathway affecting perlecan glycosylation in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. This documents biosynthetic 
        machinery defects, not core perlecan function. Golgi is a transient 
        biosynthetic compartment.
  - term:
      id: GO:0070062
      label: extracellular exosome
    evidence_type: HDA
    original_reference_id: PMID:21362503
    review:
      summary: HDA annotation from proteomics of exosomes from trabecular 
        meshwork cells. Perlecan detected in exosome preparations.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. Similar to other exosome annotations, 
        detection of this large ECM structural protein in exosome preparations 
        likely reflects contamination. Not a functional localization.
      supported_by:
        - reference_id: PMID:21362503
          supporting_text: Epub 2011 Mar 8. Protein profile of exosomes from 
            trabecular meshwork cells.
  - term:
      id: GO:0043202
      label: lysosomal lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-1667005
    review:
      summary: TAS annotation from Reactome pathway "Heparanase (HPSE) cleaves 
        heparan sulfate from its proteoglycan (lysosome)". Documents degradation
        of perlecan's heparan sulfate chains by heparanase in lysosomes during 
        turnover.
      action: KEEP_AS_NON_CORE
      reason: Non-core degradation localization. While perlecan can be taken up 
        and degraded in lysosomes, this represents a catabolic endpoint rather 
        than a functional localization. Perlecan's functions occur in the 
        extracellular space, not in lysosomes.
  - term:
      id: GO:0043202
      label: lysosomal lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2024084
    review:
      summary: TAS annotation from Reactome pathway "HS-GAGs translocate to the 
        lysosome for degradation". Documents transport of heparan sulfate 
        proteoglycans including perlecan to lysosomes for degradation.
      action: KEEP_AS_NON_CORE
      reason: Non-core degradation localization. Lysosomal degradation is a 
        catabolic process, not a site where perlecan performs its biological 
        functions. This is a terminal degradation pathway.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2022851
    review:
      summary: TAS annotation from Reactome pathway "EXT1:EXT2 transfers GlcNAc 
        to the heparan chain". Documents heparan sulfate chain elongation in 
        Golgi during perlecan biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi transit for heparan 
        sulfate synthesis is required but represents transient biosynthetic 
        processing, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2022856
    review:
      summary: TAS annotation from Reactome pathway "EXT1:EXT2 transfers GlcA to
        heparan". Documents heparan sulfate chain elongation in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi transit for HS synthesis
        is required but represents transient biosynthetic processing, not 
        functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2022860
    review:
      summary: TAS annotation from Reactome pathway "NDST1-4 can sulfate a 
        glucosamine residue in heparan to form heparan sulfate". Documents HS 
        sulfation in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. HS modifications occur in 
        Golgi during biosynthesis but not where perlecan functions biologically.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2022887
    review:
      summary: TAS annotation from Reactome pathway "NDST1-4 N-deacetylates 
        GlcNAc residues in heparan". Documents HS modification in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi modifications of HS are 
        biosynthetic steps, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2024108
    review:
      summary: TAS annotation from Reactome pathway "Some HSPGs are secreted to 
        the plasma membrane". Documents trafficking of perlecan through Golgi to
        secretion.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi is a transient 
        biosynthetic and trafficking compartment, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2076383
    review:
      summary: TAS annotation from Reactome pathway "HS3ST1 sulfates GlcN at C3 
        in heparan sulfate". Documents HS sulfation in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. HS sulfation is a biosynthetic
        modification step in Golgi, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2076392
    review:
      summary: TAS annotation from Reactome pathway "EXT1:EXT2 transfers GlcA to
        heparan". Documents HS chain elongation in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi HS biosynthesis is 
        transient, not where perlecan functions.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2076419
    review:
      summary: TAS annotation from Reactome pathway "HS6STs sulfate GlcN at C6 
        in heparan sulfate/heparin". Documents HS sulfation in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. HS sulfation in Golgi is 
        biosynthetic processing, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2076508
    review:
      summary: TAS annotation from Reactome pathway "HS2ST1 trimer sulfates IdoA
        at C2 in heparan sulfate". Documents HS sulfation in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi HS modifications are 
        biosynthetic steps, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2076611
    review:
      summary: TAS annotation from Reactome pathway "HS3ST2-6 sulfate GlcN at C3
        in heparan sulfate". Documents HS sulfation in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. HS sulfation is biosynthetic 
        processing in Golgi, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-3656254
    review:
      summary: TAS annotation from Reactome pathway "Defective EXT2 does not 
        transfer GlcNAc to heparan chain". Documents disease mutations affecting
        HS biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Documents disease mutations in
        HS biosynthesis enzymes, not core perlecan function. Golgi is transient 
        biosynthetic compartment.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-3656257
    review:
      summary: TAS annotation from Reactome pathway "Defective EXT1 does not 
        transfer GlcA to heparan". Documents disease mutations affecting HS 
        biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Documents disease mutations in
        HS biosynthesis, not core perlecan function. Golgi is transient 
        biosynthetic compartment.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-3656261
    review:
      summary: TAS annotation from Reactome pathway "Defective EXT1 does not 
        transfer GlcNAc to heparan chain". Documents disease mutations affecting
        HS biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Documents disease mutations in
        HS biosynthesis enzymes, not core perlecan function.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-3656267
    review:
      summary: TAS annotation from Reactome pathway "Defective EXT2 does not 
        transfer GlcA to heparan". Documents disease mutations affecting HS 
        biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Documents disease mutations in
        HS biosynthesis, not core perlecan function.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9036285
    review:
      summary: TAS annotation from Reactome pathway "Defective EXT1 does not 
        transfer GlcA to heparan". Documents disease mutations affecting HS 
        biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Documents disease mutations in
        HS biosynthesis, not core perlecan function.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9036289
    review:
      summary: TAS annotation from Reactome pathway "Defective EXT2 does not 
        transfer GlcA to heparan". Documents disease mutations affecting HS 
        biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Documents disease mutations in
        HS biosynthesis, not core perlecan function.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9953259
    review:
      summary: TAS annotation from Reactome pathway "EXTL3 dimer transfers 
        GlcNAc to the GAG linker". Documents HS linker synthesis in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi HS linker synthesis is 
        biosynthetic processing, not functional localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-1678694
    review:
      summary: TAS annotation from Reactome pathway "Heparanase 2 (HPSE2) binds 
        heparan sulfate proteoglycans". Documents HPSE2 binding to HSPGs 
        including perlecan.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. While heparanase 2 binds perlecan's heparan
        sulfate chains, this interaction occurs wherever perlecan is localized 
        (primarily ECM/basement membranes). The pathway annotation implies 
        plasma membrane localization, but this is not a characteristic or 
        primary localization for perlecan.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2024084
    review:
      summary: TAS annotation from Reactome pathway "HS-GAGs translocate to the 
        lysosome for degradation". Documents trafficking of HSPGs from plasma 
        membrane to lysosomes.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. This documents a degradative trafficking 
        pathway. While perlecan may transit through or near the plasma membrane 
        during internalization, this is not a primary functional localization. 
        Perlecan's core functions occur in basement membranes and ECM, not at 
        the plasma membrane.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2024108
    review:
      summary: TAS annotation from Reactome pathway "Some HSPGs are secreted to 
        the plasma membrane". Documents secretion of HSPGs.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. While perlecan is secreted and some HSPGs 
        associate with plasma membranes, perlecan's primary destination is the 
        extracellular matrix and basement membranes, not the plasma membrane. 
        This annotation likely reflects general HSPG secretion pathways rather 
        than perlecan-specific localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2404131
    review:
      summary: TAS annotation from Reactome pathway "LRPs transport 
        extracellular CR:atREs:HSPG:apoE to cytosol". Documents lipoprotein 
        uptake involving HSPGs and LRP receptors at the plasma membrane.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization. While perlecan can participate in 
        LRP-mediated endocytosis processes at the cell surface, this is not a 
        primary localization. Perlecan's core functions occur in basement 
        membranes and ECM, not at the plasma membrane.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2423785
    review:
      summary: TAS annotation from Reactome pathway "CR:atREs binds apoE and 
        HSPG". Documents carotenoid-retinoid complexes binding apoE and HSPGs.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization and function. This documents a specialized 
        lipoprotein metabolism interaction at the cell surface. While perlecan 
        can interact with apoE-containing complexes, this is not a core function
        and plasma membrane is not a primary perlecan localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2429643
    review:
      summary: TAS annotation from Reactome pathway "NREH hydrolyses atREs 
        (HSPG:apoE) to atROL and FAs". Documents metabolism of internalized 
        lipids involving HSPGs.
      action: KEEP_AS_NON_CORE
      reason: Non-core localization and function. This documents a metabolic 
        pathway involving HSPGs as coreceptors. Plasma membrane is not a primary
        perlecan localization, and this represents a peripheral function.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9694579
    review:
      summary: TAS annotation from Reactome pathway "Spike glycoprotein of 
        SARS-CoV-2 binds ACE2 on host cell". Documents SARS-CoV-2 interaction 
        with cell surface HSPGs during viral entry.
      action: KEEP_AS_NON_CORE
      reason: Non-core and non-physiological. While HSPGs including perlecan may
        facilitate SARS-CoV-2 attachment to cells, this is pathogen exploitation
        of cell surface glycans, not a physiological function. This does not 
        represent a core function or characteristic localization of perlecan.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9694661
    review:
      summary: TAS annotation from Reactome pathway "TMPRSS2 Mediated SARS-CoV-2
        Spike Protein Cleavage and Endocytosis". Documents SARS-CoV-2 viral 
        entry involving HSPGs.
      action: KEEP_AS_NON_CORE
      reason: Non-core and non-physiological. SARS-CoV-2 exploitation of HSPGs 
        is not a physiological perlecan function. Plasma membrane is not a 
        characteristic perlecan localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9698988
    review:
      summary: TAS annotation from Reactome pathway "Direct Host Cell Membrane 
        Fusion and Release of SARS-CoV-2 Nucleocapsid". Documents SARS-CoV-2 
        viral entry.
      action: KEEP_AS_NON_CORE
      reason: Non-core and non-physiological. Viral exploitation of HSPGs is not
        a physiological perlecan function. Plasma membrane is not a 
        characteristic perlecan localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9699007
    review:
      summary: TAS annotation from Reactome pathway "FURIN Mediated SARS-CoV-2 
        Spike Protein Cleavage and Endocytosis". Documents SARS-CoV-2 viral 
        entry involving HSPGs.
      action: KEEP_AS_NON_CORE
      reason: Non-core and non-physiological. SARS-CoV-2 exploitation of HSPGs 
        is not a physiological perlecan function. Plasma membrane is not a 
        characteristic perlecan localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9836899
    review:
      summary: TAS annotation from Reactome pathway "sG binds to HSPGs". 
        Documents viral glycoprotein (sG) binding to heparan sulfate 
        proteoglycans.
      action: KEEP_AS_NON_CORE
      reason: Non-core and likely non-physiological. Viral protein exploitation 
        of HSPGs is not a physiological perlecan function. Plasma membrane is 
        not a characteristic perlecan localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-1667005
    review:
      summary: TAS annotation from Reactome pathway "Heparanase (HPSE) cleaves 
        heparan sulfate from its proteoglycan (lysosome)". Actually documents 
        lysosomal degradation, not Golgi localization.
      action: KEEP_AS_NON_CORE
      reason: Non-core degradation localization. Despite Golgi annotation, this 
        pathway actually describes lysosomal heparanase activity. Both Golgi 
        biosynthesis and lysosomal degradation are non-core localizations 
        representing biosynthetic/catabolic endpoints rather than functional 
        sites.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-1889955
    review:
      summary: TAS annotation from Reactome pathway "B3GAT dimers transfer GlcA 
        to tetrasaccharide linker". Documents HS linker biosynthesis in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi HS linker synthesis is 
        transient biosynthetic processing, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-1889978
    review:
      summary: TAS annotation from Reactome pathway "B3GALT6 transfers Gal to 
        the tetrasaccharide linker". Documents HS linker biosynthesis in Golgi.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Golgi HS linker synthesis is 
        transient biosynthetic processing, not functional localization.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-3560802
    review:
      summary: TAS annotation from Reactome pathway "Defective B3GAT3 does not 
        transfer GlcA to tetrasaccharide linker". Documents disease mutations 
        affecting HS biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Documents disease mutations in
        HS biosynthesis enzymes, not core perlecan function. Golgi is transient 
        biosynthetic compartment.
  - term:
      id: GO:0005796
      label: Golgi lumen
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-4420365
    review:
      summary: TAS annotation from Reactome pathway "Defective B3GALT6 does not 
        transfer Gal to the tetrasaccharide linker". Documents disease mutations
        affecting HS biosynthesis.
      action: KEEP_AS_NON_CORE
      reason: Non-core biosynthetic localization. Documents disease mutations in
        HS biosynthesis enzymes, not core perlecan function. Golgi is transient 
        biosynthetic compartment.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:12604605
    review:
      summary: IPI annotation showing interaction with ECM1 (Q16610). 
        PMID:12604605 demonstrates perlecan C-terminus interacts with ECM1 
        C-terminus, a glycoprotein involved in bone formation and angiogenesis.
      action: MODIFY
      reason: Protein binding is uninformative. Better terms would capture 
        perlecan's specific molecular functions such as "extracellular matrix 
        structural constituent" or molecular adaptor activity for organizing ECM
        components.
      proposed_replacement_terms:
        - id: GO:0005201
          label: extracellular matrix structural constituent
        - id: GO:0060090
          label: molecular adaptor activity
      supported_by:
        - reference_id: PMID:12604605
          supporting_text: "Perlecan protein core interacts with extracellular matrix
            protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis."
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:11956183
    review:
      summary: IPI annotation showing interaction with COL13A1 (Q5TAT6). 
        PMID:11956183 demonstrates type XIII collagen ectodomain binds perlecan 
        along with fibronectin, nidogen-2, and heparin.
      action: MODIFY
      reason: Protein binding is uninformative. Better terms would capture 
        perlecan's specific role in extracellular matrix organization through 
        binding multiple ECM components including collagens.
      proposed_replacement_terms:
        - id: GO:0005201
          label: extracellular matrix structural constituent
        - id: GO:0060090
          label: molecular adaptor activity
      supported_by:
        - reference_id: PMID:11956183
          supporting_text: "The type XIII collagen ectodomain is a 150-nm rod and
            capable of binding to fibronectin, nidogen-2, perlecan, and heparin."
references:
  - id: GO_REF:0000002
    title: Gene Ontology annotation through association of InterPro records with
      GO terms.
    findings: []
  - id: GO_REF:0000024
    title: Manual transfer of experimentally-verified manual GO annotation data 
      to orthologs by curator judgment of sequence similarity.
    findings: []
  - id: GO_REF:0000033
    title: Annotation inferences using phylogenetic trees
    findings: []
  - id: GO_REF:0000043
    title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword 
      mapping
    findings: []
  - id: GO_REF:0000044
    title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular 
      Location vocabulary mapping, accompanied by conservative changes to GO 
      terms applied by UniProt.
    findings: []
  - id: GO_REF:0000117
    title: Electronic Gene Ontology annotations created by ARBA machine learning
      models
    findings: []
  - id: GO_REF:0000120
    title: Combined Automated Annotation using Multiple IEA Methods.
    findings: []
  - id: PMID:11956183
    title: The type XIII collagen ectodomain is a 150-nm rod and capable of 
      binding to fibronectin, nidogen-2, perlecan, and heparin.
    findings: []
  - id: PMID:12604605
    title: Perlecan protein core interacts with extracellular matrix protein 1 
      (ECM1), a glycoprotein involved in bone formation and angiogenesis.
    findings: []
  - id: PMID:12900424
    title: 'A novel interaction between perlecan protein core and progranulin: potential
      effects on tumor growth.'
    findings: []
  - id: PMID:14702351
    title: C-terminal and heparin-binding domains of collagenic tail subunit are
      both essential for anchoring acetylcholinesterase at the synapse.
    findings: []
  - id: PMID:16502470
    title: 'Human colostrum: identification of minor proteins in the aqueous phase
      by proteomics.'
    findings: []
  - id: PMID:19056867
    title: Large-scale proteomics and phosphoproteomics of urinary exosomes.
    findings: []
  - id: PMID:19199708
    title: Proteomic analysis of human parotid gland exosomes by 
      multidimensional protein identification technology (MudPIT).
    findings: []
  - id: PMID:20551380
    title: Proteomics characterization of extracellular space components in the 
      human aorta.
    findings: []
  - id: PMID:21126803
    title: Perlecan domain V inhibits α2 integrin-mediated amyloid-β 
      neurotoxicity.
    findings: []
  - id: PMID:21289173
    title: Heparan sulphate proteoglycan and the low-density lipoprotein 
      receptor-related protein 1 constitute major pathways for neuronal 
      amyloid-beta uptake.
    findings: []
  - id: PMID:21362503
    title: Protein profile of exosomes from trabecular meshwork cells.
    findings: []
  - id: PMID:21423176
    title: Analysis of the myosin-II-responsive focal adhesion proteome reveals 
      a role for β-Pix in negative regulation of focal adhesion maturation.
    findings: []
  - id: PMID:21596751
    title: 'Endorepellin, the angiostatic module of perlecan, interacts with both
      the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2):
      a dual receptor antagonism.'
    findings: []
  - id: PMID:23374253
    title: Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular
      endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic 
      signaling by VEGFA in endothelial cells.
    findings: []
  - id: PMID:23533145
    title: In-depth proteomic analyses of exosomes isolated from expressed 
      prostatic secretions in urine.
    findings: []
  - id: PMID:23658023
    title: Comparative proteomic analysis of supportive and unsupportive 
      extracellular matrix substrates for human embryonic stem cell maintenance.
    findings: []
  - id: PMID:23979707
    title: SILAC-based proteomics of human primary endothelial cell 
      morphogenesis unveils tumor angiogenic markers.
    findings: []
  - id: PMID:25037231
    title: Extracellular matrix signatures of human primary metastatic colon 
      cancers and their metastases to liver.
    findings: []
  - id: PMID:27068509
    title: 'Extracellular matrix remodelling in response to venous hypertension: proteomics
      of human varicose veins.'
    findings: []
  - id: PMID:27559042
    title: Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity
      in Human Atrial Fibrillation.
    findings: []
  - id: PMID:28327460
    title: Comprehensive proteomic characterization of stem cell-derived 
      extracellular matrices.
    findings: []
  - id: PMID:28675934
    title: Characterization of the Extracellular Matrix of Normal and Diseased 
      Tissues Using Proteomics.
    findings: []
  - id: PMID:8621634
    title: Perlecan and basement membrane-chondroitin sulfate proteoglycan 
      (bamacan) are two basement membrane chondroitin/dermatan sulfate 
      proteoglycans in the Engelbreth-Holm-Swarm tumor matrix.
    findings: []
  - id: Reactome:R-HSA-1592314
    title: HSPG2 (perlecan) degradation by MMP3, plasmin, (MMP12)
    findings: []
  - id: Reactome:R-HSA-1667005
    title: Heparanase (HPSE) cleaves heparan sulfate from its proteoglycan 
      (lysosome)
    findings: []
  - id: Reactome:R-HSA-1678694
    title: Heparanase 2 (HPSE2) binds heparan sulfate proteoglycans
    findings: []
  - id: Reactome:R-HSA-1878002
    title: XYLTs transfer Xyl to core protein
    findings: []
  - id: Reactome:R-HSA-1889955
    title: B3GAT dimers transfer GlcA to tetrasaccharide linker
    findings: []
  - id: Reactome:R-HSA-1889978
    title: B3GALT6 transfers Gal to the tetrasaccharide linker
    findings: []
  - id: Reactome:R-HSA-1889981
    title: B4GALT7 transfers Gal group to xylosyl-unit of the tetrasaccharide 
      linker
    findings: []
  - id: Reactome:R-HSA-2022851
    title: EXT1:EXT2 transfers GlcNAc to the heparan chain
    findings: []
  - id: Reactome:R-HSA-2022856
    title: EXT1:EXT2 transfers GlcA to heparan
    findings: []
  - id: Reactome:R-HSA-2022860
    title: NDST1-4 can sulfate a glucosamine residue in heparan to form heparan 
      sulfate (HS)
    findings: []
  - id: Reactome:R-HSA-2022887
    title: NDST1-4 N-deacetylates GlcNAc residues in heparan
    findings: []
  - id: Reactome:R-HSA-2024084
    title: HS-GAGs translocate to the lysosome for degradation
    findings: []
  - id: Reactome:R-HSA-2024108
    title: Some HSPGs are secreted to the plasma membrane
    findings: []
  - id: Reactome:R-HSA-2076383
    title: HS3ST1 sulfates GlcN at C3 in heparan sulfate
    findings: []
  - id: Reactome:R-HSA-2076392
    title: EXT1:EXT2 transfers GlcA to heparan
    findings: []
  - id: Reactome:R-HSA-2076419
    title: HS6STs sulfate GlcN at C6 in heparan sulfate/heparin
    findings: []
  - id: Reactome:R-HSA-2076508
    title: HS2ST1 trimer sulfates IdoA at C2 in heparan sulfate
    findings: []
  - id: Reactome:R-HSA-2076611
    title: HS3ST2-6 sulfate GlcN at C3 in heparan sulfate
    findings: []
  - id: Reactome:R-HSA-2396337
    title: HSPG2 binds FGF2(10-155), Fibronectn matrix, Transthyretin tetramer, 
      PDGFA homodimer, PDGFB homodimer
    findings: []
  - id: Reactome:R-HSA-2396395
    title: HSPG2 (perlecan) binds alpha-dystroglycan
    findings: []
  - id: Reactome:R-HSA-2404131
    title: LRPs transport extracellular CR:atREs:HSPG:apoE to cytosol
    findings: []
  - id: Reactome:R-HSA-2423785
    title: CR:atREs binds apoE and HSPG
    findings: []
  - id: Reactome:R-HSA-2429643
    title: NREH hydrolyses atREs (HSPG:apoE) to atROL and FAs
    findings: []
  - id: Reactome:R-HSA-2534240
    title: HSPG2 (perlecan) degradation by MMP14, MMP15
    findings: []
  - id: Reactome:R-HSA-3560802
    title: Defective B3GAT3 does not transfer GlcA to tetrasaccharide linker
    findings: []
  - id: Reactome:R-HSA-3560804
    title: Defective B4GALT7 does not transfer Gal to xylosyl-unit of the 
      tetrasaccharide linker
    findings: []
  - id: Reactome:R-HSA-3656254
    title: Defective EXT2 (in EXT1:EXT2) does not transfer GlcNAc to the heparan
      chain
    findings: []
  - id: Reactome:R-HSA-3656257
    title: Defective EXT1 (in EXT1:EXT2) does not transfer GlcA to heparan
    findings: []
  - id: Reactome:R-HSA-3656261
    title: Defective EXT1 (in EXT1:EXT2) does not transfer GlcNAc to the heparan
      chain
    findings: []
  - id: Reactome:R-HSA-3656267
    title: Defective EXT2 (in EXT1:EXT2) does not transfer GlcA to heparan
    findings: []
  - id: Reactome:R-HSA-3814820
    title: HSPG2 (perlecan) is cleaved by BMP1, TLL1, TLL2, Cathepsin L1
    findings: []
  - id: Reactome:R-HSA-4084505
    title: Laminins bind HSPG2
    findings: []
  - id: Reactome:R-HSA-4088220
    title: Endorepellin binds alpha2beta1 integrin
    findings: []
  - id: Reactome:R-HSA-4088281
    title: Endorepellin binds KDR (VEGFR2)
    findings: []
  - id: Reactome:R-HSA-4420365
    title: Defective B3GALT6 does not transfer Gal to the tetrasaccharide linker
    findings: []
  - id: Reactome:R-HSA-9036285
    title: Defective EXT1 (in EXT1:EXT2) does not transfer GlcA to heparan
    findings: []
  - id: Reactome:R-HSA-9036289
    title: Defective EXT2 (in EXT1:EXT2) does not transfer GlcA to heparan
    findings: []
  - id: Reactome:R-HSA-9694579
    title: Spike glycoprotein of SARS-CoV-2 binds ACE2 on host cell
    findings: []
  - id: Reactome:R-HSA-9694661
    title: TMPRSS2 Mediated SARS-CoV-2 Spike Protein Cleavage and Endocytosis
    findings: []
  - id: Reactome:R-HSA-9698988
    title: Direct Host Cell Membrane Membrane Fusion and Release of SARS-CoV-2 
      Nucleocapsid
    findings: []
  - id: Reactome:R-HSA-9699007
    title: FURIN Mediated SARS-CoV-2 Spike Protein Cleavage and Endocytosis
    findings: []
  - id: Reactome:R-HSA-976734
    title: Amyloid fibrils have additional components
    findings: []
  - id: Reactome:R-HSA-9836899
    title: sG binds to HSPGs
    findings: []
  - id: Reactome:R-HSA-9914537
    title: DGC complex binds AGRN and HSPG2
    findings: []
  - id: Reactome:R-HSA-9940993
    title: PXYLP1 dephosphorylates Xyl moiety
    findings: []
  - id: Reactome:R-HSA-9941039
    title: FAM20B phosphorylates Xyl moiety
    findings: []
  - id: Reactome:R-HSA-9953259
    title: EXTL3 dimer transfers GlcNAc to the GAG linker
    findings: []
  - id: Reactome:R-NUL-2534170
    title: Degradation of HSPG2 by Mmp13 and Ctss
    findings: []

HSPG2

Gene Description

Existing Annotations Review

Core Functions

Cross-linking basement membrane proteins (laminin, collagen IV, nidogens, fibrillin-1) and providing compression resistance through negatively charged heparan sulfate chains that attract water and cations

Sequestering and presenting growth factors (FGF-2, FGF-18, VEGF, BMP-2, PDGF) to their cognate receptors via heparan sulfate chains (domain I, domain V) and core protein domains (domain III), forming ternary signaling complexes that activate downstream pathways

Bridging laminin and collagen IV networks through multivalent interactions that organize basement membrane architecture

Localizing acetylcholinesterase to neuromuscular junctions through binding interactions that anchor the synaptic enzyme for proper neurotransmission

Antagonizing VEGF-mediated angiogenesis through dual receptor blockade (endorepellin fragment binds VEGFR2 and α2β1 integrin at sites distinct from VEGFA binding, inducing VEGFR2 dephosphorylation and suppressing pro-angiogenic signaling)

References

📚 Additional Documentation

Deep Research Falcon

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

Target Gene/Protein Identity (from UniProt):

MANDATORY VERIFICATION STEPS:

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

Research Target:

Output

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

Target Gene/Protein Identity (from UniProt):

MANDATORY VERIFICATION STEPS:

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

Research Target:

Citations

Deep Research Perplexity

Question

Gene Research for Functional Annotation

Output

Comprehensive Research Report on HSPG2: The Heparan Sulfate Proteoglycan Perlecan and Its Multifunctional Role in Basement Membrane Organization and Cell Signaling

Executive Summary

Molecular Architecture and Structural Organization of HSPG2/Perlecan

Gene Structure and Protein Synthesis

Multidomain Architecture and Structural Homologies

Heparan Sulfate Side Chains and Their Biochemical Significance

Structure and Enzymatic Modification of Heparan Sulfate

Functional Consequences of Glycosaminoglycan Composition

Perlecan's Role in Growth Factor Sequestration and Presentation

Fibroblast Growth Factor Binding and Signaling

Vascular Endothelial Growth Factor Signaling in Angiogenesis

Bone Morphogenetic Protein and Other Growth Factor Interactions

Basement Membrane Organization and Barrier Function

Structural Role in Basement Membrane Assembly

Hydration and Charge Density Properties

Endothelial Barrier Function in Vascular Tissues

Perlecan's Critical Functions in Skeletal Development and Growth Plate Biology

Growth Plate Development and Endochondral Ossification

Chondrocyte Regulation and Mechanotransduction

Bone Formation and Mineralization

Perlecan at the Neuromuscular Junction

Organization and Function in Synaptic Architecture

Signaling Pathways in NMJ Development and Maintenance

Perlecan's Roles in Neural Tissues and Regeneration

Blood-Brain Barrier Integrity and Repair

Neural Stem Cell Niches and Neurogenesis

Peripheral Nerve Regeneration

Endorepellin: The Angiostatic C-Terminal Fragment of Perlecan

Proteolytic Generation and Structural Organization

Dual Receptor Antagonism and Signaling Mechanisms

Autophagy Induction and Emerging Therapeutic Roles

HSPG2 Mutations and Associated Genetic Diseases

Schwartz-Jampel Syndrome

Dyssegmental Dysplasia, Silverman-Handmaker Type

Recent Findings on Splicing Variants and Evolutionary Changes

Role of Perlecan in Tumor Biology and Cancer Metastasis

Dual Pro- and Anti-Tumorigenic Functions

Radiotherapy Resistance in Prostate Cancer

Cell Dormancy in Perivascular Niches

Expression Patterns and Developmental Regulation

Tissue Distribution and Cell-Type Specific Expression

Regulation of HSPG2 Promoter Activity

Evolutionary Conservation and Ancient Origins

Conservation Across Animal Phyla

Contemporary Applications and Therapeutic Development

Recombinant Perlecan Fragments in Tissue Engineering

Perlecan in Wound Healing and Vascular Repair

Single Molecule Measurements and Mechanosensing

Molecular Degradation and Proteolytic Processing